text string | url string | crawl_date timestamp[ms] | label int64 | id string |
|---|---|---|---|---|
VANCOUVER, BC, April 14, 2022 /PRNewswire/ - Avino Silver & Gold Mines Ltd. (TSX: ASM) (NYSE: ASM) (FSE: GV6) "Avino" or "the Company") is pleased to report highlights from its first quarter 2022 production results from the Avino Mine property near Durango, Mexico.
"The first quarter of 2022 represented a significant milestone for Avino," said David Wolfin, President and CEO of Avino. "With the closing of the La Preciosa acquisition, we are excited to move forward with a goal of creating a district-scale operation which will provide significant benefits for all our stakeholders. The slight decrease in production, compared to Q4 2021, was expected due to mine sequencing into more typical gold grade zones. During the quarter, silver and copper grades remained consistent with our internal mine plan while we were able to meaningfully improve our gold and silver recoveries. We continue to focus on profitable ounces, training programs to build up our local workforce to accelerate the ramp-up period, and continued exploration below our current workings in addition to other high-grade targets on the property."
- Completed Transformational Acquisition of La Preciosa: On March 21, 2022, Avino announced the closing of the acquisition of La Preciosa from Coeur Mining Inc.
- Announced La Potosina Results: On March 9, 2022, Avino announced drill results from the La Potosina area of the Avino property, including 668 g/t AgEq over 2.95 metres. These results are following up on historic results from 2011, which included 2,737 g/t AgEq over 0.40 metres.
- Advanced the Oxide Tailings Project: With the release of the results from the 110 drill-hole program, Avino is moving forward with metallurgical testwork to progress this project to the next phase of development.
Q1 2022 came from the Avino Mine only. The Company is not expecting to process any Historical Above Ground Stockpiles at this time.
- Silver equivalent production decreased 15% to 457,798 oz*
- Silver production remained constant at 164,358 oz
- Copper production increased by 8% to 1.2 million lbs
- Gold production decreased by 66% to 801 oz
- Mill throughput increased by 7% to 111,138 tonnes
Avino released updates on drilling from a number of different areas of the Avino property, including La Potosina, Oxide Tailings Project & a summary of all other 2021 drilling.
These releases are linked here:
- Oxide Tailings – April 7, 2022
- La Potosina – March 9, 2022
- 2021 Exploration Summary – January 10, 2022
Avino is completing its conversion to dry stack tailings. We chose dry stack tailings for its environmental, safety and economic advantages with the high solids content. This significantly improves safety and stability and reduces the need to extract water from local sources by recycling the water removed from tailings. In addition, it requires less land which in turn results in a smaller environmental footprint. A time lapse video showing the progress of the construction of Tailings Storage Facility #2 is on our website at the following link.
Mill assays are performed at the Avino property's on-site lab. Check samples are sent to SGS Labs in Durango, Mexico for verification. Gold and silver assays are performed by the fire assay method with a gravimetric finish for concentrates and AAS (Atomic Absorption Spectrometry) methods for copper, lead, zinc and silver for the feed and tail grade samples. All concentrate shipments are assayed by one of the following independent third-party labs: Inspectorate in the UK, and LSI in the Netherlands and AHK.
Peter Latta, P.Eng, MBA, VP Technical Services, Avino who is a qualified person within the context of National Instrument 43-101 has reviewed and approved the technical data in this news release.
Avino is primarily a silver producer from its wholly owned Avino Mine near Durango, Mexico. The Company's silver, gold and copper production remains unhedged. The Company's mission and strategy is to create shareholder value through its focus on profitable organic growth at the historic Avino Property and the strategic acquisition of mineral exploration and mining properties. We are committed to managing all business activities in a safe, environmentally responsible, and cost-effective manner, while contributing to the well-being of the communities in which we operate. We encourage you to connect with us on Twitter at @Avino_ASM and on LinkedIn at Avino Silver & Gold Mines. To view the Avino Mine VRIFY tour, please click here.
"David Wolfin"
David Wolfin
President & Chief Executive Officer
This news release contains "forward-looking information" and "forward-looking statements" (together, the "forward looking statements") within the meaning of applicable securities laws and the United States Private Securities Litigation Reform Act of 1995, including the amended mineral resource estimate for the Company's Avino Property located near Durango in west-central Mexico (the "Avino Property") with an effective date of January 13, 2021, prepared for the Company, and La Preciosa's updated October 27, 2021 resource estimate and references to Measured, Indicated, Inferred Resources referred to in this press release. These forward-looking statements are made as of the date of this news release and the dates of technical reports, as applicable. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the future circumstances, outcomes or results anticipated in or implied by such forward-looking statements will occur or that plans, intentions or expectations upon which the forward-looking statements are based will occur. While we have based these forward-looking statements on our expectations about future events as at the date that such statements were prepared, the statements are not a guarantee that such future events will occur and are subject to risks, uncertainties, assumptions and other factors which could cause events or outcomes to differ materially from those expressed or implied by such forward-looking statements. No assurance can be given that the Company's Avino Property nor the La Preciosa Property have the amount of the mineral resources indicated in their reports or that such mineral resources may be economically extracted. Such factors and assumptions include, among others, the effects of general economic conditions, the price of gold, silver and copper, changing foreign exchange rates and actions by government authorities, uncertainties associated with legal proceedings and negotiations and misjudgments in the course of preparing forward-looking information. In addition, there are known and unknown risk factors which could cause our actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Known risk factors include risks associated with project development; the need for additional financing; operational risks associated with mining and mineral processing; the COVID-19 pandemic; volatility in the global financial markets; fluctuations in metal prices; title matters; uncertainties and risks related to carrying on business in foreign countries; environmental liability claims and insurance; reliance on key personnel; the potential for conflicts of interest among certain of our officers, directors or promoters with certain other projects; the absence of dividends; currency fluctuations; competition; dilution; the volatility of the our common share price and volume; tax consequences to U.S. investors; and other risks and uncertainties. Although we have attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. We are under no obligation to update or alter any forward-looking statements except as required under applicable securities laws. For more detailed information regarding the Company including its risk factors, investors are directed to the Company's Annual Report on Form 20-F and other periodic reports that it files with the U.S. Securities and Exchange Commission.
References to Measured & Indicated Mineral Resources and Inferred Mineral Resources in this press release are terms that are defined under Canadian rules by National Instrument 43-101 ("NI 43-101"). On October 31, 2018, the US Securities and Exchange Commission adopted Item 1300 of Regulation S-K ("Regulation SK-1300") to modernize the property disclosure requirements for mining registrants, and related guidance, under the Securities Act of 1933 and the Securities Exchange Act of 1934. All registrants are required to comply with Regulation SK-1300 for fiscal years ending after January 1, 2021. Accordingly, the Company must comply with Regulation SK-1300 for its fiscal year ending December 31, 2021, and thereafter, and the Company will no longer utilized Industry Guide 7. Regulation SK-1300 uses the Committee for Mineral Reserves International Reporting Standards ("CRIRSCO") based classification scheme for mineral resources and mineral reserves, that includes definitions for inferred, indicated, and measured mineral resources. U.S. Investors are cautioned not to assume that any part of the mineral resources in these categories will ever be converted into probable or proven mineral reserves within the meaning of Regulation S-K 1300.
View original content:
SOURCE Avino Silver & Gold Mines Ltd. | https://www.1011now.com/prnewswire/2022/04/14/avino-delivers-steady-q1-2022-production-results/ | 2022-04-14T12:07:01 | 0 | https://www.1011now.com/prnewswire/2022/04/14/avino-delivers-steady-q1-2022-production-results/ |
TEL-AVIV, Israel, April 14, 2022 /PRNewswire/ -- TriEye, the pioneer of the world's first mass-market Short-Wave Infrared (SWIR) sensing technology, announces collaboration with Toshiba Teli, a global leader in providing integrated cameras for automation. The two companies are working together to commercialise a SWIR camera for industrial-related processes and applications.
TriEye and Toshiba Teli have successfully built the world's first Industrial oriented CMOS-based HD SWIR camera. Currently, industrial machine vision systems lack vital image data required for full-range functionality. This new integration will leverage TriEye's SWIR sensing technology to provide vision systems with an additional layer of information, reshaping the industrial sector and enhancing processes capabilities. This partnership intends to make their solution available globally, introducing its advanced benefits to a wide range of verticals.
Although InGaAs-based SWIR sensing has been around for decades, it remained limited to industries like semiconductor fabrication, aerospace, and science due to the high costs and low production yield. TriEye's unique technology introduces the industry's first CMOS-based SWIR solutions for mass markets. Its technology enhances machine vision capabilities and assists in the detection of visible and invisible malfunctions, allowing them to accomplish tasks that were previously unattainable. Leveraging this solution will provide Toshiba's customers with vital information such as material sensing and quality control.
"We are excited to partner with Toshiba, such a respected and well-known industry leader," said Avi Bakal, CEO and Co-Founder of TriEye, "We believe their constant push to deliver value to their customers combined with their industrial specific advanced knowledge will be extremely beneficial to bring our SWIR sensing solution to be an industry standard."
"We are pleased to partner with TriEye and integrate its world's first CMOS-based SWIR technology," said Shinichi Itokawa, CTO of Toshiba Teli, "TriEye is providing markets with SWIR imaging capabilities needed for reliable automation in industrial processes at an unprecedented cost. This joint effort will accelerate the development of next-generation superior imaging tech capabilities for industrial cameras that will translate into every aspect of our lives. Toshiba Teli is thrilled to be at the front of this technological revolution."
Recently, TriEye's Raven sensor was named a top innovation by InVISION. In the past, the company announced collaborations with Hitachi Astemo, Porsche, Continental Engineering, Trimble and DENSO. TriEye recently announced a significant capital acquisition in funding to support their product commercialization and global expansion. This investment was led by M&G Investments and Varana Capital, Samsung Ventures, Deep Insight, Tawazun Group, Allied Group, and Discount Capital, including follow-on investors Intel Capital, Porsche and Marius Nacht.
About TriEye
TriEye is the pioneer of mass-market, CMOS-based Short-Wave infrared (SWIR) sensing solutions. Based on advanced academic research, TriEye's breakthrough and proprietary technology enables cost-effective, high-resolution image data and depth perception in all weather and lighting conditions. Founded in 2017, the company's cutting-edge technology allows perception systems to operate and deliver reliable image data and actionable information, while reducing expenditure by up to 1,000x the existing industry rates. For more information, visit www.TriEye.tech
About Toshiba Teli (Japan)
Toshiba Teli is an imaging company specializing in design, manufacture and sale of industrial camera and surveillance camera but also the provision of image-based system solution. The company continues to support corporate activities and society by providing high-precision image information through imaging system solutions focused on camera technologies. Toshiba Teli's industrial cameras are widely used as the eyes of various manufacturing and testing equipment as well as for quality control management and medical equipment. To find out more about Toshiba Teli, visit www.toshiba-teli.co.jp
Contact: news@trieye.tech
View original content:
SOURCE TriEye | https://www.wistv.com/prnewswire/2022/04/14/toshiba-teli-trieye-collaborate-deliver-swir-sensing-capabilities-industrial-vision-systems-market/ | 2022-04-14T12:07:06 | 1 | https://www.wistv.com/prnewswire/2022/04/14/toshiba-teli-trieye-collaborate-deliver-swir-sensing-capabilities-industrial-vision-systems-market/ |
Recruitment industry focuses on cyber defense against backdrop of Great Resignation
CAMBRIDGE, England, April 14, 2022 /PRNewswire/ -- Darktrace, a global leader in cyber security AI, today announced that a US-based, award-winning recruitment firm has signed a million-dollar-deal with Darktrace to ensure its business is protected from sophisticated cyber-attacks.
The company, which employs thousands of recruiters across its offices in the US and Canada and sources talent for organizations across all industries including defense, education and financial services, has deployed Darktrace's Enterprise Immune System and Darktrace Antigena to protect its digital enterprise, including its Azure cloud deployment and extensive Microsoft suite. Darktrace's partnership with Microsoft means that its Self-Learning technology is amplified in Microsoft environments such as Microsoft 365 and cloud applications as organizations increasingly rely on cloud infrastructure and virtual collaboration tools.
The staffing industry is often targeted by attackers seeking access to sensitive personal data such as passport information and social security numbers, and the reliance of recruitment professionals on links and documents sent by clients makes them a prime target for phishing emails. Amidst an unprecedented rise in the number of workers resigning from their jobs, the recruitment industry now holds more personally identifiable information, which can be more easily monetized than ever before.
Self-Learning AI can not only spot any kind of threat but can also take autonomous action to prevent it from escalating into a crisis, all while business operations continue as normal.
"Darktrace is delighted to be protecting this award-winning recruitment firm," said Poppy Gustafsson OBE, CEO of Darktrace. "Data breaches have long-lasting reputational impact, particularly within industries that are highly competitive and are trusted with personal information. It remains our mission to deliver technology that stops the negative consequences of in-progress attacks before data falls into the wrong hands. By learning the business, rather than past threats, our artificial intelligence is spotting and stopping novel attacks day-in and day-out."
About Darktrace
Darktrace (LSE: DARK.L), a global leader in cyber security AI, delivers world-class technology that protects over 6,800 customers worldwide from advanced threats, including ransomware and cloud and SaaS attacks. Darktrace's fundamentally different approach applies Self-Learning AI to enable machines to understand the business in order to autonomously defend it. Headquartered in Cambridge, UK, the Group has more than 2,000 employees worldwide. Darktrace was named one of TIME magazine's 'Most Influential Companies' for 2021.
Media Contacts
View original content:
SOURCE Darktrace | https://www.1011now.com/prnewswire/2022/04/14/award-winning-us-recruitment-company-signs-million-dollar-deal-with-darktrace/ | 2022-04-14T12:07:07 | 1 | https://www.1011now.com/prnewswire/2022/04/14/award-winning-us-recruitment-company-signs-million-dollar-deal-with-darktrace/ |
Home Health, Home Care, Hospice and Palliative Care Solutions All Meet CHAP Standards
ARLINGTON, Va., April 14, 2022 /PRNewswire/ -- After a thorough audit of its home health, home care, hospice and palliative care software solutions, Axxess is the first software platform to be awarded the seal of "CHAP Verified." Community Health Accreditation Partner (CHAP) was the first accrediting body for home and community-based health care organizations when it was created in 1965.
To earn the CHAP Verified status, Axxess was subject to a rigorous site visit similar to what is experienced by healthcare organizations, with opening and closing conferences, interviews, a review of records and quality reporting for its four care-at-home software platforms. The survey and audit helped to ensure Axxess software meets quality and compliance requirements of CHAP standards. Throughout the process, the actual CHAP standards were discussed and reviewed as part of the dialogue for verification.
Prior to the CHAP team's visit, Axxess prepared real-life scenarios to illustrate how Axxess solutions support excellence in clinician documentation of care delivery for healthcare organizations and professionals.
CHAP chose to review Axxess first because of feedback received from its surveyors and auditors over the past two years. They reported that organizations using Axxess' enterprise solutions adapted to the challenges of the COVID pandemic more easily while ensuring compliance with regulatory standards. The surveyors additionally noted that Axxess' mobile solution aided quality care delivery processes for field staff.
"A review of various Axxess dashboards confirmed a robust ability of the software platform to highlight strengths and areas for improvement for quality and reporting of clinical, financial, and operational data for healthcare organizations," said Teresa Harbour, Senior Vice President, Accreditation, at CHAP. "Axxess is not just an Electronic Medical Record but a comprehensive care at home technology platform that fosters quality and compliance. Axxess has gone above and beyond to meet the needs of their clients, and their solutions clearly make the care provider experience easier."
Added John Olajide, Founder and CEO of Axxess: "Being the first enterprise software platform to be CHAP Verified is a validation of our work for more than a decade to ensure the future of healthcare is in the home. Our clients can deliver care with confidence that our solutions meet the highest regulatory and best practice standards, which can only mean better outcomes for patients."
"I know Teresa and the CHAP team are as excited as we are about this partnership and the positive impact it will have on care delivery in the years ahead."
CHAP has invited Axxess to join in its venture with the Institute for Healthcare Improvement (IHI) to promote the delivery of age-friendly care throughout the continuum. Axxess will provide thought leadership directed at the four elements of evidence-based practice to address the shift in care delivery surrounding "the 4Ms" (What Matters, Medication, Mobility and Mentation).
About Community Health Accreditation Partner (CHAP)
CHAP is an independent, nonprofit organization accrediting providers of home and community-based care. Founded in 1965, CHAP was first to recognize the need for and value of home and community-based care standards and accreditation. As a Centers for Medicare & Medicaid Services (CMS)–approved accrediting organization, CHAP surveys organizations providing home health, hospice, and home medical equipment services to establish if Medicare Conditions of Participation and DMEPOS Quality Standard are met and recommend certification to CMS. CHAP's purpose is to partner with organizations nationwide to advance quality in the delivery of care and services in the home and community.
About Axxess
Axxess is the leading technology innovator for healthcare at home, focused on solving the most complex industry challenges. Trusted by more than 9,000 organizations that serve more than 3 million patients worldwide, Axxess offers a complete suite of easy-to-use software solutions that empower home health, home care, hospice, and palliative providers to make healthcare in the home human again. The company's collaborative culture focused on innovation and excellence is recognized nationally as a "Best Place to Work."
Contact:
Dennis Petroskey
(202) 215-6767
dpetroskey@axxess.com
View original content to download multimedia:
SOURCE Axxess | https://www.1011now.com/prnewswire/2022/04/14/axxess-is-first-healthcare-software-platform-awarded-chap-verified-seal/ | 2022-04-14T12:07:14 | 0 | https://www.1011now.com/prnewswire/2022/04/14/axxess-is-first-healthcare-software-platform-awarded-chap-verified-seal/ |
With the trends of diversifying traders' portfolio, Trade TIME has joined the market as a reliable, trustworthy broker in 2022. With its emphasis on honesty, experience of customers and innovative features, Trade TIME secures all of traders' investment and provides them with absolutely appropriate guidance on expanding traders' portfolio.
HO CHI MINH CITY, Vietnam, April 14, 2022 /PRNewswire/ -- Trading in such a volatile market like the financial one not only requires bravery but also experience, wisdom, as well as quick and accurate judgment to be able to keep up with the ups and downs of the market. There exist many investors who have experienced several different financial exchanges but still have not found their destiny. With Trade TIME's entrance into the market, this platform brings about a whole new experience for investors. In 2022, Trade TIME has released its complete overview that is analysis0based. Precisely, The Trade TIME's Review covers the following features:
Trade TIME's Offers A Wide Range Of Trading Products In 2022
When it comes to choosing a broker, it is essential for traders to evaluate the broker' financial products. That Trade TIME provides a wide range of financial instruments proves that it is trusted by many investors and the broker's products are also interested.
At Trade TIME, investors can trade diversified products, including Forex; Indices; Stocks; Commodities and Cryptocurrencies, etc.
- Forex: 80+ popular currency pairs, with fast execution speed and the best commissions in the market.
- Commodities: metals such as gold, oil, silver, crude oil and natural gas.
- CFDs: CFD trading with lowest possible spreads and no commission
- Stocks: 500+ global stocks of famous brands such as Facebook, Apple, Tesla, Coca-cola, etc. as well as the stocks listed on major US stock exchanges such as NASDAQ, NYSE and DAX.
- Cryptocurrencies: trade multiple cryptocurrencies such as Bitcoin, Ethereum, Litecoin, Ripple, and more without owning the underlying asset, wallets or currency swaps.
With approximately USD 5 trillion of the trade volume every day, Forex is a fertile trading "land" and Trade TIME is the key to open the door to this land for traders. They might have access to the market operating 24 hours a day and 5 days per week. Trade Time allows investors to trade a wide variety of currency pairs, from the most popular majors, minors and exotics.
Trade TIME's account types
When participating in the Forex market, one of the problems concerned the most by investors is account types. Depending on the capital levels, different account types will have separate incentive programs and policies.
Currently, brokers have been offering users more account types, and so is Trade TIME. This helps users to have more account options to choose the most suitable one.
At the time of this Article, Trade TIME is offering 5 types of accounts, including:
- Raw Account
- Standard Account
- Fixed Account
- VIP Account
- Crypto Account
Why traders should trade with Trade TIME
Time saving transactions
With the slogan of "Invest time and money wisely with Trade TIME", this broker is committed to providing investors with one of the trading systems with minimal slippage and fast deposit/withdrawal time.
Besides, Trade Time is also an ideal destination for trading Forex or cryptocurrencies because this broker does not widen the spread arbitrarily like some of their rivals.
With the advantage of being a new trading broker, Trade TIME prioritizes bringing the most advanced and optimal technologies to investors. It also analyses the latest trading trends so that investors can learn and make their best investment plan.
Furthermore, Trade TIME prioritizes the use of the most advanced security measures to ensure the safety of all customer information.
Customer's trading funds at TradeTIME are kept in separate bank accounts in leading local and international banks to ensure customers' funds are not included in the company's capital and never used for other purposes.
Trading Platform
Trade TIME uses the MT5 (MetaTrader 5) platform, a popular forex trading platform with more outstanding features than the MT4 version, helping traders to trade in a more convenient manner.
MT5 desktop platform has the following key features:
- MQL5 Superior environment with ultimate functionality
- Automated trading with trading bots
- Market analysis & statistics with market depth
- Forex Calendar
- Money transfer between accounts
MT5 mobile platform has the following key features:
- Compatible with all available iOS or Android-powered smartphones and has a web-based version.
- Fast execution
- Practical and friendly user-interface
- Access anytime, anywhere
- Full control of a trading account
- Possible to set price alarms on all instruments to enter orders at the most suitable time.
Trade TIME has shown its presence not only in the Vietnamese but also the international markets. And of course, no broker is perfect, so is Trade TIME. So, to be able to fully experience a broker, it is impossible to ignore traders' own personal experience. Traders can start trading with Trade TIME today by opening an account at https://secure.tradetm.com/en/register/ and try it out in their own way. Wish everyone successful deals.
About Trade TIME
Trade TIME is considered as an ideal destination for trading Forex, indices, stocks, commodities, or cryptocurrencies. Serving investors looking for a single point of access to the global financial markets is exactly what this broker is aiming at.
Established in 2021, Trade TIME is one of the relatively new broker in the market. In spite of not gaining much reputation, its dynamism, optimal technology and fast, smooth order execution are the strengths that not all brokers can offer you.
View original content to download multimedia:
SOURCE Trade TIME | https://www.wistv.com/prnewswire/2022/04/14/trade-time-becomes-one-most-dynamic-brokers-2022/ | 2022-04-14T12:07:14 | 1 | https://www.wistv.com/prnewswire/2022/04/14/trade-time-becomes-one-most-dynamic-brokers-2022/ |
MONTRÉAL, April 14, 2022 /PRNewswire/ - BCE Inc. (TSX: BCE) (NYSE: BCE) will hold its first-quarter 2022 results conference call with the financial community on Thursday, May 5, 2022 at 8:00 am eastern.
Participants will include Mirko Bibic, President and Chief Executive Officer, and Glen LeBlanc, Chief Financial Officer. Media are welcome to participate on a listen-only basis.
To participate, please dial toll-free 1-800-806-5484 or 416-340-2217 and enter passcode 6696161#. A replay will be available until midnight on June 5, 2022 by dialing 1-800-408-3053 or 905-694-9451 and entering passcode 8066296#.
A live audio webcast of the conference call will be available on BCE's website at BCE Q1-2022 conference call.
About BCE
BCE is Canada's largest communications company, providing advanced Bell broadband wireless, Internet, TV, media and business communications services. To learn more, please visit Bell.ca or BCE.ca.
Through Bell for Better, we are investing to create a better today and a better tomorrow by supporting the social and economic prosperity of our communities. This includes the Bell Let's Talk initiative, which promotes Canadian mental health with national awareness and anti-stigma campaigns like Bell Let's Talk Day and significant Bell funding of community care and access, research and workplace initiatives throughout the country. To learn more, please visit Bell.ca/LetsTalk.
Media inquiries:
Marie-Eve Francoeur
514-391-5263
marie-eve.francoeur@bell.ca
Investor inquiries:
Thane Fotopoulos
514-870-4619
thane.fotopoulos@bell.ca
View original content:
SOURCE Bell Canada | https://www.1011now.com/prnewswire/2022/04/14/bce-q1-2022-results-be-announced-may-5/ | 2022-04-14T12:07:21 | 0 | https://www.1011now.com/prnewswire/2022/04/14/bce-q1-2022-results-be-announced-may-5/ |
SAN FRANCISCO, April 14, 2022 /PRNewswire/ -- Twitter, Inc. (NYSE: TWTR) today confirmed it has received an unsolicited, non-binding proposal from Elon Musk to acquire all of the Company's outstanding common stock for $54.20 per share in cash.
The Twitter Board of Directors will carefully review the proposal to determine the course of action that it believes is in the best interest of the Company and all Twitter stockholders.
About Twitter, Inc. (NYSE: TWTR)
Twitter is what's happening and what people are talking about right now. To learn more, visit about.twitter.com and follow @Twitter. Let's talk.
Contacts
Investors:
Press
View original content:
SOURCE Twitter, Inc. | https://www.wistv.com/prnewswire/2022/04/14/twitter-confirms-receipt-unsolicited-non-binding-proposal-elon-musk/ | 2022-04-14T12:07:21 | 0 | https://www.wistv.com/prnewswire/2022/04/14/twitter-confirms-receipt-unsolicited-non-binding-proposal-elon-musk/ |
Regeneron continues to progress its next generation antibodies, and has initiated a first-in-human trial
TARRYTOWN, N.Y., April 14, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended by three months its review of the Biologics License Application (BLA) for REGEN-COV® (casirivimab and imdevimab) to treat COVID-19 in non-hospitalized patients and as prophylaxis in certain individuals. The extension is due to ongoing discussions with the FDA on pre-exposure prophylactic use, for which Regeneron has submitted additional data from its completed prophylaxis trial that the FDA has accepted for review. The FDA considers the submission of these additional data to be a Major Amendment to the BLA and has provided a new target action date of July 13, 2022. The FDA has not requested any new studies to complete its review of the current BLA at this time.
REGEN-COV, an investigational monoclonal antibody therapy, first became available to U.S. patients in November 2020, via the FDA's Emergency Use Authorization (EUA) process for medicines that may help diagnose, treat or prevent a life-threatening disease when adequate and approved alternatives are not available. In January 2022, FDA amended the EUA to exclude its use in geographic regions where infection or exposure is likely due to a variant that is not susceptible to the treatment. Therefore, REGEN-COV is not currently authorized for use in any U.S. states, territories or jurisdictions.
Regeneron remains committed to fighting this pandemic and believes that monoclonal antibody therapies will continue to play an important role. The company is progressing investigational next generation antibodies that are active against the currently circulating variants of concern, and has initiated a first-in-human clinical trial of one of these next generation antibodies.
The development and manufacturing of REGEN-COV have been funded in part with federal funds from the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, under OT number: HHSO100201700020C.
About REGEN-COV
REGEN-COV (casirivimab and imdevimab) is a cocktail of two monoclonal antibodies designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19, using Regeneron's proprietary VelocImmune® and VelociSuite® technologies. Regeneron invented the antibody cocktail and is collaborating with Roche, who is primarily responsible for development and distribution outside the U.S., where it is known as Ronapreve.
Since REGEN-COV first became available to U.S. patients under the EUA process, it has been used to treat millions of people with COVID-19 in the U.S. and around the globe. The EUA is for the duration of the declaration that circumstances exist justifying the authorization of the emergency uses under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. REGEN-COV is not approved by the FDA.
About Regeneron's VelocImmune Technology
Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create approximately one in five of all original, FDA-approved or authorized fully human monoclonal antibodies currently available. This includes REGEN-COV® (casirivimab and imdevimab), Dupixent® (dupilumab), Libtayo® (cemiplimab-rwlc), Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza® (evinacumab-dgnb) and Inmazeb™ (atoltivimab, maftivimab and odesivimab-ebgn).
AUTHORIZED USES AND LIMITATIONS OF AUTHORIZED USE
Treatment:
REGEN-COV is authorized for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death
Limitations of Authorized Use (Treatment)
- REGEN-COV is not authorized for treatment of mild to moderate COVID-19 in geographic regions where infection is likely to have been caused by a non-susceptible SARS-CoV-2 variant based on available information such as variant susceptibility to this drug and regional variant frequency.
- REGEN–COV (casirivimab and imdevimab) is not authorized for use in patients:
- Monoclonal antibodies, such as REGEN–COV, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID–19 requiring high flow oxygen or mechanical ventilation.
Post-Exposure Prophylaxis:
REGEN-COV is authorized in adult and pediatric individuals (12 years of age and older weighing at least 40 kg) for post-exposure prophylaxis of COVID-19 in individuals who are at high risk for progression to severe COVID-19, including hospitalization or death, and are:
- not fully vaccinated or who are not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination (for example, individuals with immunocompromising conditions including those taking immunosuppressive medications) and
Limitations of Authorized Use (Post-Exposure Prophylaxis)
- REGEN-COV is not authorized for post-exposure prophylaxis of COVID-19 in geographic regions where exposure is likely to have been to a non-susceptible SARS-CoV-2 variant, based on available information including variant susceptibility to this drug and regional variant frequency.
- Post-exposure prophylaxis with REGEN-COV (casirivimab and imdevimab) is not a substitute for vaccination against COVID-19.
- REGEN-COV (casirivimab and imdevimab) is not authorized for pre-exposure prophylaxis for prevention of COVID-19.
Healthcare providers should review the Fact Sheet for Healthcare Providers for information on the authorized uses of REGEN-COV and mandatory requirements of the EUA and must comply with the requirements of the EUA. The FDA Letter of Authorization is available for reference, as well as the Dear Healthcare Provider Letter and Patient Fact Sheet.
About Regeneron
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite technologies, such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the impact of SARS-CoV-2 (the virus that has caused the COVID-19 pandemic) on Regeneron's business and its employees, collaborators, and suppliers and other third parties on which Regeneron relies, Regeneron's and its collaborators' ability to continue to conduct research and clinical programs, Regeneron's ability to manage its supply chain, net product sales of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Products"), and the global economy; the nature, timing, and possible success and therapeutic applications of Regeneron's Products and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Product Candidates") and research and clinical programs now underway or planned, including without limitation the development programs relating to the casirivimab and imdevimab antibody cocktail known as REGEN-COV® in the United States and Ronapreve™ in other countries and other investigational next generation antibodies targeting SARS-CoV-2 being developed by Regeneron and referenced in this press release; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's Product Candidates (such as REGEN-COV, including based on the Biologics License Application filed with the U.S. Food and Drug Administration (the "FDA") referenced in this press release) and new indications for Regeneron's Products; the scope of any such possible regulatory approval (including whether any possible FDA approval of REGEN-COV will include prophylactic use); whether and to what extent any of Regeneron's investigational next generation antibodies targeting SARS-CoV-2 will demonstrate and retain potency against the Omicron (B.1.1.529) variant, the Delta (B.1.617.2) variant, or other existing or potential variants of SARS-CoV-2 (as applicable); uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates (such as REGEN-COV), including the impact of recommendations, guidelines, or studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the REGEN-COV prophylaxis study referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron's Products and Regeneron's Product Candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees (such as those relating to the investigational next generational antibodies targeting SARS-CoV-2 referenced in this press release) may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; the ability of Regeneron's collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates (including REGEN-COV); the ability of Regeneron to manage supply chains for multiple products and product candidates; safety issues resulting from the administration of Regeneron's Products and Regeneron's Product Candidates (such as REGEN-COV) in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates, including without limitation REGEN-COV; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron's Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's Product Candidates (including any such competing drugs and product candidates that may provide more efficacious, more easily administered, more cost-effective, or otherwise superior treatment or prophylaxis for COVID-19); unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron's agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), as well as Regeneron's collaboration with Roche relating to the casirivimab and imdevimab antibody cocktail, to be cancelled or terminated; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection, Dupixent® (dupilumab), Praluent® (alirocumab), and REGEN-COV), other litigation and other proceedings and government investigations relating to the Company and/or its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2021. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.
Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).
1 FDA will monitor conditions to determine whether use in a geographic region is consistent with this scope of authorization, referring to available information, including information on variant susceptibility [see Microbiology/Resistance Information (15)], and CDC regional variant frequency data available at: https://covid.cdc.gov/covid-data-tracker/#variant-proportions.
View original content:
SOURCE Regeneron Pharmaceuticals, Inc. | https://www.wistv.com/prnewswire/2022/04/14/us-fda-extends-review-biologics-license-application-regen-cov-casirivimab-imdevimab-treatment-prophylaxis-covid-19/ | 2022-04-14T12:07:30 | 0 | https://www.wistv.com/prnewswire/2022/04/14/us-fda-extends-review-biologics-license-application-regen-cov-casirivimab-imdevimab-treatment-prophylaxis-covid-19/ |
- Insurance Coverage of Nurtec ODT Now Totals 96 Percent of Commercial Lives or Approximately 255 Million Lives Covered in All Channels
- Nurtec ODT Label Expanded to include Lactation Data in the Prescribing and Patient Information for Breastfeeding Mothers
NEW HAVEN, Conn., April 14, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced two updates regarding Nurtec® ODT (rimegepant), the only FDA-approved medication to both treat and prevent migraine attacks in adults.
Achievement of Broader Commercial Insurance Coverage
Biohaven has secured additional commercial insurance coverage for Nurtec ODT starting in April 2022 that expands the total number of commercial lives covered to 96 percent or approximately 255 million people via all channels.
"Ensuring that people with migraine can have access to Nurtec ODT is the first priority for Biohaven," said Chris Barrett, SVP, Managed Markets and Government Affairs. "We hear from patients daily about the impact that Nurtec ODT has on their lives and the transformative effect it has in getting them back to what's important to them. We continue to focus on ways to enhance how people with migraine can easily access Nurtec ODT."
Updated Label to Include Data from Breastfeeding Women
The U.S. Food and Drug Administration has approved a label amendment of the Nurtec ODT (rimegepant) Prescribing and Patient Information to include clinical lactation data in the Use in Specific Populations section as it relates to women who are breastfeeding.
"Migraine is the most common cause of disability among women of reproductive age and this expanded label offers treating physicians and patients a migraine medication that can be further considered for those women who are breastfeeding," said Elyse Stock, MD, Chief Medical Officer. "Our data showed that excretion of rimegepant into human milk is very low and rimegepant was well tolerated by lactating women, offering them an option for the acute and preventive treatment of migraine."
The label amendment was approved based on data from a Phase 1, single-center, open-label study evaluating the excretion of a single dose of rimegepant 75 mg in the human milk of healthy lactating women, recently published in the peer-reviewed journal, Breastfeeding Medicine, the official journal of the Academy of Breastfeeding Medicine.
Migraine affects more than 30 million women in America and is the most common cause of disability among women of reproductive age (15 – 49 years).1,2 Often for women with migraine, attacks may subside during pregnancy but resume within 4 weeks of childbirth.3 Given a lack of science-based information about migraine medication for nursing mothers, women are often apprehensive about taking their migraine medications while breastfeeding.
About Nurtec ODT
Nurtec® ODT (rimegepant) is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a quick-dissolve ODT formulation that is approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine with or without aura and the preventive treatment of episodic migraine in adults. The activity of the neuropeptide CGRP is thought to play a causal role in migraine pathophysiology. Nurtec ODT is a CGRP receptor antagonist that works by reversibly blocking CGRP receptors, thereby inhibiting the biologic activity of the CGRP neuropeptide. For more information about Nurtec ODT, visit www.nurtec.com.
Rimegepant is available as Nurtec® ODT in the United States for the acute and preventive treatment of migraine in adults. Biohaven and Pfizer Inc. recently announced a positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency recommending the marketing authorization for rimegepant 75 mg for the acute and preventive treatment of migraine. If approved, the trade name will be Vydura™ in the European Union.
Indication
NURTEC ODT orally disintegrating tablets is a prescription medicine that is used to treat migraine in adults. It is for the acute treatment of migraine attacks with or without aura and the preventive treatment of episodic migraine. It is not known if NURTEC ODT is safe and effective in children.
Important Safety Information
Do not take NURTEC ODT if you are allergic to NURTEC ODT (rimegepant) or any of its ingredients. Before you take NURTEC ODT, tell your healthcare provider (HCP) about all your medical conditions, including if you:
- have liver problems,
- have kidney problems,
- are pregnant or plan to become pregnant,
- breastfeeding or plan to breastfeed.
Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
NURTEC ODT may cause serious side effects including allergic reactions, trouble breathing and rash. This can happen days after you take NURTEC ODT. Call your HCP or get emergency help right away if you have swelling of the face, mouth, tongue, or throat or trouble breathing. This occurred in less than 1% of patients treated with NURTEC ODT.
The most common side effects of NURTEC ODT were nausea (2.7%) and stomach pain/indigestion (2.4%). These are not the only possible side effects of NURTEC ODT. Tell your HCP if you have any side effects.
You are encouraged to report side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1–800–FDA–1088 or report side effects to Biohaven at 1–833–4NURTEC.
See full Prescribing Information and Patient Information.
About Migraine
Nearly 40 million people in the U.S. suffer from migraine and the World Health Organization classifies migraine as one of the 10 most disabling medical illnesses. Migraine is characterized by debilitating attacks lasting four to 72 hours with multiple symptoms, including pulsating headaches of moderate to severe pain intensity that can be associated with nausea or vomiting, and/or sensitivity to sound (phonophobia) and sensitivity to light (photophobia). There is a significant unmet need for new treatments as more than 90 percent of people with migraine are unable to work or function normally during an attack.
CGRP Receptor Antagonism
Small molecule CGRP receptor antagonists represent a novel class of drugs for the treatment of migraine. CGRP receptor antagonists work by reversibly blocking CGRP receptors, thereby inhibiting the biologic activity of the CGRP neuropeptide. For acute treatment, this unique mode of action potentially offers an alternative to other agents, particularly for patients who have contraindications to the use of triptans or who have a poor response to triptans or are intolerant to them. CGRP signal-blocking therapies have not been associated with medication overuse headache (MOH) or rebound headaches which limits the clinical utility of other acute treatments due to increases in migraine attacks that result from frequent use.
About Biohaven
Biohaven is a commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's Neuroinnovation™ portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine and a broad pipeline of late-stage product candidates across three distinct mechanistic platforms: CGRP receptor antagonism for the acute and preventive treatment of migraine; glutamate modulation for obsessive-compulsive disorder, and spinocerebellar ataxia; and MPO inhibition for amyotrophic lateral sclerosis; Kv7 Ion Channel Activators (Kv7), and Myostatin. More information about Biohaven is available at www.biohavenpharma.com.
Forward-Looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve substantial risks and uncertainties, including statements regarding the future development, timing and potential marketing approval and commercialization of NURTEC ODT (rimegepant), Vydura™ or rimegepant. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements. Additional important factors to be considered in connection with forward-looking statements are described in the "Risk Factors" section of Biohaven's Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on February 25, 2022, and Biohaven's subsequent filings with the Securities and Exchange Commission. The forward-looking statements are made as of this date and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
NURTEC and NURTEC ODT are registered trademarks of Biohaven Pharmaceutical Ireland DAC. Neuroinnovation is a trademark of Biohaven Pharmaceutical Holding Company Ltd.
Biohaven Contact
Jennifer Porcelli
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
201-248-0741
Media Contact
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
312-961-2502
1. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1204–1222.
2. GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018;17:954–976.
3. Sances G, Granella F, Nappi RE, et al. Course of migraine during pregnancy and postpartum: A prospective study. Cephalalgia 2003;23:197–205.
View original content to download multimedia:
SOURCE Biohaven Pharmaceutical Holding Company Ltd. | https://www.1011now.com/prnewswire/2022/04/14/biohaven-announces-expanded-patient-access-nurtec-odt-rimegepant-achieving-best-in-class-commercial-insurance-coverage-label-update/ | 2022-04-14T12:07:29 | 1 | https://www.1011now.com/prnewswire/2022/04/14/biohaven-announces-expanded-patient-access-nurtec-odt-rimegepant-achieving-best-in-class-commercial-insurance-coverage-label-update/ |
Advanced identity verification technology and know your customer offerings enhance Alloy's suite of fraud solutions for banks and fintechs
NEW YORK, April 14, 2022 /PRNewswire/ -- Veriff, a global identity verification provider, today announced that it is partnering with Alloy, an identity decisioning platform that helps banks and fintech companies fight fraud and remain compliant, to bolster the company's existing identity verification and know your customer (KYC) offerings. Through this partnership, Veriff will provide Alloy customers with additional identity verification capabilities and KYC solutions to leverage during client onboarding in more than 190 countries.
Veriff's identity verification technology will be made accessible through Alloy's platform, allowing fintechs and banks to verify identities quickly and effectively during new customer onboarding while meeting their KYC requirements to ensure they remain compliant. Veriff provides best-in-class KYC verification with its video-first technology and offers an extra layer of protection for users through location verification.
"We saw the financial services industry evolve dramatically over the course of the COVID-19 pandemic, and with it, a rise in fintech fraud and stringent regulations," said Janer Gorohhov, co-founder, and CPO of Veriff. "As a result, it's never been more important for financial service institutions to be steps ahead of these bad actors. We're thrilled to partner with Alloy and work together to help banks and fintechs reestablish trust online among their customer base."
Alloy serves as a command center for identity that gives financial institutions a holistic view of each customer from the day they onboard and throughout their time with the organization. Alloy's identity decisioning platform combined with Veriff's added identity verification and compliance capabilities gives financial organizations the trust and security needed to manage their onboarding, transactions and credit decisions with confidence and reliability.
"The fraud landscape is constantly shifting, and financial institutions need to be able to adjust quickly to continue mitigating fraud," said Brian Bender, VP of Strategic Alliances at Alloy. "Our partnership with Veriff enables us to connect our clients with more identity verification and KYC offerings that meet each of their compliance needs and empower them to remain agile in the evolving market.
For more information about our partnership, please visit us at www.veriff.com.
About Alloy
Alloy is the command center for identity that covers your compliance and fraud-fighting needs. Our identity decisioning platform connects you to more than 120 data sources to help you verify identities, monitor transactions, and make credit decisions - giving you a holistic view of each customer from the day they onboard and throughout their time with your organization. From automatic decisions and fewer manual reviews to smooth onboarding, Alloy is how smart banks and fintech companies like Ally Bank, Aspiration and Brex take a closer look at the whole picture. Learn more at Alloy.com and on Twitter @UseAlloy.
About Veriff
Veriff is a global online identity verification company that enables organizations to build trust with their customers through intelligent, accurate, and automated online IDV. With the largest document specimen database on the market, Veriff's intelligent decision engine can analyze thousands of technological and behavioral variables in seconds, matching people to more than 10,000 government-issued IDs from over 190 countries. Founded in 2015, Veriff serves a global portfolio of organizations across fintech, crypto, and mobility sectors. To learn more, visit www.veriff.com.
Logo - https://mma.prnewswire.com/media/1654545/Veriff_Logo.jpg
View original content:
SOURCE Veriff | https://www.wistv.com/prnewswire/2022/04/14/veriff-identity-verification-solutions-now-available-alloy-identity-decisioning-platform-clients/ | 2022-04-14T12:07:36 | 0 | https://www.wistv.com/prnewswire/2022/04/14/veriff-identity-verification-solutions-now-available-alloy-identity-decisioning-platform-clients/ |
New appointments follow second anniversary of Launch of Capital Group's RIA Insider Hub
LOS ANGELES, April 14, 2022 /PRNewswire/ -- Capital Group announced today that it has appointed three new members to its RIA Advisory Board, bringing membership to a total of 12 practitioners, specialists and industry leaders. The advisory board, formed in conjunction with the launch of Capital Group's exclusive online hub for Registered Investment Advisors (RIAs) - RIA Insider - celebrated its two year anniversary in March.
"RIAs face a number of challenges, from increasingly squeezed margins to sustaining organic growth and planning for succession. We saw a need to help RIAs address these issues and created the RIA Advisory Board two years ago as a result," said Eric Grey, Director of the Board and RIA National Sales Director at Capital Group. "We regularly share the insights from the members of this board to the RIAs we support, on everything from client management strategies to ESG investing and the need for diverse talent pools. Our three new board members will only add to the deep bench of knowledge and experience of our existing members, enabling us to create valuable resources for the thousands of RIAs whom we support and ultimately help them manage and grow their businesses."
The new members of the RIA Advisory Board include:
- Ann Gookin, Managing Director, Investment and Firm Management, Freestone Capital Management
- Damon A. White, Chief Operating Officer and Co-founder, Evermay Wealth Management
- Jayman Yi, Founder and Chief Investment Officer, Roehl & Yi
They join the following board members, who have held their roles since March 2020:
- Howard Coleman, Chief Investment Officer / General Counsel, Coldstream Wealth Management
- David DeVoe, Managing Director and Founder, DeVoe & Company
- Catherine Farley, Chief Financial Officer & Chief Compliance Officer, Oxford Financial Group, LLC
- Brian Jones, Chairman and Financial Adviser, CJM Wealth Advisers
- Rita Lee, Partner, Cerity Partners
- Kurt Miscinski, President and CEO, Cerity Partners
- Michael Novak, Founder and Managing Director, Wellspring Financial Advisors
- Ira Rapaport, CEO & Managing Member, New England Private Wealth Advisors, LLC
- Scott Rister, Co-founder and CEO, Transcend Partner Group
One of the board's longest-tenured members, Michael Novak, Founder and Managing Director, Wellspring Financial Advisors, added "I am fortunate to have served on Capital Group's RIA Advisory Board since its inception in early 2020. Since that time, we have focused our board conversations on the most critical and strategic issues facing the RIA industry. While there is so much content out there today in the RIA and wealth management space, I truly feel the insights coming out of this group, which are captured and shared by Capital Group with the industry at large via RIA Insider, are value-add to RIAs, and can be game changers in terms of how they run their business and engage their clients."
RIA Insider offers a variety of insights, tools and resources to help RIAs manage and grow their practices, including:
- Thought leadership: Access to deep insights and practical guidance shared by board members
- Marketing Lab: An easy-to-use tool that allows RIAs to create and share personalized, branded client communications — in email, social media and PDF formats — using Capital Group's client-ready articles on topical issues like market volatility.
- Consultations: RIAs can receive highly personalized consultations from experienced Capital Group specialists, who can provide insights on topics such as portfolio construction and analysis and tax, as well as trust and estate planning. This also includes access to proprietary research and portfolio analytics from Capital Group.
- Truelytics: Members can access industry-leading business intelligence platform for wealth management to measure performance and benchmark success versus peers.
- CE credit: RIAs can earn one hour of CE credit by reading, watching or listening to content available on RIA Insider.
About Capital Group
Capital Group, home of the American Funds, has been singularly focused on delivering superior results for long-term investors using high-conviction portfolios, rigorous research and individual accountability since 1931.
As of December 31, 2021, Capital Group manages more than $2.7 trillion in equity and fixed income assets for millions of individual and institutional investors around the world. Capital Group manages equity assets through three investment groups. These groups make investment and proxy voting decisions independently. Fixed income investment professionals provide fixed income research and investment management across the Capital organization; however, for securities with equity characteristics, they act solely on behalf of one of the three equity investment groups.
For more information, visit capitalgroup.com.
Media Contact:
Sarah Christiansen, Capital Group
Sarah.Christiansen@capgroup.com
Investments are not FDIC-insured, nor are they deposits of or guaranteed by a bank or any other entity, so they may lose value.
Statements attributed to an individual represent the opinions of that individual as of the date published and do not necessarily reflect the opinions of Capital Group or its affiliates. This information is intended to highlight issues and should not be considered advice, an endorsement or a recommendation.
All Capital Group trademarks mentioned are owned by The Capital Group Companies, Inc., an affiliated company or fund. All other company and product names mentioned are the property of their respective companies.
Use of this website is intended for U.S. residents only.
American Funds Distributors, Inc., member FINRA
This content, developed by Capital Group, home of American Funds, should not be used as a primary basis for investment decisions and is not intended to serve as impartial investment or fiduciary advice.
View original content to download multimedia:
SOURCE Capital Group Companies | https://www.1011now.com/prnewswire/2022/04/14/capital-group-appoints-three-new-members-ria-advisory-board/ | 2022-04-14T12:07:37 | 0 | https://www.1011now.com/prnewswire/2022/04/14/capital-group-appoints-three-new-members-ria-advisory-board/ |
New Fund Builds on Existing Partnership and Will Create First-Ever Professorship at the Scott Polar Research Institute
LOS ANGELES, April 14, 2022 /PRNewswire/ -- Viking® (www.viking.com) today announced it has partnered with the University of Cambridge to establish a new Professorship aimed at advancing research in the field of polar environmental science. The Viking Polar Marine Geoscience Fund will endow the University's Scott Polar Research Institute with its first-ever fully funded professorship—the Viking Chair of Polar Marine Geoscience. This new post will enhance the scientific leadership at the Institute and will enable the development of new lines of research into the behavior of polar environments, including polar ice sheets, sea ice and ocean circulation. The research fund builds on Viking's existing partnership with Cambridge University's Scott Polar Research Institute, which played a significant role in developing the scientific enrichment program for the company's new expedition vessels that launched earlier this year.
Viking's first expedition vessel, the Viking Octantis®, debuted in January 2022 and spent the Austral summer in Antarctica. She is currently sailing toward the Great Lakes region, where she will be based for voyages throughout the Boreal summer. Scientists from the Scott Polar Research Institute—as well as other renowned academic institutions—have been undertaking fieldwork on board Viking Octantis and have joined voyages to share their expertise with guests. A second, identical sister ship, the Viking Polaris®, will join the fleet later in 2022.
"Our intention in creating 'the thinking person's expedition' is that every voyage should provide opportunities for scientific discovery—for our guests and for our partners," said Torstein Hagen, Chairman of Viking. "In addition to offering our guests the ability to explore some of the world's most pristine destinations in comfort and in the most responsible way possible, we are proud that our expedition vessels can also be utilized as ships of opportunity for important research that might not be possible otherwise. By establishing the Viking Polar Marine Geoscience Fund, we are also ensuring that the Scott Polar Research Institute is able to continue critical work in perpetuity—some of which will be conducted on board."
Viking has created the world's leading scientific enrichment environment in an expedition setting with the help of partnerships with esteemed scientific and academic institutions. Scientists from SPRI are part of the onboard 36-person Viking Expedition Team, a diverse group of experts that lead guests on shore excursions and provide world-class lectures on each sailing. University of Cambridge specialists were also consulted in the development of The Science Lab on Viking's expedition vessels; the 380-square-foot lab is comprehensively appointed with wet and dry laboratory facilities and supports a broad range of research. Julian Dowdeswell, Professor of Physical Geography at the University of Cambridge and former director of SPRI, serves as the Chair of the Viking Research Advisory Group, a consortium of scientific leaders from Viking's partner institutions who have been actively involved in overseeing the field research being undertaken on board.
"We are delighted with the support offered by Viking through both the endowment of a new Professorship at the Institute and the opportunity to use their expedition ships as well-equipped platforms for our scientific investigations of the icy world," said Professor Dowdeswell.
Established in 1920, the Scott Polar Research Institute's mission is to enhance the understanding of the polar regions through scholarly research and publication, educate new generations of polar researchers and communicate the history and environmental significance of the polar regions to the wider community.
In addition to SPRI, Viking's other scientific partners include:
- The Cornell Lab of Ornithology: Ornithologists are regularly on board Viking's expedition vessels, undertaking post-doctoral research on new observation methods and providing guest advice and interaction.
- National Oceanic and Atmospheric Administration (NOAA) Great Lakes Environmental Research Laboratory (GLERL): Conducts innovative research on the dynamic environments and ecosystems of the Great Lakes and coastal regions to provide information for resource use and management decisions that lead to safe and sustainable ecosystems, ecosystem services, and human communities. Viking's expedition ships have been designated official NOAA / US National Weather Service weather balloon stations, from which regular launches are undertaken.
- Norwegian Institute of Water Research, NIVA: Scientists from NIVA are engaged in cross-disciplinary research programs on water-related issues. On Viking's expedition ships, NIVA FerryBoxes are installed to sample sea and lake water to provide continuous information about chlorophyll, oxygen, temperature, salinity, microplastics and related meteorological data.
- Norwegian Polar Institute: The permitting authority for our Norwegian flagged expedition vessels, who review and approve all of Viking's expedition and science activities in Antarctica.
- Oceanites: Viking has partnered with Oceanites, an American Not-for-Profit field research entity that has led on Antarctic penguin monitoring for the past thirty years.
- The Polar Citizen Science Collective: Creates opportunities for research and public education through citizen science, leveraging the reach of polar travelers to enhance understanding and protection of the polar regions.
- The IUCN Species Survival Commission Species Monitoring Specialist Group: Viking has partnered with the group to develop marine biodiversity monitoring systems that will enable expedition vessels to collect data of value to scientists and conservationists.
With the launch of Viking Expeditions in January 2022, Viking is now exploring all seven continents. Destination-focused expeditions are currently available in Antarctica and North America's Great Lakes. Viking's expedition fleet includes the new Polar Class Viking Octantis and Viking Polaris, which host 378 guests in 189 staterooms. Designed for discovery by the same team that designed the award-winning Viking Longships® and ocean ships, the new vessels are purpose-built for expeditions, at an ideal size for safety, comfort and to support an unrivalled range of activities in remote destinations. With more indoor and outdoor viewing areas than other expedition vessels, guests are as close as possible to the most magnificent scenery on earth.
Viking was founded in 1997 and provides destination-focused journeys on rivers, oceans and lakes around the world. Designed for experienced travelers with interests in science, history, culture and cuisine, Chairman Torstein Hagen often says Viking offers guests The Thinking Person's Cruise® in contrast to mainstream cruises. With more than 250 awards to its name, Viking has been rated the #1 River Cruise Line and #1 Ocean Cruise Line by Condé Nast Traveler in the publication's 2021 Readers' Choice Awards. Viking has also been consistently rated the #1 ocean cruise line and one of the best river cruise lines in Travel + Leisure's "World's Best" Awards. For additional information, contact Viking at 1-800-2-VIKING (1-800-284-5464) or visit www.viking.com. For Viking's award-winning enrichment channel, visit www.viking.tv.
View original content to download multimedia:
SOURCE Viking | https://www.wistv.com/prnewswire/2022/04/14/viking-endows-new-chair-polar-marine-geoscience-university-cambridge/ | 2022-04-14T12:07:43 | 0 | https://www.wistv.com/prnewswire/2022/04/14/viking-endows-new-chair-polar-marine-geoscience-university-cambridge/ |
The Markey Cancer Center joins Caris' extensive network of leading cancer institutions committed to utilizing clinical data to advance patient care and outcomes
IRVING, Texas, April 14, 2022 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize health care, announced today that The University of Kentucky Markey Cancer Center (Markey) has joined Caris' Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients.
The UK Markey Cancer Center was founded in 1983 and is a dedicated matrix cancer center established as an integral part of the University of Kentucky and the UK HealthCare enterprise. Markey has been a National Cancer Institute-designated cancer center since 2013, the only one in Kentucky and one of just 71 in the country. This designation allows Markey to receive research funding and many other opportunities available only to the nation's best cancer centers. Additionally, the UK Markey Cancer Center has been ranked in the Top 50 cancer hospitals in the country by U.S. News & World Report for the past five years.
"Markey Cancer Center is thrilled to join the Caris Precision Oncology Alliance and partner with other clinical institutions and researchers dedicated to improving cancer care," said Mark Evers, M.D., FACS, Director, Markey Cancer Center. "This partnership offers an unparalleled opportunity for all cancer patients to benefit from Caris' comprehensive molecular profiling, by allowing our physicians to better understand, detect and treat cancer."
The clinical programs and services of the Markey Cancer Center are integrated with the UK Albert B. Chandler Hospital. The cancer specialty teams work together with UK Chandler Hospital departments and divisions to provide primary patient care and support services as well as advanced specialty care with applicable clinical trials. Markey is among the few institutions nationwide providing multidisciplinary care through Clinical Care and Research Teams (CCARTs). Major CCARTs include breast, gynecologic, gastrointestinal, head and neck, lung, brain, hematologic and genitourinary cancers.
"Markey Cancer Center uses the latest research programs to offer breakthrough diagnostics, treatments and therapies to their patients," said Chadi Nabhan, M.D., MBA, FACP, Chairman of the Caris Precision Oncology Alliance. "Their focus on providing world-class care through innovation and research builds upon the POA's goal to promote broad-based collaboration among our member institutions in precision oncology research to improve outcomes of all patients with cancer."
The Caris Precision Oncology Alliance includes 62 cancer centers and academic institutions. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through Caris molecular profiling, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker directed trials sponsored by biopharma. Additionally, as a member of the POA, institutions have access to Caris CODEai™, the most comprehensive data solution in the industry with cancer treatment information and clinical outcomes data for over 275,000 patients covering over 1 million data points per patient.
About Caris Life Sciences
Caris Life Sciences® (Caris) is the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare and improve patient outcomes. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale clinico-genomic database and cognitive computing needed to analyze and unravel the molecular complexity of disease. This information provides an unmatched resource and the ideal path forward to conduct the basic, fundamental research to accelerate discovery for detection, diagnosis, monitoring, therapy selection and drug development to improve the human condition.
With a primary focus on cancer, Caris' suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps patients, physicians and researchers better detect, diagnose and treat patients. Caris' latest advancement, which is currently available within its Precision Oncology Alliance, is a blood-based, circulating nucleic acids sequencing (cNAS) assay that combines comprehensive molecular analysis (Whole Exome and Whole Transcriptome Sequencing from blood) and serial monitoring – making it the most powerful liquid biopsy assay ever developed.
Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Denver, Tokyo, Japan and Basel, Switzerland. Caris provides services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com or follow us on Twitter (@CarisLS).
About Markey Cancer Center
The UK Markey Cancer Center, founded in 1983, is a dedicated matrix cancer center established as an integral part of the University of Kentucky and the UK HealthCare enterprise. Markey was designated by the National Cancer Institute (NCI) in July 2013, the only one in Kentucky and one of just 71 in the country. This designation allows Markey to receive research funding and many other opportunities available only to the nation's best cancer centers. Additionally, the UK Markey Cancer Center has been ranked in the Top 50 cancer hospitals in the country by U.S. News & World Report for the past five years. The clinical programs and services of the UK Markey Cancer Center are integrated with the UK Albert B. Chandler Hospital departments and divisions to provide primary patient care and support services as well as advanced specialty care with applicable clinical trials. All diagnostic services, clinical and pathology laboratories, operating rooms, emergent and intensive care, and radiation therapy services are also provided to cancer patients through UK Chandler Hospital. The UK Markey Cancer Center is among the few institutions nationwide providing multidisciplinary care through Clinical Care and Research Teams (CCARTs). Major CCARTs include breast, gynecologic, gastrointestinal, head and neck, lung, brain, hematologic and genitourinary cancers. Markey is organized in three thematic research programs: Molecular and Cellular Oncology (MCO); Cancer Prevention and Control (CP); and Translational Oncology (TO). In addition, the UK Markey Cancer Center has five established shared resource facilities: Biospecimen Procurement and Translational Pathology (BPTP SRF); Biostatistics and Bioinformatics (BB SRF); Cancer Research Informatics (CRI SRF); Flow Cytometry and Immune Monitoring (FCIM SRF); and Redox Metabolism (RM SRF). Clinical Protocol and Data Management services support and oversee the development and facilitation of clinical trials.
Caris Life Sciences Media Contact:
Ann Obeney
Vice President, Corporate Communications
aobeney@carisls.com
469-550-1589
Markey Cancer Center Media Contact:
Mallory Olson
Public Relations Officer, UK Public Relations & Strategic Communications
mallory.olson@uky.edu
859-257-1076
View original content to download multimedia:
SOURCE Caris Life Sciences | https://www.1011now.com/prnewswire/2022/04/14/caris-precision-oncology-alliance-welcomes-university-kentucky-markey-cancer-center/ | 2022-04-14T12:07:44 | 0 | https://www.1011now.com/prnewswire/2022/04/14/caris-precision-oncology-alliance-welcomes-university-kentucky-markey-cancer-center/ |
NEW YORK, April 14, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Vertiv Holdings Co ("Vertiv" or the "Company") (NYSE: VRT) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Vertiv investors who were adversely affected by alleged securities fraud between April 28, 2021 and February 23, 2022. Follow the link below to get more information and be contacted by a member of our team:
VRT investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) the Company could not adequately respond to supply chain issues and inflation by increasing its prices; (2) as a result of the increasing costs, Vertiv's earnings would be adversely impacted; and (3) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
WHAT'S NEXT? If you suffered a loss in Vertiv during the relevant time frame, you have until May 23, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
View original content to download multimedia:
SOURCE Levi & Korsinsky, LLP | https://www.wistv.com/prnewswire/2022/04/14/vrt-lawsuit-alert-levi-amp-korsinsky-notifies-vertiv-holdings-co-investors-class-action-lawsuit-upcoming-deadline/ | 2022-04-14T12:07:50 | 1 | https://www.wistv.com/prnewswire/2022/04/14/vrt-lawsuit-alert-levi-amp-korsinsky-notifies-vertiv-holdings-co-investors-class-action-lawsuit-upcoming-deadline/ |
NEW YORK, April 14, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Celsius Holdings, Inc. ("Celsius" or the "Company") (NASDAQ: CELH) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Celsius investors who were adversely affected by alleged securities fraud between August 12, 2021 and March 1, 2022. Follow the link below to get more information and be contacted by a member of our team:
CELH investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) the Company had improperly recorded expenses for non-cash share-based compensation for second and third quarters of 2021; (2) as a result, the Company's financial statements for those periods would be restated, including to report a net loss for the third quarter of 2021; (3) there was a material weakness in Celsius's internal controls over financial reporting; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
WHAT'S NEXT? If you suffered a loss in Celsius during the relevant time frame, you have until May 16, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
View original content to download multimedia:
SOURCE Levi & Korsinsky, LLP | https://www.1011now.com/prnewswire/2022/04/14/celh-lawsuit-alert-levi-amp-korsinsky-notifies-celsius-holdings-inc-investors-class-action-lawsuit-upcoming-deadline/ | 2022-04-14T12:07:51 | 1 | https://www.1011now.com/prnewswire/2022/04/14/celh-lawsuit-alert-levi-amp-korsinsky-notifies-celsius-holdings-inc-investors-class-action-lawsuit-upcoming-deadline/ |
PERU, Ill., April 14, 2022 /PRNewswire/ -- This week CL Enterprises announced the hiring of key executives across several of its subsidiary companies to enhance management depth, business capabilities, and continued growth.
Blake Rohrabaugh joins the Tangled Roots Brewing Company as CEO, with a particular focus on driving operational excellence and growth across the company's expanding portfolio of restaurants in Illinois. A graduate of the University of Illinois, Blake brings a long and successful track record of building strong hospitality businesses. Until recently Director of Operations at Atomic Hospitality Group, he was formerly VP Operations and Beverage Innovation at the Bar Louie restaurant brand, which grew exponentially during his tenure.
As the Tangled Roots business continues to grow its brand, Keith Pearse assumes leadership of the beverage business, as CEO of TRBC Brewing and the Chicago Beer Company. His deep, two decades of beer industry experience will enhance the business across all dimensions.
Michelle Scott-Christ is joining Starved Rock Wood Products as Chief Financial Officer, at a time when the company is rapidly expanding its business. With the opening of its new showroom in Glenview, the company is experiencing significant growth in cabinet sales across Chicagoland, as well as securing sizeable new contracts with regional and national builders and contractors.
Michelle graduated from University of Dubuque with a bachelors degree in Accounting and an MBA in Business Admin. Throughout her career, she has worked in various industries and held numerous responsibilities in both private and public sectors. Initially she began in public accounting. Then twelve years ago, she joined her first manufacturing company and has been growing her industrial depth ever since, holding key leadership roles in accounting and operations for a company in the medical device industry and another in the automotive traffic control industry.
Revv Aviation sees the arrival of two senior executives: Shay Brokemond becomes CFO, while Danny Looney is joining the company as Director of Operations.
Shay has been working with Revv Aviation as a financial consultant over the past year, as the company acquired several existing Fixed Based Operators (FBOs) to create the new Revv Aviation company. An engineering graduate of Georgia Institute of Technology, with an MBA from Northwestern, Shay first came to Revv from the world of venture capital and private equity (11.2 Ventures LLC). Before that she enjoyed a long and successful career at investment bank William Blair, where she was Managing Director.
A veteran of the aviation business, Looney brings over thirty-five years of experience, as a senior executive in companies such as Sky King and Choice Air, and also as a consultant to many other businesses and governments within the aviation and aerospace sectors. Looney has expertise in many of the services Revv offers: FAA Certifications, start-up operations, airline training solutions, aircraft evaluations and acquisitions, marketing and sales, compliance, charter support and brokerage, FAA consultations and business development.
CLE President, Hinesh Patel, welcomed all the hires as an exciting new chapter in the development of the CL Enterprises Group. He stated, "This is an incredible time for the portfolio of businesses. We have unprecedented levels of growth. These dynamic executives will enable us to continue building business value and expand our ability to serve customers."
"2022 is shaping up to be a very exciting year for the company," Patel added. "Our Small Towns. Big Ideas vision has really helped us create a point of difference in the market, and we are seeing strong growth in our aviation business, our wood manufacturing business and, after two challenging years, a much more buoyant hospitality and restaurant business. We want to ensure we steer this growth in a sustainable way, and so we are delighted to be able to add such a wealth of experience and talent to the management teams of all different companies."
CL Enterprises is the holding company for the Carus-Limberger family.
View original content to download multimedia:
SOURCE CL Enterprises | https://www.1011now.com/prnewswire/2022/04/14/cl-enterprises-welcomes-new-executives-response-strong-growth/ | 2022-04-14T12:07:57 | 1 | https://www.1011now.com/prnewswire/2022/04/14/cl-enterprises-welcomes-new-executives-response-strong-growth/ |
Conference Call Scheduled for 10:00 a.m. Eastern Time
NEW YORK, April 14, 2022 /PRNewswire/ -- W. P. Carey Inc. (NYSE: WPC), a net lease real estate investment trust, announced today that it will release its financial results for the first quarter ended March 31, 2022 before the market opens on Friday, April 29, 2022.
The company will host a conference call and live audio webcast to discuss its financial results at 10:00 a.m. Eastern Time the same day, details of which are provided below.
Live Conference Call and Audio Webcast
Date/Time: Friday, April 29, 2022 at 10:00 a.m. Eastern Time
Call-in Number: 1 (877) 465-1289 (U.S.) or +1 (201) 689-8762 (international)
Please dial in at least 10 minutes prior to the start time.
Live Audio Webcast and Replay: www.wpcarey.com/earnings
W. P. Carey Inc.
W. P. Carey ranks among the largest net lease REITs with an enterprise value of approximately $22 billion and a diversified portfolio of operationally critical commercial real estate that includes 1,304 net lease properties covering approximately 156 million square feet as of December 31, 2021. For nearly five decades, the company has invested in high-quality single-tenant industrial, warehouse, office, retail and self-storage properties subject to long-term net leases with built-in rent escalators. Its portfolio is located primarily in the U.S. and Northern and Western Europe and is well-diversified by tenant, property type, geographic location and tenant industry.
www.wpcarey.com
Institutional Investors:
Peter Sands
1 (212) 492-1110
institutionalir@wpcarey.com
Individual Investors:
W. P. Carey Inc.
1 (212) 492-8920
ir@wpcarey.com
Press Contact:
Anna McGrath
1 (212) 492-1166
amcgrath@wpcarey.com
View original content to download multimedia:
SOURCE W. P. Carey Inc. | https://www.wistv.com/prnewswire/2022/04/14/w-p-carey-inc-release-first-quarter-2022-financial-results-friday-april-29-2022/ | 2022-04-14T12:07:57 | 0 | https://www.wistv.com/prnewswire/2022/04/14/w-p-carey-inc-release-first-quarter-2022-financial-results-friday-april-29-2022/ |
SAN ANTONIO, April 14, 2022 /PRNewswire/ -- Clear Channel Outdoor Holdings, Inc. (NYSE: CCO) (the "Company") will release 2022 first quarter results before the market opens on Tuesday, May 10, 2022, by 7:00 a.m. and will host a conference call to discuss the results at 8:30 a.m. Eastern Time.
The conference call number is 1-844-200-6205 (U.S. callers) and 1-929-526-1599 (international callers), and the access code for both is 056622. A live audio webcast of the conference call will be available on the "Events and Presentations" section of the Company's website (www.investor.clearchannel.com). The related earnings materials, including reconciliations of any non-GAAP financial measures to GAAP financial measures and any other applicable disclosures, will be available on the "Financials" section of the Company's website after 7:00 a.m. Eastern Time.
Approximately two hours after the live conference call, a replay of the webcast will be available for a period of thirty days on the "Events and Presentations" section of the Company's website.
About Clear Channel Outdoor Holdings, Inc.
Clear Channel Outdoor Holdings, Inc. ("CCOH") (NYSE: CCO) is at the forefront of driving innovation in the out-of-home advertising industry. Our dynamic advertising platform is broadening the pool of advertisers using our medium through the expansion of digital billboards and displays and the integration of data analytics and programmatic capabilities that deliver measurable campaigns that are simpler to buy. By leveraging the scale, reach and flexibility of our diverse portfolio of assets, we connect advertisers with millions of consumers every month across more than 500,000 print and digital displays in 26 countries.
View original content to download multimedia:
SOURCE Clear Channel Outdoor Holdings, Inc. | https://www.1011now.com/prnewswire/2022/04/14/clear-channel-outdoor-holdings-inc-announces-date-2022-first-quarter-earnings-release-conference-call/ | 2022-04-14T12:08:04 | 1 | https://www.1011now.com/prnewswire/2022/04/14/clear-channel-outdoor-holdings-inc-announces-date-2022-first-quarter-earnings-release-conference-call/ |
New Chief Revenue Officer and Head of People will help propel Wavelo's global growth
TORONTO, April 14, 2022 /PRNewswire/ - Today Wavelo, a disruptive telecom software provider and a division of Tucows (NASDAQ: TCX) (TSX: TC), proudly announced that it has added two seasoned executives to the company's leadership team: Michael Koenig as Chief Revenue Officer (CRO) and Karaka Leslie as Head of People.
With decades of combined experience in their respective fields, Michael and Karaka are vital additions to the Wavelo team and will be critical in helping propel the company's global growth.
"Wavelo is on a mission to revolutionize a historically rigid industry. We provide flexible software to help telecom operators maximize value from their existing networks, which ultimately provides their customers with a better experience," said Justin Reilly, Chief Executive Officer of Wavelo. "This is a titanic industry to tackle and we need the best and brightest working on our team. That's exactly who Michael and Karaka are. We dream big and so do they. With years of extensive, proven experience between them, we are incredibly fortunate to have them on our team and are confident and excited about the work that they will do."
Wavelo launched in early 2022, driven by its partnerships with DISH Wireless and Ting Internet. To support the company's ambitious plans for growth, Michael and Karaka will bring their own unique and valued experience to the leadership team:
- Michael Koenig, Chief Revenue Officer: Michael is a highly accomplished and diversified technology leader with over 15 years of software as a service (SaaS) experience and a broader focus on building high-performing, disruptive software solutions. In his early career, Michael helped build Automattic—the company responsible for creating dozens of beloved platforms, such as WordPress. He has also held roles as the Chief Operating Officer at both Sweet and Time Doctor. In his new position, Michael will lead Wavelo's revenue management practice, touching on operations, sales and corporate development.
- Karaka Leslie, Head of People: Karaka is a highly respected leader, bringing over 15 years of progressive strategic people and human capital management experience to this position. She comes to Wavelo after two years as the Head of Strategic Initiatives at Tucows, where she leveraged employee feedback and market research to spearhead a variety of new people programs that made tangible impacts on company culture. In her new role, Karaka will oversee Wavelo's people division, introducing world-class practices that will enable teams to do their best work while scaling alongside the company as it grows.
The Wavelo executive team also includes: Hanno Liem, Chief Technology Officer (CTO); Tom McGillivray, Vice-President of Customer Experience (CX); Justin Reilly, Chief Executive Officer (CEO); and Neil Shah, Chief Product Officer (CPO).
To learn more about Wavelo, the company's mission or its flexible software solutions, please visit wavelo.com.
Wavelo, a division of Tucows (NASDAQ: TCX, TSX: TC), is a modern, cloud-based platform designed to radically simplify OSS/BSS technology management and improve internet access worldwide. Serving communication service providers globally, Wavelo offers a suite of flexible software to enable mobile and internet access, provisioning, billing, subscriptions, and more. Connecting disparate business and operational systems and seamlessly integrating into operators' existing infrastructure, Wavelo enables operators to keep pace with network innovation and focus on providing a superior customer experience. Learn more at wavelo.com.
Tucows helps connect more people to the benefit of internet access through communications service technology, domain services, and fiber-optic internet infrastructure.
Ting (https://ting.com/internet) delivers fixed fiber Internet access with outstanding customer support. Wavelo (http://wavelo.com) is a telecommunications software suite for service providers that simplifies the management of mobile and internet network access, provisioning, billing and subscription, developer tools, and more. OpenSRS (https://opensrs.com), Enom (https://www.enom.com) and Ascio (https://ascio.com) combined manage approximately 25 million domain names and millions of value-added services through a global reseller network of over 35,000 web hosts and ISPs. Hover (https://hover.com) makes it easy for individuals and small businesses to manage their domain names and email addresses. More information can be found on Tucows' corporate website (https://tucows.com).
View original content to download multimedia:
SOURCE Tucows Inc. | https://www.wistv.com/prnewswire/2022/04/14/wavelo-expands-leadership-team-with-two-new-executive-hires/ | 2022-04-14T12:08:06 | 1 | https://www.wistv.com/prnewswire/2022/04/14/wavelo-expands-leadership-team-with-two-new-executive-hires/ |
ALPINE, Utah, April 14, 2022 /PRNewswire/ -- The Clemson University Tigers and SponsorCX announce a partnership that enhances the way the athletic department will manage sponsor relationships going forward. Through this partnership, SponsorCX will provide its software services to the university paving the way for an engaging sponsorship management solution.
After bringing their multi-media rights in house, the university has been looking for a unique and innovative way to ensure their partnership program is organized and efficient while providing best-in-class service to sponsors.
"It's an honor to partner with one of the most iconic collegiate athletic departments in the country," says Jason Smith, founder and CEO of SponsorCX. "Clemson University is a gold-standard institution that demands the highest performance both in competition and in the classroom. This approach is no different in their attitude towards taking care of corporate sponsors. We're excited to help them take their sponsorship program to the next level."
Serving clients across various industries, including sports, entertainment, events, arts, and non-profits, SponsorCX provides a suite of online automated sponsorship management tools, including:
- Customer Relationship Management (CRM)
- Fulfillment
- Inventory management
"SponsorCX truly checked all the boxes for Clemson," said Mike Money, Assistant Athletic Director. "It met all our needs from a functionality standpoint, the pricing was very fair, and they have a strong commitment to customer service which was extremely important to us. We are excited about our partnership and future with SponsorCX."
About SponsorCX
SponsorCX is a leader in sponsorship management within the sports, entertainment, causes, arts, and events industries. It is a complete sponsorship management tool to assist in managing sales, fulfillment, and inventory to maximize sponsorship revenue. The company was founded in 2017, and continues to grow rapidly as the newest and most innovative sponsorship software solution in the industry. Learn more at sponsorcx.com.
About the Clemson University Tigers Clemson University is home to one of the nation's most prominent athletic and academic programs, located on Lake Hartwell in Clemson, South Carolina, and is home to more than 26,000 undergraduate and graduate students. Clemson and IPTAY support nearly 500 student-athletes across 21 varsity sports. Clemson's football program, which won National Championships in 1981, 2016 and 2018, draws more than 500,000 people to campus annually. Clemson teams have won seven team national Championships, including Men's Soccer in 2021. The athletic department has seen graduation success rates among student-athletes above 90 percent for seven years running. Clemson and the Greenville-Spartanburg DMA is one of the most engaged areas in the nation related to college sports.
Contact: admin@sponsorcx.com
View original content to download multimedia:
SOURCE SponsorCX | https://www.1011now.com/prnewswire/2022/04/14/clemson-tigers-choose-sponsorcx-its-software-solution-sponsorship-management/ | 2022-04-14T12:08:11 | 1 | https://www.1011now.com/prnewswire/2022/04/14/clemson-tigers-choose-sponsorcx-its-software-solution-sponsorship-management/ |
EXTON, Pa., April 14, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter 2022 financial results before the market opens on Thursday, April 28, 2022, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. To participate on the call, please dial 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is 6690124.
A live broadcast of the conference call will be available at the Company's website, www.westpharma.com, in the "Investors" section. Management will refer to a slide presentation during the call, which will be made available on the day of the call. To view the presentation, select "Presentations" in the "Investors" section of the Company's website.
An online archive of the broadcast will be available at the site three hours after the live call and will be available through Thursday, May 5, 2022, by dialing 855-859-2056 (U.S.) or 404-537-3406 (International). The conference ID is 6690124.
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With approximately 10,000 team members across 50 sites worldwide, West helps support our customers by delivering over 45 billion components and devices each year.
Headquartered in Exton, Pennsylvania, and in business for nearly a century, West in its fiscal year 2021 generated $2.83 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.
All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.
View original content to download multimedia:
SOURCE West Pharmaceutical Services, Inc. | https://www.wistv.com/prnewswire/2022/04/14/west-host-first-quarter-2022-conference-call/ | 2022-04-14T12:08:15 | 0 | https://www.wistv.com/prnewswire/2022/04/14/west-host-first-quarter-2022-conference-call/ |
CHICAGO, April 14, 2022 /PRNewswire/ -- Conagra Brands, Inc. (NYSE: CAG) today announced that its board of directors approved a quarterly dividend payment of $0.3125 per share of CAG common stock to be paid on June 1, 2022 to stockholders of record as of the close of business on April 29, 2022.
About Conagra Brands
Conagra Brands, Inc. (NYSE: CAG), headquartered in Chicago, is one of North America's leading branded food companies. Guided by an entrepreneurial spirit, Conagra Brands combines a rich heritage of making great food with a sharpened focus on innovation. The company's portfolio is evolving to satisfy people's changing food preferences. Conagra's iconic brands, such as Birds Eye®, Marie Callender's®, Banquet®, Healthy Choice®, Slim Jim®, Reddi-wip®, and Vlasic®, as well as emerging brands, including Angie's® BOOMCHICKAPOP®, Duke's®, Earth Balance®, Gardein®, and Frontera®, offer choices for every occasion. For more information, visit www.conagrabrands.com.
For more information, please contact:
MEDIA: Mike Cummins
312-549-5257
Michael.Cummins@conagra.com
INVESTORS: Bayle Ellis
312-549-5958
IR@conagra.com
View original content to download multimedia:
SOURCE Conagra Brands, Inc. | https://www.1011now.com/prnewswire/2022/04/14/conagra-brands-announces-quarterly-dividend-payment/ | 2022-04-14T12:08:18 | 0 | https://www.1011now.com/prnewswire/2022/04/14/conagra-brands-announces-quarterly-dividend-payment/ |
TAMPA, Fla. (WFLA) — A North Tampa family is safe after escaping a fire that broke out at their home early Thursday morning.
The Tampa Fire Rescue responded to a fire in the 10000 block of N. 14th Street around 1:45 a.m., and saw flames and smoke on the south side of the home.
Officials said the home’s residents were able to escape. Crews tried to save the cat, but it died in the fire.
The fire was under control in 20 minutes. No injuries were reported.
Officials said the American Red Cross was called to assist the family.
The cause of the fire remains under investigation. | https://www.wfla.com/news/hillsborough-county/family-escapes-north-tampa-house-fire-cat-dies/ | 2022-04-14T12:08:22 | 0 | https://www.wfla.com/news/hillsborough-county/family-escapes-north-tampa-house-fire-cat-dies/ |
The brand honors cannabis-loving fans, launching flavor to accentuate any buzz with smoky, herbal flavors available starting April 18
DALLAS, April 14, 2022 /PRNewswire/ -- Let's be blunt: Wingstop Inc. (Nasdaq: WING) knows their wings are the ultimate munchies and that 4/20 is a sacred holiday for their guests. So, in celebration of the most chill day of the year, the wing joint is honoring their cannabis-loving fans with a limited-edition, 4/20-inspired flavor called Blazed & Glazed, available starting on April 18 in restaurants nationwide.
Crafted with a blend of hemp seeds, terpenes, strawberry and cayenne pepper, the new flavor is designed to taste like 4/20 – capturing the herbal notes of the holiday and may even produce a mouth-tingling sensation – although the flavor won't actually get you high.
"Some of our biggest fans aren't just pairing their favorite wings with seasoned fries," said Marisa Carona, Chief Growth Officer. "And while many brands are starting to give a nod to 4/20, we're going higher than ever this year by dedicating an entire flavor to it. As the cannabis industry grows, so does Wingstop's desire to engage this audience."
While Wingstop is no stranger to weed culture, this is the first year the brand has created a custom flavor in honor of the holiday. Wingstop's Blazed & Glazed flavor is available in restaurants nationwide starting on April 18 through 22, or while supplies last, on Wingstop.com and the Wingstop app. The flavor, and Wingstop food truck, will also meet celebrants at Hippie Hill in San Francisco's Golden Gate Park on April 20 to infuse flavor into the festival.
About Wingstop
Founded in 1994 and headquartered in Dallas, TX, Wingstop Inc. (NASDAQ: WING) operates and franchises more than 1,700 locations worldwide. The Wing Experts are dedicated to Serving the World Flavor through an unparalleled guest experience and use of a best-in-class technology platform, all while offering classic and boneless wings, tenders, and Thigh Bites, always cooked to order and hand sauced-and-tossed in fans' choice of 11 bold, distinctive flavors. Wingstop's menu also features signature sides including fresh-cut, seasoned fries and freshly-made ranch and bleu cheese dips.
In fiscal year 2021, Wingstop's system-wide sales increased 20.2% to approximately $2.3 billion, marking the 18th consecutive year of same store sales growth. With a vision of becoming a Top 10 Global Restaurant Brand, its system is comprised of independent franchisees, or brand partners, who account for approximately 98% of Wingstop's total restaurant count of 1,731 as of December 25, 2021. During the fiscal quarter ended December 25, 2021, Wingstop generated 61.3% of sales via digital channels including Wingstop.com and the Wingstop app. Over the next three years, Wingstop intends to increase digital sales through continued investments in its technology platform and scaling its platform globally.
A key to this business success and consumer fandom stems from The Wingstop Way, which includes a core value system of being Authentic, Entrepreneurial, Service-minded, and Fun. The Wingstop Way extends to the brand's environmental, social and governance platform as Wingstop seeks to provide value to all stakeholders.
Rounding out a strong year in 2021, the Company was ranked #1 on Technomic 500's "Fastest Growing Franchise" and #22 on Entrepreneur Magazine's "Franchise 500," maintained its certification as a Great Place to Work, was named as a finalist for The Innovation SABRE Award's Best New Product/Brand Launch category for its Thighstop campaign, and named to Fast Company's "The World's Most Innovative Companies" list ranking #4 in the dining category.
For more information visit www.wingstop.com or www.wingstop.com/own-a-wingstop and follow @Wingstop on Twitter, Instagram, Facebook, and TikTok. Learn more about Wingstop's involvement in its local communities at www.wingstopcharities.org.
Media Contact
Maddie Lupori
Media@wingstop.com
View original content to download multimedia:
SOURCE Wingstop Restaurants Inc. | https://www.wistv.com/prnewswire/2022/04/14/wingstop-introduces-limited-time-420-inspired-flavor-blazed-amp-glazed/ | 2022-04-14T12:08:23 | 0 | https://www.wistv.com/prnewswire/2022/04/14/wingstop-introduces-limited-time-420-inspired-flavor-blazed-amp-glazed/ |
OAKLAND, Calif., April 14, 2022 /PRNewswire/ -- "After repeated requests to the Stockton Police Department for a position statement regarding their justification for the killing of an unarmed 54 year old Grandmother on 2-22-22, they finally responded by posting an April 7, 2022 public relations piece with select body cam clips of the incident in an attempt to twist the narrative to their favor," said Gary Gwilliam, Esq, with Gwilliam Ivary Chiosso Cavalli & Brewer, the Law Firm retained by the family of Tracy Gaeta.
"Nationally recognized standards prohibit officers from firing at moving vehicles absent the most compelling circumstances. Stockton PD has quickly moved to stand by Officer Ribera rather than hold him accountable. When listening to the select video clips posted by the Stockton Police Department, one can clearly hear over 30 shots being discharged in under a minute," said Jayme Walker, Esq. of Gwilliam Ivary Chiosso Cavalli & Brewer who continued, "We are going to fight for this family".
The Stockton PD noted at 42 seconds in their PR posting that "The officer notified dispatch that the driver was possibly a Black male, 50 years in age,…".
Angelina Austin, Esq. with Gwilliam Ivary Chiosso Cavalli & Brewer said, "Like too many black women across this country, Tracy Gaeta is yet another victim of preventable police violence".
Alex Gaeta Jr., son of Tracy Gaeta stated, "I love my mom and miss her. She was such a warm hearted, kind soul woman. She always saw the light in others and was such a delight to be around. I am so distraught and beside myself trying to understand why such a violent excessive use of force was used to handle this situation. I just want justice for my mother".
Tressie Gaeta, daughter of Tracy Gaeta, said, "My mother, Tracy Gaeta, was a loving, caring mother and grandmother to my children and to everyone that she knew. She was the life of the party, and always knew how to put a smile on your face. She loved spending time with her grandchildren taking them to beaches and amusement parks. My children and I are going to miss her tremendously. I hope that we can find justice because she did not deserve to die like that".
###
Contact: Gary Gwilliam ggwilliam@giccb.com , Jayme Walker jwalker@giccb.com and Angelina Austin aaustin@giccb.com through email or by calling 510-832-5411
View original content to download multimedia:
SOURCE The Law Firm of Gwilliam Ivary Chiosso Cavalli & Brewer | https://www.1011now.com/prnewswire/2022/04/14/controversial-police-shooting-results-death-beloved-grandmother/ | 2022-04-14T12:08:24 | 1 | https://www.1011now.com/prnewswire/2022/04/14/controversial-police-shooting-results-death-beloved-grandmother/ |
TAMPA, Fla. (WFLA) — Authorities are investigating after a pedestrian was struck and killed by a vehicle in Tampa on Thursday morning.
The deadly collision happened in the area of Hillsborough Avenue and 34th Street.
The eastbound lanes of Hillsborough Avenue will be closed until further notice.
This story is developing and will be updated. | https://www.wfla.com/news/local-news/pedestrian-hit-killed-by-vehicle-on-hillsborough-avenue-in-tampa/ | 2022-04-14T12:08:28 | 0 | https://www.wfla.com/news/local-news/pedestrian-hit-killed-by-vehicle-on-hillsborough-avenue-in-tampa/ |
Joins Over Ninety Federal Agencies Releasing Equity Action Plans
WASHINGTON, April 14, 2022 /PRNewswire/ -- The U.S. Consumer Product Safety Commission (CPSC) announced a public forum for all interested stakeholders to discuss its newly released Equity Action Plan, which was created in response to Executive Order 13985 – "Advancing Racial Equity and Support for Underserved Communities Through the Federal Government." The CPSC Equity Action Plan Roundtable will give the public an opportunity to discuss steps the agency can take to better address existing racial disparities in injury rates and deaths caused by certain consumer products. The CPSC Equity Action Plan Roundtable will also focus on best practices to learn from, and communicate with, underserved communities regarding product safety hazards.
The CPSC Equity Action Plan Roundtable, which will be formally noticed in the Federal Register in the coming days, will be held at the CPSC in Bethesda, Maryland, on May 25, 2022, at 1 p.m., with an option for virtual participation. It will be open to the public. The CPSC Equity Action Plan Roundtable will allow all interested stakeholders to provide CPSC staff with feedback on the newly released Equity Action Plan to assist CPSC in protecting the public via regulation, enforcement, and education from unreasonable risks of injury and death involving consumer products.
"In an effort to equitably serve all consumers, CPSC is focused on improving our data collection to better assess disparities and our efforts to reach the communities that are most in need," said CPSC Chair Alex Hoehn-Saric. "I encourage everyone to participate in the CPSC Equity Action Plan Roundtable to help us listen to, and learn from, those most impacted by these inequities."
The agency's Equity Action Plan lays out challenges and barriers to achieving more equitable outcomes with respect to product safety and steps the agency can take to address the identified barriers. The identified issues include that Black Americans are a higher risk of death from generator-related carbon monoxide poisoning, pool and spa drowning, and residential fires.
In addition, CPSC's Equity Action Plan commits to agency-wide staff training about equity, public education about hazards, improvements in the quality of our data about injuries, seeking to expand personnel with expertise in underserved communities, standards development (both voluntary and mandatory) to prevent hazards, new demographically informed, targeted enforcement and investigation actions, outreach to impacted communities to gather information and feedback, and new research to learn more about underserved communities.
CPSC will provide more information about recent notable equity-related accomplishments and new equity initiatives in the weeks to come. For details, questions, and registration information about the CPSC Equity Action Plan Forum please contact CPSC's Consumer Ombudsman at consumerombudsman@cpsc.gov.
To read the full CPSC Equity Action Plan
To learn more about government-wide equity efforts: https://www.performance.gov/equity
CPSC is also working on advancing the agency's internal diversity, equity, inclusion, and accessibility (DEIA) efforts in response to Executive Order 14035 (Federal Register :: Diversity, Equity, Inclusion, and Accessibility in the Federal Workforce).
About the U.S. CPSC
The U.S. Consumer Product Safety Commission (CPSC) is charged with protecting the public from unreasonable risk of injury or death associated with the use of thousands of types of consumer products. Deaths, injuries, and property damage from consumer product-related incidents cost the nation more than $1 trillion annually. CPSC's work to ensure the safety of consumer products has contributed to a decline in the rate of injuries associated with consumer products over the past 50 years.
Federal law prohibits any person from selling products subject to a Commission ordered recall or a voluntary recall undertaken in consultation with the CPSC.
For lifesaving information:
- Visit CPSC.gov.
- Sign up to receive our e-mail alerts.
- Follow us on Facebook, Instagram @USCPSC and Twitter @USCPSC.
- Report a dangerous product or a product-related injury on www.SaferProducts.gov.
- Call CPSC's Hotline at 800-638-2772 (TTY 301-595-7054).
- Contact a media specialist.
View original content to download multimedia:
SOURCE U.S. Consumer Product Safety Commission | https://www.1011now.com/prnewswire/2022/04/14/cpsc-announces-stakeholder-roundtable-may-25-2022-hear-public-new-equity-action-plan/ | 2022-04-14T12:08:31 | 0 | https://www.1011now.com/prnewswire/2022/04/14/cpsc-announces-stakeholder-roundtable-may-25-2022-hear-public-new-equity-action-plan/ |
Tesla CEO Elon Musk is offering to buy Twitter, saying the social media platform he has criticized for not living up to free speech principles needs to be transformed as a private company.
Twitter Inc. said in a regulatory filing on Thursday that Musk, currently the company’s biggest shareholder, has proposed buying the remaining shares of Twitter that he doesn’t already own at $54.20 per share, an offer worth more than $43 billion.
Musk called that price his best and final offer, although he provided no details on financing. The offer is non-binding and subject to financing and other conditions.
“I invested in Twitter as I believe in its potential to be the platform for free speech around the globe, and I believe free speech is a societal imperative for a functioning democracy,” Musk said in the filing. “However, since making my investment I now realize the company will neither thrive nor serve this societal imperative in its current form. Twitter needs to be transformed as a private company.”
Twitter said it has received Musk’s offer and will decide whether it is in the best interests of shareholders to accept or continue to operate as a publicly traded company.
Musk revealed in regulatory filings over recent weeks that he’d been buying shares in almost daily batches starting Jan. 31, ending up with a stake of about 9%. Only Vanguard Group’s suite of mutual funds and ETFs controls more Twitter shares.
The billionaire has been a vocal critic of Twitter in recent weeks, mostly over his belief that it falls short on free speech principles. The social media platform has angered followers of Donald Trump and other far-right political figures who’ve had their accounts suspended for violating its content standards on violence, hate or harmful misinformation. Musk also has a history of his own tweets causing legal problems.
After Musk announced his stake, Twitter quickly offered him a seat on its board on the condition that he not own more than 14.9% of the company’s outstanding stock, according to a filing. But he said five days later that he’d declined.
He didn’t explain why, but the decision coincided with a barrage of now-deleted tweets from Musk proposing major changes to the company, such as dropping ads — its chief source of revenue — and transforming its San Francisco headquarters into a homeless shelter. Musk left a few clues on Twitter about his thinking, such as by “liking” a tweet that summarized the events as Musk going from “largest shareholder for Free Speech” to being “told to play nice and not speak freely.”
Musk’s 81 million Twitter followers make him one of the most popular figures on the platform, rivaling pop stars like Ariana Grande and Lady Gaga. But his prolific tweeting has sometimes gotten him into trouble with the SEC and others.
Musk and Tesla in 2018 agreed to pay $40 million in civil fines and for Musk to have his tweets approved by a corporate lawyer after he tweeted about having the money to take Tesla private at $420 per share. That didn’t happen, but the tweet caused Tesla’s stock price to jump. Musk’s latest trouble with the SEC could be his delay in notifying regulators of his growing stake in Twitter.
Musk has described himself as a “free speech absolutist” and has said he doesn’t think Twitter is living up to free speech principles — an opinion shared by followers of Donald Trump and a number of other right-wing political figures who’ve had their accounts suspended for violating Twitter content rules.
Shares of Twitter jumped 11% before the market open. The stock is still down from its 52-week high of about $73. Shares of Tesla, the electric vehicle manufacturer that Musk heads, slipped about 0.9%. | https://www.wfla.com/news/national/tesla-ceo-elon-musk-offers-to-buy-twitter-for-43-billion/ | 2022-04-14T12:08:34 | 1 | https://www.wfla.com/news/national/tesla-ceo-elon-musk-offers-to-buy-twitter-for-43-billion/ |
NEW YORK, April 14, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Cerence Inc. ("Cerence Inc." or the "Company") (NASDAQ: CRNC) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Cerence Inc. investors who were adversely affected by alleged securities fraud between February 8, 2021 and February 4, 2022. Follow the link below to get more information and be contacted by a member of our team:
CRNC investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) the global semiconductor shortage had a materially negative impact on demand for Cerence's software licenses; (2) defendants masked the impact of the semiconductor shortage on demand for the Company's software licenses by pulling forward sales; and (3) as a result of the above, defendants' statements about Cerence's business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
WHAT'S NEXT? If you suffered a loss in Cerence Inc. during the relevant time frame, you have until April 26, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
View original content to download multimedia:
SOURCE Levi & Korsinsky, LLP | https://www.1011now.com/prnewswire/2022/04/14/crnc-lawsuit-alert-levi-amp-korsinsky-notifies-cerence-inc-investors-class-action-lawsuit-upcoming-deadline/ | 2022-04-14T12:08:37 | 1 | https://www.1011now.com/prnewswire/2022/04/14/crnc-lawsuit-alert-levi-amp-korsinsky-notifies-cerence-inc-investors-class-action-lawsuit-upcoming-deadline/ |
MONMOUTH JUNCTION, N.J., April 14, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has registered a new subsidiary, CytoSorbents Medical UK Limited, with plans to establish a direct sales presence within the United Kingdom (UK) and Ireland. CytoSorbents previously sold CytoSorb® via distributor partners within the region. With a new direct commercialization presence, CytoSorbents expects to focus its resources and expertise to expand the use of CytoSorb® in hospitals throughout this territory, while providing world-class support and education for physicians and healthcare professionals. The UK is the third largest medical device market in Europe and the sixth largest in the world. CytoSorbents will now directly commercialize its products in 15 countries, with sales in more than 70 countries worldwide.
CytoSorbents recently hired Mr. Shaun Whittemore as Country Manager - UK & Ireland, to drive and coordinate market development in the region. Mr. Whittemore brings 20 years of sales, marketing and product specialist experience supporting large, global medical technology companies including LivaNova, Johnson & Johnson, and Smith+Nephew. Prior to joining CytoSorbents, Mr. Whittemore was most recently Commercial Manager, UK & Ireland at LivaNova.
"I am delighted to be part of this exciting opportunity to further develop and grow the market for CytoSorb in the United Kingdom and the Republic of Ireland and expect to leverage my insight and expertise from a career extending over two decades within the healthcare sector. I believe the benefits of our innovative blood purification technology will make a positive impact on the lives of treated patients throughout the region," said Whittemore.
Dr. Christian Steiner, Executive Vice President, Sales and Marketing of CytoSorbents stated, "As we establish a direct sales team in the UK and Ireland, we are excited to work more closely with physicians to improve awareness and usage of CytoSorb in its many applications in critical care and cardiac surgery. We also expect to continue working with the UK's National Health Service (NHS), one of the world's largest and well-renowned healthcare systems, to educate them on the clinical benefits and cost-effectiveness of our technology. To begin with, we plan to highlight last year's NICE Medtech innovation briefing on the use of CytoSorb to reduce the risk of bleeding during cardiothoracic surgery in patients on blood thinning medications in the UK health system. Our direct sales expansion into one of the largest medical device markets in the world is just one of many new initiatives intended to drive our core growth overall."
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. Its flagship product, CytoSorb®, is approved in the European Union with distribution in more than 70 countries around the world as an extracorporeal cytokine adsorber designed to reduce the "cytokine storm" or "cytokine release syndrome" seen in common critical illnesses that may result in massive inflammation, organ failure and patient death. These are conditions where the risk of death can be extremely high, yet few to no effective treatments exist. CytoSorb is also being used during and after cardiothoracic surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. More than 162,000 cumulative CytoSorb devices have been utilized as of December 31, 2021. CytoSorb was originally introduced into the European Union under CE-Mark as a first-in-kind cytokine adsorber. Additional CE-Mark label expansions were received for the removal of bilirubin and myoglobin in clinical conditions such as liver disease and trauma, respectively, and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with imminent or confirmed respiratory failure. The DrugSorb™-ATR Antithrombotic Removal System, which is based on the same polymer technology as CytoSorb, has also been granted FDA Breakthrough Designation for the removal of ticagrelor, as well as FDA Breakthrough Designation for the removal of the direct oral anticoagulant (DOAC) drugs, apixaban and rivaroxaban, in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company has initiated two FDA approved pivotal trials designed to support U.S. marketing approval of DrugSorb-ATR. The first is the 120-patient, 20 center STAR-T (Safe and Timely Antithrombotic Removal-Ticagrelor) randomized, controlled trial evaluating the ability of intraoperative DrugSorb-ATR use to reduce perioperative bleeding risk in patients on ticagrelor undergoing cardiothoracic surgery. The second is the 120-patient, 25 center STAR‑D (Safe and Timely Antithrombotic Removal-Direct Oral Anticoagulants) randomized, controlled trial, evaluating the intraoperative use of DrugSorb–ATR to reduce perioperative bleeding risk in patients undergoing cardiothoracic surgery on direct oral anticoagulants, including apixaban and rivaroxaban.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of more than $39.5 million from DARPA, the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S. Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM), Air Force Material Command (USAF/AFMC), and others. The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, DrugSorb™-ATR, ContrastSorb, and others. For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com or follow us on Facebook and Twitter.
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, expectations regarding the future impacts of COVID-19 or the ongoing conflict between Russia and the Ukraine, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 10, 2022, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Please Click to Follow Us on Facebook and Twitter
Investor Relations Contact:
Terri Anne Powers
Vice President, Investor Relations and Corporate Communications
(732) 482-9984
tpowers@cytosorbents.com
U.S. Public Relations Contact:
Eric Kim
Rubenstein Public Relations
212-805-3052
ekim@rubensteinpr.com
View original content to download multimedia:
SOURCE CytoSorbents Corporation | https://www.1011now.com/prnewswire/2022/04/14/cytosorbents-expand-direct-sales-cytosorb-united-kingdom-sixth-largest-medical-device-market-world/ | 2022-04-14T12:08:46 | 0 | https://www.1011now.com/prnewswire/2022/04/14/cytosorbents-expand-direct-sales-cytosorb-united-kingdom-sixth-largest-medical-device-market-world/ |
BURBANK, Calif., April 14, 2022 /PRNewswire/ -- Dr. Ron Paul, a longtime advocate of sound money and common-sense economics, has partnered with Birch Gold Group in an effort to educate the nation on methods to insulate their savings from debasement.
Dr. Paul has spent a lifetime serving his country as a medical doctor, a U.S. Air Force veteran and a Congressional representative for the state of Texas. He's written more than 20 books on economic and legal subjects, and is an established critic of both deficit spending and the Federal Reserve's monetary policies.
When asked about this partnership, Dr. Paul said, "Before I started working with Birch Gold, they asked me, 'What's your case for buying gold today?' I said, 'Well, it's the same as it's been for the last 5,000 years!'"
Essentially, Dr. Paul's case for buying gold comes down to financial stability. "Just maintaining what you have is a major challenge today," he said.
Phillip Patrick, senior Precious Metals Specialist with Birch, added, "People confuse not having enough buying power with not having enough money. So they want more money, because they can't pay the grocery bill."
But every time the Federal Reserve prints more money, it reduces the buying power of all other dollars in the world. More money doesn't create more wealth, it just creates inflation.
In Dr. Paul's words, "A lot of people don't even understand that inflation is a tax on your buying power. If you're an American with the relatively modest goal of just keeping your money safe, well, I've got to warn you, it's harder today than it's ever been."
And that's one of the major advantages of opening a gold IRA with Birch Gold Group.
"I'm a big believer in education," Dr. Paul said. "Most of my work has been focused on educating Americans on the benefits of liberty and sound money. And Birch Gold believes in education, first and foremost."
To learn more about how to protect your savings with physical gold and silver, visit https://www.BirchGold.com or call (800) 355-2116.
About Birch Gold Group:
Birch Gold Group (https://www.birchgold.com), the Precious Metal IRA Specialists, is a leading dealer of physical gold and silver in the United States. The business helps people protect their savings, either for retirement as part of a Gold IRA or Silver IRA, or to take physical delivery of precious metals. It has an A+ rating with the Better Business Bureau (BBB). The Birch Gold team of professionals has decades of combined experience, including past positions with Citigroup, Dun & Bradstreet, and IBM.
View original content to download multimedia:
SOURCE Birch Gold Group | https://www.1011now.com/prnewswire/2022/04/14/dr-ron-paul-partners-with-birch-gold-group-educate-americans-wealth-preservation/ | 2022-04-14T12:08:52 | 0 | https://www.1011now.com/prnewswire/2022/04/14/dr-ron-paul-partners-with-birch-gold-group-educate-americans-wealth-preservation/ |
EVANSVILLE, Ind., April 14, 2022 /PRNewswire/ -- Escalade, Inc. (NASDAQ: ESCA, or the "Company"), a leading manufacturer and distributor of sporting goods and indoor/outdoor recreational equipment, today announced results for the first quarter 2022.
(As compared to the first quarter 2021)
- Net Sales increased 22.3% to $72.4 million
- Organic growth, excluding the contribution from acquisitions was 12.2%
- Gross margin declined 165 basis points, while Gross Profit increased 15.4%
- Operating income increased 26.6% to $9.0 million
- Net income increased to $6.7 million, or $0.49 per diluted share vs. $0.39 per share for Q1 2021
- Announced $0.15 per share cash dividend to shareholders of record on May 31, 2022
For the three months ended March 19, 2022, Escalade posted net sales of $72.4 million, net income of $6.7 million and diluted earnings per share of $0.49.
During the first quarter Escalade completed its acquisition of Brunswick Billiards®, the largest and oldest provider of billiards tables, game tables, and game room furniture in the United States. The Escalade Board of Directors also approved a 7.1% increase in the quarterly dividend from $0.14 to $0.15.
First quarter 2022 results benefited from strong organic sales growth across the basketball, archery, pickleball, and indoor game categories, together with contributions from the Company's acquisition of Brunswick Billiards®.
Gross margin declined 165 basis points due to continued challenges related to the global supply chain, raw materials cost inflation and labor constraints. Tight overhead cost control led to a 26.6% increase in operating income. A marginally higher tax rate and 2.7% smaller share base contributed to a 22.3% increase in net income and 25.4% increase in diluted EPS.
Three Year Quarterly Comparison
"We are very pleased with the results in Q1," stated Walter P. Glazer, Jr., President and CEO of Escalade. "Nearly all categories performed very well which validates the strength of our brand portfolio and consumer acceptance of our range of products. Our product teams continue to innovate and bring compelling sporting goods, games, and related items to market while our sourcing and logistics professionals navigate the challenging global supply chain. We continue to 'onshore' items we can produce in our domestic manufacturing facilities and remain focused on the integration of the Brunswick acquisition, which we expect will be accretive to earnings beginning in the second half of 2022."
"The first quarter was positively impacted by sales pulled forward from Q2 and favorable mix. In the near term, we anticipate continued supply chain pressures, including delays and excess logistics costs. We are also carefully monitoring point of sale data along with consumer behavior and sentiment, given rising interest rates, inflation, and geopolitical uncertainty," continued Glazer. "We have seen a slowdown in demand for fitness products following unsustainable growth over the past two years. Longer term, we believe consumers will continue to value the positive experiences and memories created with the fun, healthy activities they can enjoy with the Escalade lifestyle," concluded Glazer.
Net sales for the first quarter of 2022 were $72.4 million compared to net sales of $59.2 million for the same quarter in 2021, an increase of $13.2 million or 22.3%.
Gross margin for the first quarter of 2022 was 27.8%, compared to 29.5% for the same period in the prior year. Gross profit for the first quarter of 2022 was $20.1 million compared to gross profit of $17.4 million for the same quarter in 2021.
Selling, general and administrative expenses (SG&A) were $10.5 million for the quarter compared to $9.9 million for the same period in the prior year, an increase of $0.6 million or 6.6%. SG&A, as a percent of sales, for the first quarter of 2022 decreased to 14.5% from 16.7% reported for the same period prior year.
Operating income for the first quarter of 2022 was $9.0 million compared to operating income of $7.1 million for the same period in the prior year.
Net income for the first quarter of 2022 was $6.7 million, or $0.49 diluted earnings per share compared to net income of $5.4 million, or $0.39 diluted earnings per share for the same quarter in 2021.
The Company announced a quarterly dividend of $0.15 per share to be paid to all shareholders of record on May 31, 2022 and disbursed on June 7, 2022.
CONFERENCE CALL
A conference call will be held Thursday, April 14, 2022, at 11:00 a.m. ET to review the Company's financial results, discuss recent events and conduct a question-and-answer session.
A webcast of the conference call and accompanying presentation materials will be available in the Investor Relations section of Escalade's website at www.escaladeinc.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time in order to register, download, and install any necessary audio software.
To participate in the live teleconference:
To listen to a replay of the teleconference, which subsequently will be available through April 28, 2022:
Founded in 1922, and headquartered in Evansville, Indiana, Escalade designs, manufactures, and sells sporting goods, fitness, and indoor/outdoor recreation equipment. Our mission is to connect family and friends creating lasting memories. Leaders in our respective categories, Escalade's brands include Brunswick Billiards®; STIGA® table tennis; Accudart®; RAVE Sports® water recreation; Victory Tailgate® custom games; Onix® pickleball; Goalrilla™ basketball; Lifeline® fitness; Woodplay® playsets; and Bear® Archery. Escalade's products are available online and at leading retailers nationwide. For more information about Escalade's many brands, history, financials, and governance please visit www.escaladeinc.com.
Patrick Griffin
Vice President - Corporate Development & Investor Relations
812-467-1358
This report contains forward-looking statements relating to present or future trends or factors that are subject to risks and uncertainties. These risks include, but are not limited to: specific and overall impacts of the COVID-19 global pandemic on Escalade's financial condition and results of operations; the impact of competitive products and pricing; product demand and market acceptance; new product development; Escalade's ability to achieve its business objectives, especially with respect to its Sporting Goods business on which it has chosen to focus; Escalade's ability to successfully achieve the anticipated results of strategic transactions, including the integration of the operations of acquired assets and businesses and of divestitures or discontinuances of certain operations, assets, brands, and products; the continuation and development of key customer, supplier, licensing and other business relationships; Escalade's ability to develop and implement our own direct to consumer e-commerce distribution channel; Escalade's ability to successfully negotiate the shifting retail environment and changes in consumer buying habits; the financial health of our customers; disruptions or delays in our business operations, including without limitation disruptions or delays in our supply chain, arising from political unrest, war, labor strikes, natural disasters, public health crises such as the coronavirus pandemic, and other events and circumstances beyond our control; Escalade's ability to control costs; Escalade's ability to successfully implement actions to lessen the potential impacts of tariffs and other trade restrictions applicable to our products and raw materials, including impacts on the costs of producing our goods, importing products and materials into our markets for sale, and on the pricing of our products; general economic conditions; fluctuation in operating results; changes in foreign currency exchange rates; changes in the securities markets; continued listing of the Company's common stock on the NASDAQ Global Market and/or inclusion in market indices such as the Russell 2000; Escalade's ability to obtain financing and to maintain compliance with the terms of such financing; the availability, integration and effective operation of information systems and other technology, and the potential interruption of such systems or technology; risks related to data security of privacy breaches; and other risks detailed from time to time in Escalade's filings with the Securities and Exchange Commission. Escalade's future financial performance could differ materially from the expectations of management contained herein. Escalade undertakes no obligation to release revisions to these forward-looking statements after the date of this report.
View original content to download multimedia:
SOURCE Escalade, Incorporated | https://www.1011now.com/prnewswire/2022/04/14/escalade-reports-first-quarter-2022-results/ | 2022-04-14T12:08:59 | 1 | https://www.1011now.com/prnewswire/2022/04/14/escalade-reports-first-quarter-2022-results/ |
CHICAGO and SCOTTSDALE, Ariz., April 14, 2022 /PRNewswire/ -- EVERSANA™, the pioneer of next-generation commercial services to the global life sciences industry, and UpScriptHealth™, the leading telehealth and virtual prescribing platform serving life sciences companies, today announced a strategic partnership to create a direct-to-patient platform that will transform the patient experience to help accelerate access to therapies worldwide.
The EVERSANA and UpScriptHealth digital platform guides patients through a seamless, online experience to determine if they qualify for a given treatment, receive a prescription, navigate benefits and have medications dispensed to their homes through a single platform while receiving patient support services as needed.
"Many patients struggle to get the care they need due to a fragmented approach to telehealth, patient engagement and virtual prescribing. Our pharmaceutical clients need better options for their patients," said Jim Lang, CEO, EVERSANA. "Together with UpScriptHealth, we offer a digital solution that will simplify the process for patients and their caregivers and provide faster access to treatments at the lowest possible cost."
The solution combines UpScriptHealth's telehealth and virtual prescribing technology with EVERSANA's commercialization services including data and analytics, agency, digital engagement, patient support, adherence services, specialty pharmacy, dispensing, and shipping. The end-to-end solution provides patients with a simplified, virtual experience to directly engage with clinicians.
"Linking our independent client-branded telehealth and virtual prescribing platform with EVERSANA's end-to-end commercialization services will lead to a new wave of adoption of direct-to-patient models in the pharmaceutical industry. We are excited to partner with EVERSANA in helping life sciences organizations accelerate patient access to life-improving therapies," said Peter Ax, CEO, UpScriptHealth.
The digital-first solution will help more patients find the treatments they need while receiving ongoing support to stay on therapies to improve outcomes.
The partnership builds on EVERSANA's continued investments in innovative, digital solutions to support better patient experiences, and extends UpScriptHealth's leadership in telehealth and virtual prescribing solutions for pharmaceutical clients. The solution leverages the power of data and analytics through ACTICS by EVERSANA™ for identifying and engaging the right patients and creates an on-brand, seamless digital experience for patients and their caregivers.
About EVERSANA™
EVERSANA™ is the leading provider of global services to the life sciences industry. The company's integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit EVERSANA.com or connect through LinkedIn and Twitter.
About UpScriptHealth™
UpScriptHealth™ is a comprehensive, direct-to-consumer telehealth and virtual prescribing platform that is innovating the way customers get the medications they need. UpScriptHealth has been innovating telehealth for over 20 years and remains committed to improving the lives of consumers by providing immediate and long-term convenient access to medical therapies. We embody values of transparency and integrity that have strengthened our core philosophy of care. To learn more about UpScriptHealth, visit www.UpScriptHealth.com.
Media Contacts:
EVERSANA
Matt Braun
Director, Corporate Communications
matt.braun@eversana.com
+1-414-434-4830
UpScriptHealth
Dan Snyder
Chief Marketing Officer
dsnyder@UpScriptHealth.com
+1-619-846-2301
View original content to download multimedia:
SOURCE Eversana | https://www.1011now.com/prnewswire/2022/04/14/eversana-upscripthealth-announce-integrated-direct-to-patient-platform-transforming-patient-journey-accelerate-therapy-access-affordability-adherence/ | 2022-04-14T12:09:06 | 0 | https://www.1011now.com/prnewswire/2022/04/14/eversana-upscripthealth-announce-integrated-direct-to-patient-platform-transforming-patient-journey-accelerate-therapy-access-affordability-adherence/ |
ATLANTA, April 14, 2022 /PRNewswire/ -- United Digestive, a leading physician practice management company focused on gastroenterology, today announced Neal C. Patel, MD as its President.
"I am eager and excited to serve United Digestive in this way. I've been so proud to be a part of this organization, particularly with the growth we've seen over the last year," said Neal C. Patel, MD.
Patel joined Atlanta Gastroenterology Associates, an affiliated practice of United Digestive, in 2014 and has held various leadership roles within the organization ever since. He currently serves on United Digestive's physician executive committee and most recently, served as Chief Strategy Officer.
"We are thrilled to welcome Dr. Patel into his new role," said Mark Gilreath, CEO for United Digestive. "His leadership, drive, and commitment are an asset to United Digestive team members, providers, and management. Neal's strong clinical experience and background in finance make him the ideal candidate for this position. He will undoubtedly excel in his new role."
The role of President, new for the organization, will focus on enhancing operational excellence and continued growth initiatives. The appointment further reinforces United Digestive's commitment to a dyadic leadership model and investment in elevating clinicians to leadership roles, allowing providers the benefits of experienced management, while maintaining clinical autonomy.
"I've had the pleasure of working closely with Neal for the last eight years," said Chief Medical Officer John Suh, MD. "Neal's dedication to and vision for the organization make him the perfect fit for this role and I'm looking forward to seeing our continued growth."
About United Digestive
United Digestive is a leading physician practice management organization serving GI physicians and gastroenterology practices nationwide. Practices that are part of United Digestive benefit from advanced infrastructure and operational insights, along with investments in regional growth. Physician Partners enjoy a dyad leadership model with reduced administrative burden and local support to allow them to focus on providing the highest-quality patient care. United Digestive is growing at a rapid pace, with more than 20 ASCs and 200 providers practicing in four states – Georgia, Florida, North Carolina, and South Carolina.
Contact:
Ashley Pollard
Marketing Communications Specialist
ashley.pollard@uniteddigestive.com
404-888-7575 x1146
View original content to download multimedia:
SOURCE United Digestive | https://www.1011now.com/prnewswire/2022/04/14/expanded-dyad-leadership-model-united-digestive-announces-dr-neal-c-patel-president/ | 2022-04-14T12:09:13 | 0 | https://www.1011now.com/prnewswire/2022/04/14/expanded-dyad-leadership-model-united-digestive-announces-dr-neal-c-patel-president/ |
NEW YORK, April 14, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Meta Platforms, Inc. ("Meta Platforms, Inc." or the "Company") (NASDAQ: FB) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Meta Platforms, Inc. investors who were adversely affected by alleged securities fraud between March 2, 2021 and February 2, 2022. Follow the link below to get more information and be contacted by a member of our team:
FB investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Apple's iOS privacy changes were having a material impact on Meta's ability to provide the kind of targeted advertising that its customers wanted and, as a result, customer ad spending was dropping precipitously; (2) Meta's mitigation efforts were either not properly implemented or ineffective; (3) measurement of ads was not accurate as mitigation efforts were failing; and (4) Meta did not have a plan in place to properly address the impact of the iOS privacy changes.
WHAT'S NEXT? If you suffered a loss in Meta Platforms, Inc. during the relevant time frame, you have until May 9, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
View original content to download multimedia:
SOURCE Levi & Korsinsky, LLP | https://www.1011now.com/prnewswire/2022/04/14/fb-lawsuit-alert-levi-amp-korsinsky-notifies-meta-platforms-inc-investors-class-action-lawsuit-upcoming-deadline/ | 2022-04-14T12:09:20 | 0 | https://www.1011now.com/prnewswire/2022/04/14/fb-lawsuit-alert-levi-amp-korsinsky-notifies-meta-platforms-inc-investors-class-action-lawsuit-upcoming-deadline/ |
TALLINN, Estonia, April 14, 2022 /PRNewswire/ -- CER.live, a cybersecurity ranking and certification platform, has released the rating of top 1,500 cryptocurrencies by cybersecurity. It is the first security rating covering such a big number of cryptocurrencies. The rating indicates that cybersecurity is heavily underestimated by most crypto projects.
The Cryptocurrency Security Rating is published on CER.live, it is open to everyone. The rating includes the top 1,500 cryptocurrencies by CoinGecko. All cryptocurrencies were evaluated according to these criteria:
- Project audit;
- Bug bounty program;
- Insurance;
- Team composition;
- Previous hack cases.
"There are close to 1,5K popular cryptocurrencies with >$2M market cap. How to choose among all of them a project to invest in? It causes real confusion among investors. CER 2.0 will simplify your choice. The rating will allow investors to choose only among secure projects. Those projects that do not meet even minimum security standards will be forced to decide between investing in security or exiting the market", comment by Kostiantyn Oleshko, product owner at CER.live.
The rating is designed for both individual investors and corporate players. The security score given to crypto projects will be integrated into their pages on CoinGecko. Before entering into cooperation with a project or establishing a partnership, a company will clearly see whether it interacts with a reliable player. The rating will prevent the flow of assets to unsecured projects.
The purpose of CER 2.0 is to mitigate the scope of crime in the crypto world. In 2021, users lost $14B due to crypto crime. It is the cost of the top 7 most expensive stadiums in the world.
"Crypto industry has a huge scope of security work ahead. Just less than 10% of all audited projects meet the desired security level while only 1.2% of projects have all 3 crucial security components in place (audit, bug bounty program, insurance). The rating may be shocking for many investors", brief facts from CER 2.0 by Kostiantyn.
CER 2.0 is the logical continuation of CER 1.0 security rating of crypto exchanges. These 2 ratings now cover all categories of the crypto market. CER 1.0 has already changed the cybersecurity landscape in the crypto exchanges industry. CER cybersecurity score is included in the Trust Score given by CoinGecko to crypto exchanges. The number of crypto exchanges with security audits and bug bounty programs doubled between 2020 and 2021. The mega hacks of crypto exchanges now take place very rarely.
Looking forward to seeing similar positive security transformations in the cryptocurrency market.
View CER 2.0. rating at: https://cer.live
CER on Twitter: https://twitter.com/cer_live
Journalists and corporate players can reach us by: contact@cer.live
Photo - https://mma.prnewswire.com/media/1796910/CER_Live_1.jpg
View original content to download multimedia:
SOURCE CER.Live | https://www.1011now.com/prnewswire/2022/04/14/first-cryptocurrency-security-rating-top-1500-projects-evaluated/ | 2022-04-14T12:09:26 | 1 | https://www.1011now.com/prnewswire/2022/04/14/first-cryptocurrency-security-rating-top-1500-projects-evaluated/ |
Physicians in Indiana, New York City, and Washington are among the first to administer Illuccix® – demonstrating coast-to-coast availability of this new imaging agent
Typically diagnosed in men over 50, prostate cancer is the second leading cause of cancer death in American men, after lung cancer[1]
INDIANAPOLIS, April 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces first commercial doses of its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium Ga-68 gozetotide injection), also known as 68Ga-PSMA-11 injection.
As Illuccix rolls out nationally across the United States, physicians in Indianapolis (Indiana University School of Medicine), New York City, and Seattle are among the first to administer this new PSMA PET[2] imaging agent that can help health care professionals (HCPs) diagnose the stage and spread of disease – an important step for the optimal care of men with prostate cancer.
Illuccix is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in patients with prostate cancer with:
- suspected metastasis who are candidates for initial definitive therapy;
- suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
Prostate cancer is the most common cancer in American men after skin cancer. According to the American Cancer Society, more than 268,000 men in the U.S. will be diagnosed this year with prostate cancer, and nearly 35,000 will die from their disease. Reliable and flexible diagnostic tools are essential for treatment teams in narrowing the gap between understanding the spread of disease and appropriate individualized treatment by healthcare professionals.
Illuccix is now widely available across the United States, significantly improving patient access to PSMA PET imaging. PSMA PET imaging is emerging as a standard of care in the U.S. having been included in latest NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer.[3]
"Early detection and staging can help guide more informed disease management decisions. Tools such as Illuccix PSMA-PET are incredibly valuable as we look for better ways to manage prostate cancer in men," said Dr. Michael Koch, Professor and Chair of the Department of Urology at the Indiana University School of Medicine and a physician-scientist at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.
Professor Mark Green, Director of Radiopharmaceutical Sciences and Professor of Radiology & Imaging Sciences at the Indiana University School of Medicine, added "The success of Telix in gaining FDA-approval for kit-formulated 68Ga-PSMA-11 represents an innovation for prostate cancer patients. Telix is providing a much-needed avenue for widespread clinical access to PSMA-targeted PET for improved understanding of the location and extent of a patient's disease. These imaging insights can be important as the physician develops an individualized treatment plan."
Illuccix is now available to order from 117 pharmacies in the Telix network, providing coverage to approximately 85 percent of PET imaging sites across the U.S. with more sites to be added over the coming months.
Dr. Christian Behrenbruch, Group CEO and Managing Director of Telix Pharmaceuticals Limited said, "Telix is delivering on its promise to deliver product and a distribution network that will allow physicians and their patients greater convenience and flexible access to advanced prostate cancer imaging, a significant unmet medical need. Until now, PSMA-PET imaging has had patchy availability and limited patient scheduling flexibility. Illuccix changes this by enabling rapid on-site hospital preparation or convenient delivery from nearby commercial nuclear pharmacies."
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.
About Illuccix®
Telix's lead product, Illuccix (kit for preparation of gallium Ga 68 gozetotide (also known as 68Ga PSMA-11) injection), has been approved by the U.S. Food and Drug Administration (FDA),[4] and by the Australian Therapeutic Goods Administration (TGA).[5] Telix is also progressing marketing authorisation applications for this investigational candidate in Europe[6] and Canada.[7]
INDICATIONS AND USAGE
Illuccix®, after radiolabeling with Ga 68, is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:
- with suspected metastasis who are candidates for initial definitive therapy
- with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Risk for Misdiagnosis
Image interpretation errors can occur with gallium Ga 68 gozetotide PET. A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer. The performance of gallium Ga 68 gozetotide for imaging of biochemically recurrent prostate cancer seems to be affected by serum PSA levels and by site of disease. The performance of gallium Ga 68 gozetotide for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by Gleason score. Gallium Ga 68 gozetotide uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes such as Paget's disease, fibrous dysplasia, and osteophytosis. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended.
Radiation Risks
Gallium Ga 68 gozetotide contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk for cancer. Ensure safe handling to minimize radiation exposure to the patient and health care workers. Advise patients to hydrate before and after administration and to void frequently after administration.
ADVERSE REACTIONS
The safety of gallium Ga 68 gozetotide was evaluated in 960 patients, each receiving one dose of gallium Ga 68 gozetotide. The average injected activity was 188.7 ± 40.7 MBq (5.1 ± 1.1 mCi). No serious adverse reactions were attributed to gallium Ga 68 gozetotide. The most commonly reported adverse reactions were nausea, diarrhea, and dizziness, occurring at a rate of < 1%.
DRUG INTERACTIONS
Androgen deprivation therapy and other therapies targeting the androgen pathway
Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, can result in changes in uptake of gallium Ga 68 gozetotide in prostate cancer. The effect of these therapies on performance of gallium Ga 68 gozetotide PET has not been established.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report adverse reactions to Telix by calling 1-844-455-8638 or emailing pharmacovigilance@telixpharma.com.
See full U.S. Prescribing Information at illuccix-prescribing-information.pdf (illuccixhcp.com)
Telix Investor Relations
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Corporate Communications and Investor Relations
Email: kyahn.williamson@telixpharma.com
Telix Media Relations
Mr. Greg Kueterman
Email: gkueterman@gmail.com
This announcement has been authorised for release by Dr. Christian Behrenbruch, Managing Director and Group Chief Executive Officer.
Legal Notices
This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company's good-faith assumptions as to the financial, market, regulatory and other considerations that exist and affect the Company's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical studies, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix's product candidates, if or when they have been approved; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions.
The Telix Pharmaceuticals name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved).
[1] American Cancer Society.
[2] Positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions
[3] NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.3.2022. Available at: https://www.nccn.org/guidelines/category_1.
[4] ASX disclosure 20 December 2021.
[5] ASX disclosure 2 November 2021.
[6] ASX disclosure 10 December 2021.
[7] ASX disclosure 16 December 2020.
View original content to download multimedia:
SOURCE Telix Pharmaceuticals Limited | https://www.1011now.com/prnewswire/2022/04/14/first-patients-dosed-with-illuccix-telixs-approved-prostate-cancer-imaging-agent/ | 2022-04-14T12:09:33 | 0 | https://www.1011now.com/prnewswire/2022/04/14/first-patients-dosed-with-illuccix-telixs-approved-prostate-cancer-imaging-agent/ |
NEW YORK, April 14, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Homology Medicines, Inc. ("Homology" or the "Company") (NASDAQ: FIXX) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Homology investors who were adversely affected by alleged securities fraud between June 10, 2019 and February 18, 2022. Follow the link below to get more information and be contacted by a member of our team:
FIXX investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) the Company had overstated the efficacy and risk mitigation of its lead product candidate, HMI-102; (ii) accordingly, it was unlikely that the Company would be able to commercialize HMI102 in its present form; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
WHAT'S NEXT? If you suffered a loss in Homology during the relevant time frame, you have until May 24, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
View original content to download multimedia:
SOURCE Levi & Korsinsky, LLP | https://www.1011now.com/prnewswire/2022/04/14/fixx-lawsuit-alert-levi-amp-korsinsky-notifies-homology-medicines-inc-investors-class-action-lawsuit-upcoming-deadline/ | 2022-04-14T12:09:40 | 0 | https://www.1011now.com/prnewswire/2022/04/14/fixx-lawsuit-alert-levi-amp-korsinsky-notifies-homology-medicines-inc-investors-class-action-lawsuit-upcoming-deadline/ |
FlowPath Recognized by Technology Association of Georgia as Leader in the Innovation Economy for the Creation of Its All-in-One Facility Management Platform.
ATLANTA, April 14, 2022 /PRNewswire/ -- FlowPath, a leading facility operations software platform, was recently nominated by the Technology Association of Georgia (TAG) as one of the Top 40 Innovative Technology Companies in Georgia. FlowPath's innovative technology solves critical problems facing the facility management industry, allowing operators to optimize their workflows, integrate third-party vendors into their processes, and automate managing the full lifecycle of their facilities. Recognized as leaders in helping fuel the innovation economy, the FlowPath team is invited to showcase their capabilities at the Georgia Technology Summit on April 26-27th, 2022.
Founded in 2019, FlowPath is a facilities management software company on a mission to be the system of record for the world's built infrastructure, being the single software solution for automating the maintenance, operations, and services of where we work, live, and play.
"This nomination is not only a wonderful recognition of how far we have come in the short life of FlowPath, but also a strong confirmation of the direction we are heading," said Alex Cummings, FlowPath's Co-Founder and CEO. "This highlights the impact our company has been able to achieve in our community and beyond. Truly, it is an honor to be included and associated with the other outstanding companies recognized past and present."
As a Top-40 nominee, the FlowPath team will showcase at The Georgia Technology Summit (GTS). The GTS annually brings together over 1,200 technology leaders, entrepreneurs, and academics at a two-day forum for thought leadership and collaboration, new experiences, and discussions with some of the nation's leading brands.
"This year's Top 40 companies represent a wide range of technology industries that power Georgia's innovation economy," said Dennis Zakas, Georgia's Top 40 Innovative Company Awards Chair. "Based on the quality of the winners and the history of the award, it's likely that some of today's Top 40 companies will be the unicorns of tomorrow."
About FlowPath
Founded in 2019, FlowPath is a facilities management software that automates work orders, maintenance, communication, notifications, projects, and reporting in a simple-to-use platform that can be leveraged across industries. To learn more, visit https://www.getflowpath.com.
About Technology Association of Georgia (TAG)
TAG's mission is to Connect, Promote, Influence, and Educate Georgia's technology ecosystem to advance the innovation economy. Through those four foundational strategies TAG serves the technology community, helping to support, grow and ignite tech leaders, companies, and the overall Georgia economy.
TAG serves more than 30,000 members statewide through regional chapters in Metro Atlanta, Augusta, Columbus, Macon/Middle Georgia, and Savannah. TAG hosts more than 150 events each year and serves as an umbrella organization for 20+ professional societies. For more information, visit https://www.tagonline.org.
MEDIA CONTACT
Megan Harris
Head of Marketing
megan.harris@getflowpath.com
View original content to download multimedia:
SOURCE FlowPath | https://www.1011now.com/prnewswire/2022/04/14/flowpath-nominated-top-40-innovative-technology-company-georgia/ | 2022-04-14T12:09:47 | 0 | https://www.1011now.com/prnewswire/2022/04/14/flowpath-nominated-top-40-innovative-technology-company-georgia/ |
SHANGHAI, April 14, 2022 /PRNewswire/ -- April 13, 2022, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH, 02196.HK) announced that the Novel Coronavirus (2019-nCoV) Antigen Detection Kit (Colloidal Gold) self-developed by Fosun Diagnostics Co., Ltd. ("'Fosun Diagnostics"), a subsidiary company of Fosun Pharma has received approval from the China's National Medical Products Administration (NMPA) for the commercial and clinical use of rapid antigen testing in COVID-19 screening.
Fosun Diagnostics' Novel Coronavirus (2019-nCoV) Antigen Detection Kit (Colloidal Gold) adopted the in- vitro qualitative detection method of Novel Coronavirus (2019-nCoV) Nucleocapsid antigen in nasopharyngeal swab samples from patients with respiratory and fever-related symptoms within 7 days, quarantine observers, and other antigen detection needs. Fosun Diagnostics' Novel Coronavirus Antigen Detection Kit is equipped with high sensitivity and specificity, strong anti-interference ability and no cross-reactivity among viruses and bacteria. The kit is easy to use and quick to operate and deliver results in 15 minutes. It has a variety of reagents to meet various testing needs at point of demand whenever required.
The product has obtained the EU CE certification, duly completed BfArM registration in Germany, and officially endorsed by the EU Health Security Committee Common List (EU common list).
Lately, the State Council's of China under the Joint Prevention & Control for novel coronavirus pneumonia has decided to include antigen detection as a key supplement to nucleic acid detection under the "New Coronavirus Antigen Detection Application Plan (Pilot Trial)". Fosun Diagnostics' Novel Coronavirus Antigen Detection Kit will contribute and continue serving the needs of pandemic prevention and control upon its recent approval.
Adhering to Independent Innovation and Providing Comprehensive Solutions for Covid-19 Nucleic Acid Testing
Since the outbreak of COVID-19, Fosun Pharma as a global innovation-driven pharmaceutical and healthcare group has fully integrated its business and global resources with timely response actively undertaking our social responsibilities in combating COVID-19 pandemic control.
As one of the Group's key strategic development segments, Fosun Diagnostics independently developed the Novel Coronavirus (2019-nCoV) RT-PCR Detection Kit with the NMPA's approval for emergency use in March 2020 while obtained the Registration Certificate for Medical Device (in vitro diagnostic reagents). Our Covid-19 test kits have also acquired relevant qualifications and certifications in the United States, European Union, Australia and many other countries and regions.
Fosun Diagnostics provides a comprehensive solution of reagents, equipment and consumables for the Novel Coronavirus nucleic acid testing. With clinically-validated, we offer many enhanced advantages in terms of fast and secure, flexible throughput, high sensitivity and reliable results. Fosun Diagnostics' Novel Coronavirus Detection Kit is capable to detect 3 targets (ORF1ab, N and E genes) simultaneously. And our primer probe sequence is independently developed and designed with a sensitivity of up to 300 copies/mL and hence, grossly improved the detection rate for infected people with low virus content or asymptomatic people.
About Fosun Pharma
Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196. SH, 02196. HK) is a global innovation-driven pharmaceutical and healthcare industry group deep-rooted in China. Fosun Pharma directly operates businesses including pharmaceutical manufacturing, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its areas in the pharmaceutical distribution and retail business.
Fosun Pharma is patient-centered and clinical needs-oriented. The company enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, license-in, and in-depth incubation. Fosun Pharma has formed technological platforms for innovative small molecule drugs, antibody drugs, and cell therapy with a focus on key disease areas including oncology and immunomodulation, metabolism and digestive system, and central nervous system. Fosun Pharma also vigorously explores cutting-edge technologies, such as RNA, oncolytic viruses, gene therapy and PROTAC, to enhance its innovation capabilities.
Guided by the 4IN strategy (Innovation, Internationalization, Integration, and Intelligentization), Fosun Pharma will uphold the development model of "innovation transformation, integrated operation, and steady growth", with the mission of creating shareholder values as well as promoting the global networks through strengthening its innovative R&D and in-licensing ability and enriching its product pipelines. Fosun Pharma will actively promote the digital and physical business layout in the pharmaceutical and healthcare industry and is committed to becoming a first-class enterprise in the global mainstream medical and health market.
For more information, please visit our official website: www.fosunpharma.com.
Fosun Pharma Forward-looking statements
This press release contains forward-looking statements. All statements other than statements of historical fact contained in this press release, including, without limitation, the discussions of Fosun Pharma's business strategies and expectations concerning future operations, margins, profitability, liquidity and capital resources, the future development of Fosun Pharma's industry and the future development of the general economy of Fosun Pharma's key markets and any statements preceded by, followed by or that include words and expressions such as "expect", "seek", "believe", "plan", "intend", "estimate", "project", "anticipate", "may", "will", "would" and "could" or similar words or statements, as they relate to Fosun Pharma's or its management, are intended to identify forward-looking statements. These statements are subject to certain known and unknown risks, uncertainties and assumptions, which may cause Fosun Pharma's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Accordingly, you should not place undue reliance on any forward-looking information. Subject to the requirements of applicable laws, rules and regulations, Fosun Pharma does not have any and undertakes no obligation to update or otherwise revise the forward- looking statements in this press release, whether as a result of new information, future events or developments or otherwise. In this press release, statements of or references to Fosun Pharma's intentions are made as of the date of this press release. Any such intentions may change in light of future developments. All forward-looking statements contained in this press release are qualified by reference to the cautionary statements set out above.
View original content to download multimedia:
SOURCE Fosun Pharma | https://www.1011now.com/prnewswire/2022/04/14/fosun-diagnostics-receives-china-nmpa-approval-its-independently-developed-novel-coronavirus-antigen-detection-kit-amidst-national-efforts-pandemic-prevention-control/ | 2022-04-14T12:09:53 | 0 | https://www.1011now.com/prnewswire/2022/04/14/fosun-diagnostics-receives-china-nmpa-approval-its-independently-developed-novel-coronavirus-antigen-detection-kit-amidst-national-efforts-pandemic-prevention-control/ |
HONG KONG, April 14, 2022 /PRNewswire/ -- "MOAR by Joan Cornellà", collaboration between Joan Cornellà and FWENCLUB, was met with strong market response during the public sale on April 7th (HKT). The trade volume reaches at 7,753 ETH (about US$23.7 million*), surpassing Bored Ape Yacht Club & AZUKI in 7-day volume. The first phase of the NFT launch has completed successfully and the second phase - mini game "SEIBWOZ" (spelling as: ZOMBIES) will be released in mid 2022, with rewarding winners free airdrop.
The 5,555 limited edition NFTs were sold as "blind boxes" and the visuals were only revealed on April 10th. NFT market predicts the market enthusiasm will continue with rising prices and trade volume before the project enters the metaverse in November 2022.
FWENCLUB released a sneak peek of "SEIBWOZ" on April 13th. It is a strategic adventure game set in the metaverse with zombies' invasion. Humans, zombies and cyborgs are locked in the MOAR building. MOAR's NFT holders start the game as survivors of the metaverse and battle against zombies to save the granny. Winners would earn a free airdrop as reward. More details of the mini game will be announced via the official website and Discord channel.
Apart from the stunning trade volume on 2nd market after the "unboxing", celebs and artists could not wait to show off their unique NFT PFP on social media, including KAWS, Brooklyn Beckham and Yuto Horigome.
The first phase of the public sale had a mint price of 0.5 ETH (about US$1,528.59*) and was open to Diamond Hand FWENCLUB supporters. A total of 1,644 NFTs were sold in just 2 minutes. The second phase of the public sale with 2,466 NFTs priced at 0.5 ETH were sold in 2 minutes at 0.5 ETH a piece, and there was no need for another round of auctioning. The remaining NFTs went to those on the WL, such as those who won official contests and eligible members who hold Hana Yusuke NFTs. They were able to purchase the NFTs at the discounted price of 0.35 ETH.
*As of 13 Apr, 5PM
INSTAGRAM & TWITTER @fwenclub @sirjoancornella #fwenclub #joancornella
View original content to download multimedia:
SOURCE FWENCLUB | https://www.1011now.com/prnewswire/2022/04/14/fwenclubs-nft-project-moar-by-joan-cornell-reaches-top-collection-7-day-volume-opensea/ | 2022-04-14T12:10:00 | 0 | https://www.1011now.com/prnewswire/2022/04/14/fwenclubs-nft-project-moar-by-joan-cornell-reaches-top-collection-7-day-volume-opensea/ |
VAUGHAN, ON, April 14, 2022 /PRNewswire/ - GFL Environmental Inc. (NYSE: GFL) (TSX: GFL) ("GFL" or the "Company") announced today that it has reached an agreement with the Canadian Competition Bureau (the "Bureau") to address concerns raised by the Bureau with the Company's acquisition of the solid waste and environmental services businesses of Terrapure Environmental Ltd., which acquisition closed on August 17, 2021.
GFL worked collaboratively with the Bureau to expeditiously reach an agreement under which GFL has agreed to divest of four liquid waste facilities and three tank farms, located in Western Canada. These sites were expected to generate annual aggregate revenue of approximately $20 million in 2022.
The Company is pleased to have reached an arrangement with the Bureau on this matter and will work to complete the proposed divestiture as soon as possible. This agreement now concludes the Bureau's legal action against GFL.
GFL, headquartered in Vaughan, Ontario, is the fourth largest diversified environmental services company in North America, providing a comprehensive line of non-hazardous solid waste management, infrastructure & soil remediation and liquid waste management services through its platform of facilities throughout Canada and in more than half of the U.S. states. Across its organization, GFL has a workforce of more than 18,000 employees.
View original content to download multimedia:
SOURCE GFL Environmental Inc. | https://www.1011now.com/prnewswire/2022/04/14/gfl-environmental-inc-reaches-agreement-with-canadian-competition-bureau/ | 2022-04-14T12:10:09 | 1 | https://www.1011now.com/prnewswire/2022/04/14/gfl-environmental-inc-reaches-agreement-with-canadian-competition-bureau/ |
NEW YORK, April 14, 2022 /PRNewswire/ -- Global Net Lease, Inc. (NYSE: GNL) ("GNL" or the "Company") announced today it will release its financial results for the first quarter ended March 31, 2022 on Thursday, May 5, 2022 before the start of trading on the New York Stock Exchange.
The Company will host a conference call and audio webcast on Thursday, May 5, 2022, beginning at 1:00 p.m. ET, to discuss the first quarter results and provide commentary on business performance. The call will be conducted by GNL's management team and a question and answer session with analysts and investors will follow the prepared remarks.
Dial-in instructions for the conference call and the replay are outlined below. This conference call will also be broadcast live over the Internet and can be accessed by all interested parties through the GNL website, www.globalnetlease.com, in the "Investor Relations" section. To listen to the live call, please go to the "Investor Relations" section of the Company's website at least 15 minutes prior to the start of the call to register and download any necessary audio software. For those who are not able to listen to the live broadcast, a replay will be available shortly after the call on the GNL website.
Conference Call Details
Live Call
Dial-In (Toll Free): 1-877-407-0792
International Dial-In: 1-201-689-8263
Conference Replay*
Domestic Dial-In (Toll Free): 1-844-512-2921
International Dial-In: 1-412-317-6671
Conference Replay Number: 13728725
*Available from 4:00 p.m. ET on May 5, 2022 through August 5, 2022.
About Global Net Lease, Inc.
Global Net Lease, Inc. (NYSE: GNL) is a publicly traded real estate investment trust listed on the NYSE focused on acquiring a diversified global portfolio of commercial properties, with an emphasis on sale-leaseback transactions involving single tenant, mission critical income producing net-leased assets across the United States, Western and Northern Europe. Additional information about GNL can be found on its website at www.globalnetlease.com.
Important Notice
The statements in this press release that are not historical facts may be forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the outcome to be materially different. In addition, words such as "anticipates," "believes," "expects," "estimates," "projects," "plans," "intends," "may," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of GNL's control, which could cause actual results to differ materially from the results contemplated by the forward-looking statements. These risks and uncertainties include the potential adverse effects of the ongoing global COVID-19 pandemic, including actions taken to contain or treat COVID-19, on GNL, GNL's tenants and the global economy and financial markets and that the information about rent collections may not be indicative of any future period, as well as those set forth in the Risk Factors section of GNL's most recent Annual Report on Form 10-K for the year ended December 31, 2021 filed on February 24, 2022, and all other filings with the SEC after that date, as such risks, uncertainties and other important factors may be updated from time to time in GNL's subsequent reports. Further, forward-looking statements speak only as of the date they are made, and GNL undertakes no obligation to update or revise any forward-looking statement to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time, unless required by law.
Contacts:
Investors and Media:
Email: investorrelations@globalnetlease.com
Phone: (212) 415-6510
View original content to download multimedia:
SOURCE Global Net Lease, Inc. | https://www.1011now.com/prnewswire/2022/04/14/global-net-lease-announces-release-date-first-quarter-2022-results/ | 2022-04-14T12:10:18 | 0 | https://www.1011now.com/prnewswire/2022/04/14/global-net-lease-announces-release-date-first-quarter-2022-results/ |
Leading window treatment franchise expands its foothold in Texas, providing locals with their familiar end-to-end window treatment consultations
AUSTIN, Texas, April 14, 2022 /PRNewswire/ -- Gotcha Covered, a leader in custom window treatment consultation in the U.S. and Canada, increases its presence in Texas with the opening of Gotcha Covered of Central Austin.
The new location is owned and operated by Claudia Carolina Carrillo. Focused on offering end-to-end consultative solutions, this business will provide the best in soft and hard window treatments to homeowners in Greater Austin, Dripping Springs, Driftwood, Buda and Manor while offering a variety of blinds, draperies, smart solutions and much more.
"At Gotcha Covered, we take pride in creating memorable, first-class experiences for our clients through our signature, end-to-end consultative services," said Paul Linenberg, president of Gotcha Covered. "We are excited to bring Claudia into the Gotcha Covered family and are confident she will provide Central Austin and the surrounding areas with the same level of excellence expected by thousands of other homeowners around the country."
Carrillo started her career as an interior designer. Working internationally in Mexico at Cabo Development, she returned to the United States to continue putting her passion into practice at Five Elements Furniture and RH of Austin, Texas.
Carrillo soon came across Gotcha Covered via a franchise broker offering to help her expand her opportunities with her own business. After diving deeper into the company, its business model and the royalty structure, she knew this was the right move for her.
"I have worked a long time in interior design here in Austin and developed a strong eye for what our community both wants and needs to beautify their home interiors," Carrillo said. "Gotcha Covered seemed to fit this perfectly, and the more I learned about it the more I realized the Gotcha Covered franchise is went beyond my expectations. As a new business owner with independent knowledge in the window treatment niche, I have felt very supported in all aspects of getting started with my new business. The corporate team is very approachable, and the follow-up and execution has been exceptionally professional every step of the way. We are thrilled to be open for business!"
Concerning the overall goal for the new Gotcha Covered of Central Austin, Carrillo said she wants to serve her community and support her clients with meaningful and delightful window treatments they can enjoy for years to come.
"I want them to not only experience the transformation of their space, I want them to be surrounded by both its beauty and its purpose," Carrillo said.
Adding 27 new franchise locations in 2021, Gotcha Covered currently has over 130 total franchises across the U.S. and Canada. The franchise has been operating under the Gotcha Covered name since 2009.
For more information or to schedule an appointment with Gotcha Covered of Central Austin, visit https://www.gotchacovered.com/central-austin.
About Gotcha Covered
Gotcha Covered is a leader in custom soft and hard window treatment consultation in the U.S. and Canada. Flying under their Gotcha Covered flag since 2009, they offer custom window treatments including blinds, draperies, shutters and much more. They offer end-to-end consultation with the customer's specific needs and goals in mind. The company currently has over 130 total franchises across the U.S. and Canada.
MEDIA CONTACT:
Heather Ripley
Ripley PR
865-977-1973
hripley@ripleypr.com
View original content to download multimedia:
SOURCE Gotcha Covered | https://www.1011now.com/prnewswire/2022/04/14/gotcha-covered-opens-new-center-central-austin-texas/ | 2022-04-14T12:10:25 | 0 | https://www.1011now.com/prnewswire/2022/04/14/gotcha-covered-opens-new-center-central-austin-texas/ |
NEW YORK, April 14, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Grab Holdings Limited ("Grab Holdings" or the "Company") (NASDAQ: GRAB) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Grab Holdings investors who were adversely affected by alleged securities fraud between November 12, 2021 and March 2, 2022. Follow the link below to get more information and be contacted by a member of our team:
GRAB investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Grab's driver supply declined during the third quarter; (2) as a result, Grab continued to invest heavily in driver and consumer incentives to "preemptively recalibrate driver supply"; (3) as a result, the Company's financial results would be adversely impacted, including, among other things, a significant decline in revenue; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
WHAT'S NEXT? If you suffered a loss in Grab Holdings during the relevant time frame, you have until May 16, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
View original content to download multimedia:
SOURCE Levi & Korsinsky, LLP | https://www.1011now.com/prnewswire/2022/04/14/grab-lawsuit-alert-levi-amp-korsinsky-notifies-grab-holdings-limited-investors-class-action-lawsuit-upcoming-deadline/ | 2022-04-14T12:10:31 | 0 | https://www.1011now.com/prnewswire/2022/04/14/grab-lawsuit-alert-levi-amp-korsinsky-notifies-grab-holdings-limited-investors-class-action-lawsuit-upcoming-deadline/ |
TSX: GPR | NYSE American: GPL
Consolidated production of 17,913 Au eq oz in line with the Company's plan to return to steady-state production in H2 2022
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated October 15, 2021, to its short form base shelf prospectus dated September 10, 2021.
VANCOUVER, BC, April 14, 2022 /PRNewswire/ - Great Panther Mining Limited (TSX: GPR) (NYSE-A:GPL) ("Great Panther" or the "Company"), a growth-oriented precious metals producer focused on the Americas, reports production results for the three months ended March 31, 2022, from its two wholly-owned operating mines, Tucano in Brazil and Topia in Mexico.
First Quarter 2022 Production Highlights
- Consolidated metal production of 17,913 gold equivalent ounces ("Au eq oz"), inclusive of 14,319 gold ounces ("Au oz") and 173,698 silver ounces
- Total gold production at Tucano of 14,037 Au oz
- Total silver equivalent production at Topia of 290,694 silver equivalent ounces ("Ag eq oz")
"I am pleased to report that production for the quarter was in line with expectations as we build back steady-state production at Tucano," stated Alan Hair, Chair and Interim CEO of Great Panther. "We remain on track to return to a normalized rate of production in the second half of the year. In addition, an extensive drilling program at the Urucum North underground project has been completed. Engineering studies and permitting are underway and construction work is expected to commence in late 2022 with gold production from the Urucum North underground mine anticipated to come onstream in 2023."
2022 Consolidated Operating Results
The Company's operations are on track to meet previously announced consolidated production guidance for 2022 of 100,000 to 119,000 Au eq oz. The mine plan for Tucano reflects more stripping in the first half of 2022 with the second half of 2022 expected to account for at least 65% of annual production guidance.
Tucano
To overcome previously indicated contractor performance issues, the mobilization of our new mining contractor, MINAX, commenced during the quarter. The Company continues to work closely with its current contractor, U&M, to ensure a safe and efficient transition with MINAX. MINAX is expected to fully mobilize its fleet by the end of May. During the transition, Tucano will continue to offset U&M's mined tonnage deficit with capacity from the new MINAX mine fleet.
Despite ounce production being lower compared to the first quarter of 2021 ("Q1 2021"), production in the first quarter of 2022 ("Q1 2022") at Tucano was positively affected by mine reconciliation and higher milled ore tonnage due to the high availability of the MINAX mine fleet to rehandle stockpiles. In line with expectations, production decreased 39% in Q1 2022 when compared to the first quarter of 2021 to 14,037 Au oz, primarily attributed to ongoing stripping of the TAP AB, TAP C and Urucum North pits, which resulted in low ore production triggering higher consumption of the low-grade stockpiles. Rain levels recorded in March and during the first quarter were 65% and 32% higher, respectively, compared to historical averages, which had a negative impact on mine development.
Topia
Silver equivalent production at Topia in Q1 2022 was 290,694 Ag eq oz compared with 363,318 Ag eq oz in Q1 2021, a decrease of 20% primarily due to lower tonnes milled in the absence of stockpiles, and lower gold and silver grades. These factors were partly offset by higher gold recovery and the increase in production attributed to the change in metal equivalency ratios for zinc. The mine development meterage during this period was 40% higher compared to Q1 2021 as preparations for full mine production in mines 1522, La Prieta, Rosario and Durangueño will support future production from these key ore sources for the next three quarters.
Guanajuato Mine Complex
The Guanajuato Mine Complex ("GMC") is currently on care and maintenance while the Company awaits the permits from CONAGUA necessary to extend the tailings facility. Consequently, there was no production at the GMC during Q1 2022. Great Panther continues to proactively engage with CONAGUA in regards of the tailings dam permit and to explore other alternatives to maximize value from the GMC.
First Quarter 2022 Financial Results
Great Panther has scheduled the release of its first quarter 2022 financial results for Thursday, May 12, 2022, after market close. The Company will host a conference call and webcast to discuss the results on Friday, May 13, 2022, at 9:00 AM PT/12:00 PM ET.
Live webcast and registration: https://www.greatpanther.com/investors/webcasts/
Conference call
Canada and US Toll-Free: + 1 800 319 4610
International Toll: + 1 604 638 5340
A replay of the webcast will be available on the Webcasts section of Great Panther's website approximately one hour after the conference call. Audio replay will be available until June 13, 2022.
Audio replay
Canada and US Toll-Free: + 1 800 319 6413
International Toll: + 1 604 638 9010
Replay Access Code: 8842
Technical Disclosure
The technical information contained in this news release has been reviewed and approved by Fernando A. Cornejo, P. Eng., Chief Operating Officer, a non-independent Qualified Person for the purposes of National Instrument 43-101 - Standards of Disclosure for Mineral Projects.
ABOUT GREAT PANTHER
Great Panther is a growing gold and silver producer focused on the Americas. The Company owns a diversified portfolio of assets in Brazil, Mexico and Peru that includes three gold and silver mines, an advanced development project and a large land package with district-scale potential. Great Panther is focused on creating long-term stakeholder value through safe and sustainable production, reinvesting into exploration and pursuing acquisition opportunities to complement its existing portfolio. Great Panther trades on the Toronto Stock Exchange trading under the symbol GPR, and on the NYSE American under the symbol GPL.
CAUTIONARY STATEMENT ON FORWARD-LOOKING INFORMATION
This news release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 and forward-looking information within the meaning of Canadian securities laws (together, "forward-looking statements"). Such forward-looking statements may include, but are not limited to, statements regarding (i) the Company's expectations for of a return to steady state production in the second half of 2022; (ii) the Company's ability to execute its growth plan and to unlock value from its asset portfolio, (iii) the expected timing and success for mobilization of MINAX and the Company's ability to offset U&M's mined tonnage deficits with the MINAX fleet, (iv) the expected cost and timing for receipt of permits, mine development and commencement of production from the underground Urucum North project at Tucano, (v) the potential for the production from the La Prieta, Rosario and Durangueño mines to support for the next three quarters at Topia, (vi) the Company's ability to secure a tailings facility expansion permit for the GMC mine or to successfully negotiate an agreement for third-party processing of the GMC tailings, and (vii) the Company's ability to meet its 2022 production and cost guidance.
These forward-looking statements and information reflect the Company's current views with respect to future events and are necessarily based upon a number of assumptions that, while considered reasonable by the Company, are inherently subject to significant operational, business, economic and regulatory uncertainties and contingencies. These assumptions include: continued operations and exploration work in 2022 occur without significant interruption due to COVID-19 or any other reason; the accuracy of the Company's geological modeling at Tucano and the assumptions upon which they are based, ore grades and recoveries; prices for gold, silver, and base metals remaining as estimated; currency exchange rates remaining as estimated; prices for energy inputs, labour, materials, supplies and services (including transportation); all necessary permits, licenses and regulatory approvals for the Company's operations and exploration work are received in a timely manner on favourable terms; Tucano will be able to continue to use cyanide in its operations; the Company will not be required to further impair Tucano as the current open pit mineral reserves are depleted through mining; the ability to procure equipment and operating supplies without interruption and that there are no material unanticipated variations in the cost of energy or supplies; operations not being disrupted by issues such as pit-wall failures or instability, mechanical failures, labour disturbances and workforce shortages, illegal occupations or mining, seismic events, and adverse weather conditions; and the Company's ability to comply with environmental, health and safety laws. The foregoing list of assumptions is not exhaustive.
These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements expressed or implied by such forward-looking statements to be materially different. Such factors include, among others, risks and uncertainties relating to: the impact of COVID-19 on the Company's ability to operate and conduct exploration work, including drilling plans, as anticipated, and the risk of an unplanned partial or full shutdown of the Company's mines and processing plants, whether voluntary or imposed, which would adversely impact the Company's revenues, financial condition and ability to meet its production and cost guidance and fund its capital programs and repay its indebtedness; the inherent risk that estimates of Mineral Reserves and Resources may not be accurate and accordingly that mine production will not be as estimated or predicted; planned exploration activities, may not result in the discovery of new Mineral Resources/definition of Mineral Resources and readers are cautioned that Mineral Resources that are not Mineral Reserves have no defined economic viability; open pit mining operations at Tucano have a limited established mine life and the Company may not be able to extend the mine life for Tucano open pit operations beyond 2023 as anticipated; gold, silver and base metal prices may decline or may be less than forecasted; fluctuations in currency exchange rates (including the U.S. dollar to Brazilian real exchange rate) may increase costs of operations; operational and physical risks inherent in mining operations (including pit wall collapses, tailings storage facility failures, environmental accidents and hazards, industrial accidents, equipment breakdown, unusual or unexpected geological or structural formations, cave-ins, flooding and severe weather) may result in unforeseen costs, shut downs, delays in production and drilling and exposure to liability; potential political and social risks involving Great Panther's operations in a foreign jurisdiction; the potential for unexpected costs and expenses or overruns; shortages in the ability to procure equipment and operating supplies without interruption; employee and contractor relations; relationships with, and claims by, local communities; the Company's ability to obtain all necessary permits, licenses and regulatory approvals in a timely manner on favourable terms; changes in laws, regulations and government practices in the jurisdictions in which the Company operates; legal restrictions related to mining; diminishing quantities or grades of mineral reserves as properties are mined; operating or technical difficulties in mineral exploration, changes in project parameters as plans continue to be refined; the Company's inability to meet its production forecasts or to generate the anticipated cash flows from operations could result in the Company's inability to meet its scheduled debt payments when due or to meet financial covenants to which the Company is subject or to fund its exploration programs as planned; ability to maintain and renew agreements with local communities to support continued operations; there is no assurance that the Company will be able to identify or complete acquisition opportunities of, if completed, that such acquisitions will be accretive to the Company; the risk that incremental closure bond requirements with respect to the Company's Coricancha mine could have a material and adverse effect on the company's liquidity and could require additional financing to be raised; the Company's ability to raise additional financing as debt comes due or to undertake its planned exploration and development activities; the risk that the Company's defense in respect of the fish mortality event at Areia and Silvestre Creeks is not accepted by the Brazilian authorities and the Company is required to pay all or a portion of the fines issued on December 21, 2021 and that these payments have a material adverse impact on the Company's financial condition; and other risks and uncertainties, including those described in respect of Great Panther in its most recent annual information form, and management's discussion and analysis and material change reports filed with the Canadian Securities Administrators available at www.sedar.com and reports on Form 40-F and Form 6-K filed with the Securities and Exchange Commission and available at www.sec.gov.
There is no assurance that these forward-looking statements will prove accurate or that actual results will not vary materially from these forward-looking statements. Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated, described, or intended. Accordingly, readers are cautioned not to place undue reliance on forward looking statements. Forward-looking statements and information are designed to help readers understand management's current views of our near- and longer-term prospects and may not be appropriate for other purposes. The Company does not intend, nor does it assume any obligation to update or revise forward-looking statements or information, whether as a result of new information, changes in assumptions, future events or otherwise, except to the extent required by applicable law.
View original content to download multimedia:
SOURCE Great Panther Mining Limited | https://www.1011now.com/prnewswire/2022/04/14/great-panther-reports-first-quarter-2022-production-results/ | 2022-04-14T12:10:40 | 1 | https://www.1011now.com/prnewswire/2022/04/14/great-panther-reports-first-quarter-2022-production-results/ |
HOUSTON, April 14, 2022 /PRNewswire/ -- Group 1 Automotive, Inc. (NYSE: GPI) ("Group 1" or the "Company"), an international, Fortune 300 automotive retailer with 202 dealerships located in the U.S. and U.K., today announced that it will release financial results for the first quarter ended March 31, 2022 on Wednesday, April 27, 2022, before market open. Earl J. Hesterberg, Group 1's president and chief executive officer, and the company's senior management team will host a conference call to discuss the results later that morning at 10:00 a.m. ET.
The conference call will be simulcast live on the Internet at http://www.group1corp.com/events. A webcast replay will be available for 30 days. A copy of the Company's presentation will also be made available at http://www.group1corp.com/company-presentations.
The conference call will also be available live by dialing in 10 minutes prior to the start of the call at:
A telephonic replay will be available following the call through May 4, 2022, by dialing:
Group 1 owns and operates 202 automotive dealerships, 268 franchises, and 46 collision centers in the United States and the United Kingdom that offer 34 brands of automobiles. Through its dealerships, the Company sells new and used cars and light trucks; arranges related vehicle financing; sells service contracts; provides automotive maintenance and repair services; and sells vehicle parts.
Group 1 discloses additional information about the Company, its business, and its results of operations at www.group1corp.com, www.group1auto.com, www.group1collision.com, www.acceleride.com, www.facebook.com/group1auto, and www.twitter.com/group1auto.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which are statements related to future, not past, events and are based on our current expectations and assumptions regarding our business, the economy and other future conditions. In this context, the forward-looking statements often include statements regarding our strategic investments, goals, plans, projections and guidance regarding our financial position, results of operations and business strategy, and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "should," "foresee," "may" or "will" and similar expressions. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting us will be those that we anticipate. Any such forward-looking statements are not assurances of future performance and involve risks and uncertainties that may cause actual results to differ materially from those set forth in the statements. These risks and uncertainties include, among other things, (a) general economic and business conditions, (b) the level of manufacturer incentives, (c) the future regulatory environment, (d) our ability to obtain an inventory of desirable new and used vehicles, (e) our relationship with our automobile manufacturers and the willingness of manufacturers to approve future acquisitions, (f) our cost of financing and the availability of credit for consumers, (g) our ability to complete acquisitions and dispositions and the risks associated therewith, (h) foreign exchange controls and currency fluctuations, (i) the impacts of COVID-19 on our business, (j) the impacts of any potential global recession, (k) our ability to maintain sufficient liquidity to operate, (l) the risk that proposed transactions will not be consummated in a timely manner, and (m) our ability to successfully integrate recent and future acquisitions. For additional information regarding known material factors that could cause our actual results to differ from our projected results, please see our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise.
Investor contacts:
Jason Babbitt
Vice President, Treasurer
Group 1 Automotive, Inc.
jbabbitt@group1auto.com
Media contacts:
Pete DeLongchamps
Senior Vice President, Manufacturer Relations, Financial Services and Public Affairs
Group 1 Automotive, Inc.
pdelongchamps@group1auto.com
or
Clint Woods
Pierpont Communications, Inc.
713-627-2223
cwoods@piercom.com
View original content:
SOURCE Group 1 Automotive, Inc. | https://www.1011now.com/prnewswire/2022/04/14/group-1-automotive-schedules-release-first-quarter-2022-financial-results/ | 2022-04-14T12:10:46 | 0 | https://www.1011now.com/prnewswire/2022/04/14/group-1-automotive-schedules-release-first-quarter-2022-financial-results/ |
MONTREAL, April 14, 2022 /PRNewswire/ - Georges Marciano, the original founder of GUESS, is absolutely shocked by a series of false statements he discovered in March 2022, in a YouTube video called "The #GUESS Brand Story: Told By Paul & Maurice Marciano". The story as told and the account of events as recited are plainly wrong, according to Georges Marciano. "Paul makes outrageous false claims about the inception, he history of GUESS and its own involvement therein. He is taking undue credit and is distorting reality in a very concerning way, on the verge of impersonation", says Georges Marciano.
In order to set the record straight – and leave a legacy for his kids – Georges Marciano recalls the true and original story of GUESS:
"I started making ties in Marseille with the label Georges Marciano. My first store in Marseille was called Blow Up – in ready-to-wear, it was later renamed MGA, for Maurice Georges Armand, the first initials of my two brothers and me.
Later, I opened 4 stores on the harbour of Bandol-Cassis-Toulon, etc.
I came on vacation from Bandol to LA in 1977 with my friend Philippe Mevellec, for a week, at the Hilton in Beverly Hills. When we got back to Bandol, I told my two brothers, Armand and Maurice, that I wanted to go back to California to try my luck with Philippe and open a store for the Mackeen brand, a very well-known jeans brand in Marseille, whose owner was a friend – David Mechaly. We left a month later with very little money and found a small place to rent in Century city in Beverly Hills. Philippe and I found a small apartment in Westwood where we were staying for almost a year. We decorated the shop ourselves with wooden shelves and the sign was Mackeen (in large print). Immediate success.
A friend from Bandol came to join us, Alain Grosso, with his wife Noëlle.
Around 1979, my brother Maurice joined me in LA to open an MGA (Maurice-Georges-Armand) store, which I had founded in Marseille a few years earlier.
The MGA store finally opened in Beverly Hills. I had the idea of making a brand of jeans. So I found a collaborator, Georges Atlan, who worked in the jeans industry in LA. Paul was still in France with Armand for almost 2 years. They both arrived in LA in 1981.
I found a small room of 800 sq-ft. on the twelfth floor of a building in downtown LA, on Broadway Street. In the same building was Gene Montesano and Jeff Hamilton, it was very fun. My suite was 1201-1203. Georges Atlan was my partner in the company called Via Europa, where I owned 80% and Atlan the rest.
My ex-wife, Melinda, came to help us every day.
The first label we created was called Blue Way, but this label is not popular. Going downtown, on Olympic Blvd with my friend Atlan, a billboard bearing the title "GUESS WHAT IS THE BEST HAMBURGER? BIG BOY" catches my attention every morning. I hardly spoke English at the time. I asked my friend what "GUESS" meant in French and as he answered, I said "GUESS what?" as for him to tell me again: that's when I finally understood the meaning of GUESS. I found the word fabulous because it is pronounced in the same way in all languages.
We therefore took the decision to change the name Blue Way for the name GUESS. As I needed a logo, I simply used the traffic stop sign as an inspiration, which became the famous red and white triangle. An employee who worked with us suggested we put a question mark in the logo: the GUESS label was born! Immediate success. Then I asked my brother Maurice to come and help since he was very strong in manufacturing. Shortly after, my big brother Armand came to help us too.
My friend Atlan gave me back his 20% of the company, which I had given him for free, and about a year later I gave Maurice and Armand 40% of the new GUESS company.
This is therefore the real start of the company. Paul never participated in the creation of the company. Armand and Maurice gave shares to Paul, despite my objections. It was only in 1989 that Paul was admitted to the board of directors of GUESS."
Georges Marciano considers that "history has its eyes on us: liars will be recalled as liars and even worst. The GUESS story is a great story, and it deserves truth and respect."
View original content:
SOURCE Georges Marciano | https://www.1011now.com/prnewswire/2022/04/14/guess-original-founder-georges-marciano-tells-real-story-guess-after-false-claims-social-media/ | 2022-04-14T12:10:54 | 1 | https://www.1011now.com/prnewswire/2022/04/14/guess-original-founder-georges-marciano-tells-real-story-guess-after-false-claims-social-media/ |
Company's patented digital printing technology can be fully customized to enhance
instant ticket player experience with high-resolution artwork and new playstyles
LONDON, April 14, 2022 /PRNewswire/ -- International Game Technology PLC ("IGT") (NYSE: IGT) announced today the introduction of its Infinity Instants™ games that are created using multiple patented digital printing technologies to transform and enhance instant ticket design and gameplay. The innovative printing techniques are unlike any others in the industry and produce games with high definition, richly colored symbols and graphics on the front and back of a ticket, and with unparalleled scene variety and flexibility.
"The technology behind Infinity Instants disrupts and revolutionizes traditional instant ticket printing and endorses IGT's commitment to delivering growth-driving, player-tested, innovative solutions for lotteries," said Jay Gendron, IGT Chief Operating Officer, Global Lottery. "The digital preparation process of Infinity Instants allows for every element of the instant ticket to be fully customized, creating an infinite number of possibilities. This high level of detail generates opportunities for lotteries to engage players through more appealing graphics and enhanced playstyles."
IGT Infinity Instants tickets are printed on a physical press but produced through a series of digital printing processes and technologies, allowing for endless flexibility for the design, production, and marketing of instant ticket games. With Infinity Instants, the variable game symbols on instant tickets are generated in full color at the highest known resolution in the industry. The digital production process also allows for every ticket in the pack to display unique artwork.
The transformative Infinity Instants tickets have thus far launched in four U.S. lottery markets and have demonstrated strong performance.
For more information about IGT's lottery business, visit IGT.com and follow us on LinkedIn.
About IGT
IGT (NYSE:IGT) is a global leader in gaming. We deliver entertaining and responsible gaming experiences for players across all channels and regulated segments, from Lotteries and Gaming Machines to Sports Betting and Digital. Leveraging a wealth of compelling content, substantial investment in innovation, player insights, operational expertise, and leading-edge technology, our solutions deliver unrivaled gaming experiences that engage players and drive growth. We have a well-established local presence and relationships with governments and regulators in more than 100 countries around the world, and create value by adhering to the highest standards of service, integrity, and responsibility. IGT has approximately 10,500 employees. For more information, please visit www.igt.com.
Contact:
Phil O'Shaughnessy, Global Communications, toll free in U.S./Canada +1 (844) IGT-7452;
outside U.S./Canada +1 (401) 392-7452
Francesco Luti, +39 06 5189 9184; for Italian media inquiries
James Hurley, Investor Relations, +1 (401) 392-7190
© 2022 IGT
The trademarks and/or service marks used herein are either trademarks or registered trademarks of IGT, its affiliates or its licensors.
View original content to download multimedia:
SOURCE International Game Technology PLC | https://www.1011now.com/prnewswire/2022/04/14/igt-transforms-instant-tickets-with-infinity-instants-games/ | 2022-04-14T12:11:01 | 1 | https://www.1011now.com/prnewswire/2022/04/14/igt-transforms-instant-tickets-with-infinity-instants-games/ |
Badgr to become "Canvas Badges" tool, with new "Canvas Credentials" offering more advanced functionality as paid service
SALT LAKE CITY, April 14, 2022 /PRNewswire/ -- Instructure Holdings, Inc. (Instructure) (NYSE: INST) today announced it has completed the acquisition of partner Concentric Sky, the makers of Badgr. Currently the default micro-credentialing tool within Canvas LMS, Badgr will be rebranded as "Canvas Badges" as it joins the Instructure Learning Platform. Canvas LMS customers can also upgrade to Badgr Pro's advanced suite of tools in new "Canvas Credentials," offering unlimited badging, leaderboards, analytics and personalized pathway progress visualizations. The deal underscores Instructure's commitment to building the education industry's most integrated teaching and learning platform to support lifelong learning.
"We know colleges and universities are seeking innovative new ways to support non-traditional learners and that those students want greater agency to demonstrate skills and achievements to potential employers," said Steve Daly, CEO of Instructure. "With Badgr, the Concentric Sky team has developed the gold standard for verifiable, skill-aligned micro-credentials, fast becoming the currency between learning outcomes and employment opportunities. This deal enables us to continue to expand the Instructure Learning Platform to support the evolving needs of all types of educational institutions and the diverse student populations they serve."
According to Instructure's 2021 State of Student Success and Engagement in Higher Education survey, preparing students for post-graduate careers is the #1 concern, however, administrators and students agree that this is where institutions struggle most. 84% of respondents defined student success as work/career readiness, a rise from 78% in 2020. Skills-based learning also emerged as a priority, with 70% of respondents saying that having definable skills is more important than course titles or a degree.
Whether as part of K12, a traditional undergraduate program or non-traditional programs like certificates and boot camps, Canvas Credentials allows schools to seamlessly award badges that verify and track academic achievements, including competency-based education (CBE). Canvas Credentials is the leading credentialing platform with stackable learning pathways and shareable learner records. By incorporating Canvas Credentials' stackable digital credentialing technology, Instructure empowers schools to help students navigate personalized learning journeys and enables them to carry proof of their academic achievements and skills development throughout their life.
Founded in 2005, Concentric Sky has grown to nearly 90 employees and serves millions of users by providing recognition from over 25,000 issuing organizations in 160 countries. Concentric Sky has been a long-time contributor to the field of open technology standards, joining forces with the MacArthur Foundation to lead the development of Open Badges 2.0 in 2015 and co-founding the Open Skills Network in 2020.
"From day one we've been focused on helping learning organizations connect people to opportunities and delivering a more equitable future by changing the way the world recognizes achievement," said Wayne Skipper, founder and CEO of Concentric Sky. "The power of the Instructure Learning Platform is its commitment to openness and equity, and our two companies share a fundamental belief in the importance of open technology standards for advancing equity in education. Instructure has demonstrated a strong desire to carry that work forward and I feel confident that together we can accelerate our mission to advance learning at every level."
The Instructure Learning Platform is an open, reliable, and extensible learning ecosystem enabling a digital learning environment for educators, students, and institutions. The platform is made up of several key pillars—such as learning management, assessment, and analytics—that work together to enrich, support, and connect every aspect of teaching and learning. Canvas Badges and Canvas Credentials will be vital parts of the learning management pillar, which also includes Canvas LMS. As part of Instructure's deep commitment to openness, Canvas LMS will continue to support the seamless integration of other third-party credential management and badging solutions.
Instructure (NYSE: INST) is an education technology company dedicated to elevating student success, amplifying the power of teaching, and inspiring everyone to learn together. Today the Instructure Learning Platform supports more than 30 million educators and learners around the world. Learn more at www.instructure.com.
This press release contains "forward-looking" statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the acquisition of Concentric Sky and its impact upon Instructure. These statements are not guarantees of future performance, but are based on management's expectations as of the date of this press release and assumptions that are inherently subject to uncertainties, risks, and changes in circumstances that are difficult to predict. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements. Important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements include the risk factors described in the Instructure's initial public offering prospectus filed with the Securities and Exchange Commission (the "SEC") on July 23, 2021, and other documents filed with the SEC and could cause actual results to vary from expectations. All information provided in this press release is as of the date hereof and Instructure undertakes no duty to update this information except as required by law.
MEDIA CONTACT:
Brian Watkins
Corporate Communications
Instructure
801-610-9722
brian.watkins@instructure.com
INVESTOR CONTACT:
Denise Garcia
Alex Liloia
Hayflower Partners
646-918-4041
Investors@Instructure.com
View original content to download multimedia:
SOURCE Instructure Holdings, Inc. | https://www.1011now.com/prnewswire/2022/04/14/instructure-acquires-concentric-sky-makers-badgr-adding-stackable-digital-credentialing-technology-instructure-learning-platform/ | 2022-04-14T12:11:07 | 0 | https://www.1011now.com/prnewswire/2022/04/14/instructure-acquires-concentric-sky-makers-badgr-adding-stackable-digital-credentialing-technology-instructure-learning-platform/ |
Virtual mental health company to grow clinical operations, commercial, and technology teams to help health systems and community health centers deliver timely and appropriate care to patients in need
AUSTIN, Texas, April 14, 2022 /PRNewswire/ -- Iris Telehealth, a leading provider of telepsychiatry services for health systems and community health centers across the U.S., announced today that they have raised $40 million in Series B funding to accelerate their vision of improving outcomes for patients with serious mental illness. Founded in 2013, Iris is dedicated to delivering quality, sustainable behavioral healthcare so their partner organizations can better support the patients who need it most.
With behavioral health patients accounting for 56% of total health costs and 77% of U.S. counties facing a psychiatrist shortage, providing timely, quality care to patients with serious mental illness has never been more critical – or challenging. With this funding, Iris intends to further assist their partner healthcare organizations in solving this challenge by helping care for and triage patients across the continuum, matching each patient with the right next level of care.
"For the past nine years, our goal has been to provide high-quality virtual behavioral health services to help healthcare organizations increase access to life-saving care and improve their patient outcomes," said Andy Flanagan, CEO of Iris Telehealth. "This funding will help us quickly scale our services to support more healthcare organizations. We plan to leverage this funding to create a positive, long-term impact on mental healthcare in communities across the country."
Through this additional capital, Iris plans to invest in four main areas to accelerate the expansion of their behavioral health services:
- Growing their clinical operations team to meet the growing customer demand and ensure long-term customer success
- Scaling their go-to-market strategy to deliver quality, sustainable behavioral healthcare to more enterprise health systems and community health centers
- Expanding their product and technology capabilities to help health systems manage patients across the continuum, ensuring the right patient is receiving the right care at the right time
- Augmenting their team of clinical and corporate employees to meet the increasing needs of patients and partners while maintaining a culture that is supportive, connected, and rooted in the shared mission of helping organizations meet their goals through exceptional care
Leading this funding round are Concord Health Partners and Columbia Pacific Advisors. In 2019, Concord Health Partners collaborated with the American Hospital Association (AHA) to launch their AHA Fund to help hospitals and health systems innovate and transform the way they deliver healthcare.
"Iris has an impressive track record of partnering with health systems and other providers to enhance behavioral health services by facilitating access to the appropriate level of care," said James Olsen, Founder and Managing Partner of Concord Health Partners. "We are excited to support Iris, expand its reach, and further enhance its technology capabilities."
Columbia Pacific Advisors was an initial Iris investor and is now expanding their commitment to further support the company as they work to expand access to much-needed behavioral healthcare services.
"We have seen Iris grow for many years and believe they are just getting started," said Stan Baty, Co-Founder and Managing Partner of Columbia Pacific Advisors. "We look forward to helping them scale to support more healthcare organizations and patients in need of quality behavioral healthcare."
Now serving almost 200 hospitals and community health centers, Iris has grown exponentially over the last 18 months as healthcare organizations seek to provide timely, quality care to their patients. Iris's combination of high-quality providers, best-in-class support, expertise to optimize care models, and technology has enabled customers to reimagine how behavioral health services are provided across the continuum of care.
Iris Telehealth helps healthcare organizations consistently increase access to quality mental healthcare for their patients by providing the clinicians, staff support, and knowledge to build a sustainable telepsychiatry department. With clinical grounding and emphasis on human relationships, Iris Telehealth identifies best-fit providers for each unique organization and ensures long-term commitment to meeting their partner's needs, allowing them to provide the highest quality care to their patients and community. For more information, please visit iristelehealth.com.
View original content to download multimedia:
SOURCE Iris Telehealth | https://www.1011now.com/prnewswire/2022/04/14/iris-telehealth-raises-40-million-series-b-funding-combat-behavioral-healthcare-crisis/ | 2022-04-14T12:11:14 | 1 | https://www.1011now.com/prnewswire/2022/04/14/iris-telehealth-raises-40-million-series-b-funding-combat-behavioral-healthcare-crisis/ |
The system targets equipment such as haul trucks, loaders, bulldozers, and excavators, at construction sites, mines, quarries, and industrial plants
JERUSALEM, April 14, 2022 /PRNewswire/ -- Israeli startup Ception has unveiled an AI-based system that reduces accidents and improves productivity and profitability of heavy equipment at construction sites, mines, quarries, and industrial plants. The system is set to lower operation costs and contribute to sustainability in these demanding work environments.
Equipment such as articulated trucks, haul trucks, loaders, bulldozers, and excavators, is involved in severe accidents on a daily basis. Accidents include collisions, overturning, and falling into chasms, costing lives, and damaging property. Moreover, operations without advanced technological equipment are inefficient, incurring heavy and unnecessary costs, and prolong the time needed to complete projects.
MineCept - full situational awareness
To tackle the heavy equipment challenges, Ception developed MineCept. The system is based on a SaaS business model, which offers the customer a collection of apps via the same hardware kit and supports a wide range of scenarios in the field. The system uses advanced real-time high-definition 3D mapping and precise positioning technology, based on visual feed rather than GPS, to provide full situational awareness of the machine's surrounding environment by cross-referencing information from different sensors and a range of image processing algorithms and deep learning.
MineCept, which is installed on the heavy vehicles, provides operators, site managers and safety managers real-time information and insights to improve safety and operational efficiency in general.
MineCept includes three parts. The first is a modular hardware kit that is easily installed on heavy equipment and is OEM-agnostic. It includes a compute unit, communications component, and sensors. The basic kit includes cameras with an option of adding Lidar and radar sensors based on the application and the user requirements. The second part is an assistance system for the machine's operator. It includes a display screen installed in the operator's cabin. This system provides visual and sound alerts, as well as support for different operational tasks. The third part is the site management system, which includes real-time information and insights about what is happening at the site.
MineCept's management system obtains a comprehensive holistic picture of all the operational and safety parameters and summarizes the hazards (potholes, puddles, rocks, etc.) and events at the site for the manager in an accessible way. Above this level, the artificial intelligence tools provide insights and enable the forecasting of bottlenecks in the different processes and safety failure points before they occur (preventative safety).
For example, if heavy vehicles or a heavy vehicle and a person get too close, an alarm is immediately sent to the operators so they can avoid a collision, or if a heavy equipment operator is momentarily distracted, causing him to go off the road or move in reverse towards a chasm, he will get a life-saving warning.
The system contributes to streamlining operations by supporting diverse apps, such as performance monitoring, comparing planning to execution in the field, measuring the volume of stockpiles, and monitoring cycle times. At the same time, MineCept verifies that the site is operating in compliance with regulatory safety instructions, such as continuous measurement of the height of safety berms.
Successful deployments
Ception's system is used by leading mining and construction companies in various projects and industrial sites in Israel and over the globe. In the mining industry, MineCept is used by ICL Group, one of the world's leading fertilizers producers, which operates heavy equipment at its phosphate mine in southern Israel. In the field of construction and infrastructure, MineCept was used by Netivei Israel, the national transport infrastructure company, as a part of a project aimed at improving the safety and efficiency of heavy equipment.
Ception has been selected the building materials giant Cemex as one of the top 50 startups in the construction technology sector. At the same time, Ception is collaborating with Cemex's Israeli subsidiary, Readymix Industries. The startup also won a recent workforce technologies competition, where leading construction companies such as Bouygues, Suffolk and Limak acted as judges, and will represent Israel in the global competition later this year.
The company is in advanced negotiations for collaboration with one of Israel top construction companies. As part of the agreement, the building company will invest in Ception and deploy its systems in the company's heavy equipment.
Solving acute safety, efficiency, and sustainability problems
Tal Israel, Co-Founder and CEO of Ception, says, "The construction, building materials, mining and quarrying industries are huge markets that suffer from acute safety, efficiency, and sustainability problems and are always looking for innovative solutions. There is currently a gap of technological solutions in this discipline. Some of the solutions are geared towards a high level of automation, but suffer from various barriers, including technological limitations, high prices, and regulatory restrictions. Conversely, solutions that rely on basic technologies do not offer an adequate response and suffer from serious reliability problems."
Israel concludes: "The automation and Industry 4.0 revolutions have brought immense technological advances in edge computing, sensing technologies, artificial intelligence, deep learning, and other fields. Ception is not waiting for the automation revolution to be complete and is applying these innovative technologies to provide precise and reliable solutions at good prices."
About Ception
Ception was founded in 2019 by CEO Tal Israel and CTO Yossi Buda, who have been working for almost 15 years in developing advanced driving systems and autonomous vehicle solutions at Israel Aerospace Industries and General Motors. In their last positions before founding the company, they headed the development of several unmanned ground vehicles and autonomous systems. To date, the company has received $7 million in funding, including seed funding from MoreVC and a grant from the Israel Innovation Authority.
Images can be downloaded here. Statistics on relevant accidents are here.
Media contact:
Amir Ben Artzi, Meirovitch PR
amir@meirovitch.com
View original content:
SOURCE Ception | https://www.1011now.com/prnewswire/2022/04/14/israeli-startup-ception-unveils-new-ai-based-system-improve-safety-productivity-profitability-heavy-equipment/ | 2022-04-14T12:11:24 | 1 | https://www.1011now.com/prnewswire/2022/04/14/israeli-startup-ception-unveils-new-ai-based-system-improve-safety-productivity-profitability-heavy-equipment/ |
Firm to team with ROTEC to deploy FR-RO Technology
DALLAS, April 14, 2022 /PRNewswire/ -- Jacobs (NYSE:J) was selected by PUB, Singapore's National Water Agency, to design and supervise construction and commissioning of the Changi NEWater Factory 3 (CNF3), the third NEWater plant to be located at the Changi Water Reclamation Plant (WRP) and one of the world's largest and most advanced water reclamation plants.
CNF3 will be one of the first reclamation plants globally to use Membrane Bioreactor (MBR) filtrate to feed reverse osmosis (RO) membranes. Using MBR will improve the quality of treated used water for NEWater production and prolong the life of RO membranes. CNF3 will incorporate water technology firm ROTEC's proprietary reverse osmosis flow reversal technology (FR-RO) into the design of the RO system to increase the recovery rate of NEWater from 75% to 90%.
"Using a holistic, integrated approach not only helps Singapore address its water needs but offers possible solutions for other countries around the world facing similar water security challenges," said Jacobs Chair & CEO Steve Demetriou. "The CFN3 project is yet another way Jacobs is addressing climate response and sustainability through innovative design."
Design of CNF3 is underway and construction is expected to begin later in 2022, with the plant expected to be completed in 2024. CNF3 will be owned and operated by PUB.
FR-RO technology has also been incorporated into the design of the mega Tuas Water Reclamation Plant, which has an integrated NEWater plant, where Jacobs and ROTEC collaborated for the first time after a successful demonstration project between PUB and ROTEC. Both CNF3 and the NEWater plant at Tuas WRP will produce NEWater by passing MBR filtrate though reverse osmosis and ultraviolet light disinfection.
NEWater is one of Singapore's Four National Taps and a resilient water source. Jacobs was PUB's delivery partner for Changi WRP Phase 1, which opened in 2009, and is currently working with PUB to deliver Changi WRP Phase 2 expansion using MBR technology.
"We are delighted to continue our working relationship with PUB and Jacobs by incorporating ROTEC's proprietary flow reversal technology into the design of CNF3," said ROTEC CEO Dr. Noam Perlmuter. "Maintaining sustainable flux through RO membranes by inhibiting mineral scaling and limiting bio-fouling potential is the key to reducing energy consumption and maximizing water recovery. This is good for PUB, Singapore and the planet."
Jacobs will discuss the Changi Water Reclamation Plant and its collaboration with PUB at Singapore International Water Week (SIWW2022), April 17-21.
At Jacobs, we're challenging today to reinvent tomorrow by solving the world's most critical problems for thriving cities, resilient environments, mission-critical outcomes, operational advancement, scientific discovery and cutting-edge manufacturing, turning abstract ideas into realities that transform the world for good. With $14 billion in revenue and a talent force of approximately 55,000, Jacobs provides a full spectrum of professional services including consulting, technical, scientific and project delivery for the government and private sector. Visit jacobs.com and connect with Jacobs on Facebook, Instagram, LinkedIn and Twitter.
Certain statements contained in this press release constitute forward-looking statements as such term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such statements are intended to be covered by the safe harbor provided by the same. Statements made in this release that are not based on historical fact are forward-looking statements. We base these forward-looking statements on management's current estimates and expectations as well as currently available competitive, financial and economic data. Forward-looking statements, however, are inherently uncertain. There are a variety of factors that could cause business results to differ materially from our forward-looking statements, including, but not limited to, the impact of the COVID-19 pandemic, including the emergence and spread of variants of COVID-19, the efficacy and availability of vaccines and treatments, and the related reaction of governments on global and regional market conditions and the company's business. For a description of some additional factors that may occur that could cause actual results to differ from our forward-looking statements, see the discussions contained under Item 1 - Business; Item 1A - Risk Factors; Item 3 - Legal Proceedings; and Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recently filed Annual Report on Form 10-K, ,and Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations; Item 1 - Legal Proceedings; and Item 1A - Risk Factors in our most recently filed Quarterly Report on Form 10-Q,, as well as the company's other filings with the Securities and Exchange Commission. The company is not under any duty to update any of the forward-looking statements after the date of this press release to conform to actual results, except as required by applicable law.
For press/media inquiries:
Kerrie Sparks
214.583.8433
View original content to download multimedia:
SOURCE Jacobs | https://www.1011now.com/prnewswire/2022/04/14/jacobs-selected-design-changi-newater-factory-3/ | 2022-04-14T12:11:31 | 1 | https://www.1011now.com/prnewswire/2022/04/14/jacobs-selected-design-changi-newater-factory-3/ |
HOUSTON, April 14, 2022 /PRNewswire/ -- KBR (NYSE: KBR) was awarded a $62 million, five-year recompete task order to provide conception-to-completion development, testing, engineering and analysis services for the U.S. Army Program Executive Office (PEO) Missiles and Space, Tactical Aviation and Ground Munitions Project Office, and Strategic and Operational Rockets and Missiles (STORM) Project Office.
KBR was awarded this task order under the DoD Information Analysis Center (IAC) Multiple Award Contract (MAC) vehicle. The U.S. Air Force 774th Enterprise Sourcing Squadron awarded these DoD IAC MAC task orders to develop and create new knowledge for the enhancement of the Defense Technical Information Center repository as well as the Research and Development and Science and Technology (S&T) communities. KBR has served PEO Missiles and Space for over 20 years.
"KBR is proud to continue to work with the Army to fulfill the strategic and operational requirements for our soldiers and allies," said Byron Bright, President of KBR Government Solutions. "We have supported PEO Missiles and Space through many mission challenges and look forward to maintaining that relationship."
The company will carry out these duties at Redstone Arsenal in Huntsville, Alabama.
KBR is proud to be a leader in advancing air, space, cyber and missile defense systems for the U.S. military. For more than 35 years, KBR has supported U.S. Army air and missile defense systems. The company drives innovation by combining engineering, technical and scientific expertise with its full life cycle capabilities, mission knowledge and future-focused technologies. Known for excelling in complex and extreme environments, KBR is trusted to overcome the nation's most pressing challenges.
About DoD IAC Program
The DoD IAC, sponsored by the Defense Technical Information Center, provides technical data management and research support for DoD and federal government users. Established in 1946, the IAC program serves the DoD S&T and acquisition communities to drive innovation and technological developments by enhancing collaboration through integrated scientific and technical information development and dissemination for the DoD and broader S&T community.
About KBR
We deliver science, technology and engineering solutions to governments and companies around the world. KBR employs approximately 28,000 people performing diverse, complex and mission critical roles in 34 countries.
KBR is proud to work with its customers across the globe to provide technology, value-added services, and long- term operations and maintenance services to ensure consistent delivery with predictable results. At KBR, We Deliver.
Visit www.kbr.com
Forward Looking Statement
The statements in this press release that are not historical statements, including statements regarding future financial performance, are forward-looking statements within the meaning of the federal securities laws. These statements are subject to numerous risks and uncertainties, many of which are beyond the company's control that could cause actual results to differ materially from the results expressed or implied by the statements. These risks and uncertainties include, but are not limited to: the significant adverse impacts on economic and market conditions of the COVID-19 pandemic and the company's ability to respond to the resulting challenges and business disruption; the recent dislocation of the global energy market; the company's ability to manage its liquidity; the outcome of and the publicity surrounding audits and investigations by domestic and foreign government agencies and legislative bodies; potential adverse proceedings by such agencies and potential adverse results and consequences from such proceedings; changes in capital spending by the company's customers; the company's ability to obtain contracts from existing and new customers and perform under those contracts; structural changes in the industries in which the company operates; escalating costs associated with and the performance of fixed-fee projects and the company's ability to control its cost under its contracts; claims negotiations and contract disputes with the company's customers; changes in the demand for or price of oil and/or natural gas; protection of intellectual property rights; compliance with environmental laws; changes in government regulations and regulatory requirements; compliance with laws related to income taxes; unsettled political conditions, war and the effects of terrorism; foreign operations and foreign exchange rates and controls; the development and installation of financial systems; the possibility of cyber and malware attacks; increased competition for employees; the ability to successfully complete and integrate acquisitions; and operations of joint ventures, including joint ventures that are not controlled by the company.
The company's most recently filed Annual Report on Form 10-K, any subsequent Form 10-Qs and 8-Ks, and other U.S. Securities and Exchange Commission filings discuss some of the important risk factors that the company has identified that may affect its business, results of operations and financial condition. Except as required by law, the company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
This material is based upon work supported by the DoD Information Analysis Center Program (DoD IAC), sponsored by the Defense Technical Information Center under Contract No. FA8075-18-D-0015.
Approved for Public Release, Distribution Unlimited. Any opinions, findings and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the DoD.
View original content to download multimedia:
SOURCE KBR, Inc. | https://www.1011now.com/prnewswire/2022/04/14/kbr-provide-research-analysis-us-army-with-62m-task-order/ | 2022-04-14T12:11:39 | 1 | https://www.1011now.com/prnewswire/2022/04/14/kbr-provide-research-analysis-us-army-with-62m-task-order/ |
- Achieved quarterly revenue of US$1.1 million (US$1.5 million year-to-date) – proceeds from the RTO related financing closed during Q3, were fully deployed for two months of the quarter.
- Proved the resilience of the Company's all-weather strategy by maintaining balance sheet strength during FQ3, including January 2022, which was one of the most volatile months for cryptocurrencies in recent years.
- Strengthened engineering team and appointed CTO to lead the development of MetaBridge – a proprietary platform that will enable institutional investors to securely deploy capital at scale across a variety of DeFi protocols and applications.
VANCOUVER, BC, April 14, 2022 /PRNewswire/ - Liquid Meta Capital Holdings Ltd. ("Liquid Meta" or the "Company") (NEO: LIQD) (FRANKFURT: N5F), a decentralized finance infrastructure and technology company focused on bridging the gap between traditional and decentralized finance, today announced the financial results for the three and nine months ended February 28, 2022. All amounts are expressed in U.S. Dollars unless otherwise stated.
Third Quarter Financial Highlights (Three months ended February 28, 2022)
- Revenue of $1,108,946
- Net loss of $4,539,656
- Net loss of $1,025,050, excluding share-based compensation and listing expenses
- As at February 28, 2022, the Company had total assets of $26,558,562
Management Commentary
Jonathan Wiesblatt, CEO commented, "Since our public launch in December 2021, our team has made important strides toward the achievement of Liquid Meta's core objective – the development of the proprietary terminal platform MetaBridge technology. During the quarter, the Company developed and implemented several important MetaBridge modules, which are currently being used in our daily liquidity mining operations. Subsequent to the end of the quarter, we announced the addition of an experienced Chief Technology Officer (CTO), which we expect will accelerate the building of critical applications and development protocols for the commercialization of our platform."
Mr. Wiesblatt continued, "As we continue to build MetaBridge, our team is committed to deploying capital in a prudent manner to maintain balance sheet strength, build shareholder value and ensure the ability to accelerate our core technology roadmap. Liquid Meta has successfully deployed the capital on its balance sheet across a select group of blockchains, DeFi applications (Dapps) and liquidity pools (LPs). Our all-weather liquidity mining strategy has generated consistent daily revenue despite elevated volatility in the crypto market during the fiscal third quarter. I am pleased to report that in the third quarter of fiscal 2022, Liquid Meta generated revenue of $1.1 million on its capital base, which was only fully deployed for two months of the quarter. 2022 will be an important year for Liquid Meta as the team continues to build what we believe will be the premier gateway for institutional access to DeFi."
January was one of the most volatile months in recent years across all risky assets including cryptocurrencies and adjacent crypto markets like DeFi. During the month of January, certain crypto assets including the largest crypto tokens BTC and ETH lost ~20% and 30% of their value during the month. A basket of layer 1 tokens that Liquid Meta uses in its staking and liquidity mining operations lost an average of 42% in the month of January. Although global asset values plummeted during January including most crypto tokens, Liquid Meta was able to preserve its balance sheet through an active hedging program, a diversified liquidity mining strategy, and limited exposure to unhedged assets. The overall impact to Liquid Meta's balance sheet was less than 2% of total assets deployed. Furthermore, market conditions normalized in the second half of February and March, with yields on the portfolio rising to pre-January levels.
At its core, Liquid Meta is building a technology-enabled liquidity mining company focused on the next generation of blockchain-based protocols, platforms, and applications. Liquid Meta has assembled a comprehensive engineering team that is building proprietary technology in order to access, automate, and operate across a variety of DeFi protocols and applications at scale, which can then be used to onboard third-party capital, or be licensed as software to institutional investors. Major attributes of Meta Bridge include asset monitoring, performance analysis, reporting & accounting, pre-trade compliance and network security.
One of Liquid Meta's key priorities for 2022 is to advance and commercialize a technology stack specifically developed for institutional investors to access DeFi. During the third quarter, Liquid Meta made substantial progress towards achieving this goal by strengthening the engineering team, and subsequent to quarter end, the Company appointed Daniel Opperman as CTO to oversee the build of development protocols for the commercialization of MetaBridge.
Key Developments – Third Quarter
- On December 22, 2021, Liquid Meta began trading on the NEO exchange under the symbol LIQD
- On December 23, 2021, the Company announced the appointment of Stephen Harper and Tom Kang to the Company's Board of Directors
- On January 10, 2022, the Company announced the appointment of Clara Bullrich to the Company's Board of Directors
- On January 13, 2022, the Company announced a partnership with XLD Finance to provide liquidity to XLD's stablecoin-based ecosystem
- On January 25, 2022, Liquid Meta announced a partnership with Civic Technologies
- Liquid Meta has now deployed over US$20 million dollars across various blockchains, Dapps and LPs
- Incorporated direct node integration to 9 different blockchains on our search engine. These integrations represent the foundations of MetaBridge enabling Liquid Meta to automate our operation and capture DeFi transaction activity. Blockchains include Ethereum, Binance Smart Chain, Polygon, Avalanche, Fantom, Ronin, Solana, Terra and Arbitrum
- Developed proprietary applications that capture transaction activity and financial performance across blockchains, Dapps and LPs
- We have completed the first phase of our comprehensive liquidity mining hedging strategy. Liquid Meta is currently using internally developed software to test and deploy hedging strategies across different tokens and market environments. We continue to deploy more of these technologies across a greater number of liquidity pools (LPs)
Outlook
- Over the next 12-months Liquid Meta will be focused on advancing the development of tools and software products for the commercialization of MetaBridge. and scaling its liquidity mining operation
- Liquid Meta has now deployed greater than $20.0 million of liquidity across DeFi. The additional capital deployed is expected to produce daily revenue that will exceed the run rates produced in the Q3 results
- Will focus on developing partnership opportunities across DeFi
Update on Ronin Network
As previously disclosed, Liquid Meta has provided liquidity to an LP on a decentralized exchange (DEX) that exists on the Ronin Network, and which is interconnected to the bridge that experienced the security breach. The Company is pleased to share that this DEX has now been restored and reopened following an update by Sky Mavis and the Ronin team. LPs such as Liquid Meta are now able to freely and securely enter or exit the DEX.
On April 6, 2022, Sky Mavis announced that it has raised a US$150M funding round to reimburse user funds affected by the Ronin Network breach. Led by crypto exchange Binance, this combined with Sky Mavis and Axie balance sheet funds, should ensure that all users are reimbursed. The Ronin Network bridge will open once it has undergone a security upgrade and several audits, which can take several weeks. In the meantime, Binance is supporting the Ronin Network by providing ETH withdrawals and deposits for Axie Infinity users, allowing most of them to operate freely. Further updates from the Ronin Network can be followed here.
"We are pleased to share that the DEX with approximately $2 million dollars of Liquid Meta's funds has now been fully restored and we are now able to access funds and continue to mine our liquidity position. At Liquid Meta, we remain cognizant of the risks within the digital currency industry and have in place a robust set of criteria we utilize to select Dapps and LPs where we deploy our liquidity. These include a thorough analysis, overview of teams, founders of the exchange, audited Dapps, Total Value Locked (TVL) on platform, liquidity as well as the quality of networks and blockchains, among others," commented Mr. Wiesblatt.
Liquid Meta is focused on the DeFi segment of the digital asset ecosystem through its liquidity mining business. Every time a transaction occurs within the LP, the protocol generates a service fee for the transaction, a portion of which is distributed to liquidity providers in the form of fees for providing a service to the protocol. Additionally, in some cases, liquidity miners can also earn protocol reward tokens by protocols and applications, which are offered as incentives and additional revenue generating opportunities for liquidity miners for interacting and providing liquidity to various protocols.
Financial Statements and MD&A
Liquid Meta's financial Statements for the quarter ended February 28, 2022 and Management's Discussion and Analysis (the "MD&A") for the three and nine-months ended February 28, 2022 are available on SEDAR at www.sedar.com.
Liquid Meta is a decentralized finance infrastructure and technology company that is powering the next generation of open-access protocols and applications. The Company is creating the bridge between traditional and decentralized finance while ushering in a new era of financial infrastructure that benefits anyone, anywhere.
To learn more visit: Website | LinkedIn | Twitter
Cautionary Notice
Neo Exchange has not reviewed or approved this press release for the adequacy or accuracy of its contents.
Notice Regarding Forward-Looking Information:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Liquid Meta to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption "Risks and Uncertainties" in the Company's Filing Statement dated as of December 17, 2021 which is available for view on SEDAR at www.sedar.com. Forward-looking statements contained herein are made as of the date of this press release and Liquid Meta disclaims, other than as required by law, any obligation to update any forward-looking statements whether as a result of new information, results, future events, circumstances, or if management's estimates or opinions should change, or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.
Liquid Meta's operations could be significantly adversely affected by the effects of a widespread global outbreak of a contagious disease, including the recent outbreak of illness caused by COVID-19. It is not possible to accurately predict the impact COVID-19 will have on operations and the ability of others to meet their obligations, including uncertainties relating to the ultimate geographic spread of the virus, the severity of the disease, the duration of the outbreak, and the length of travel and quarantine restrictions imposed by governments of affected countries. In addition, a significant outbreak of contagious diseases in the human population could result in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could further affect operations and the ability to finance its operations.
View original content to download multimedia:
SOURCE Liquid Meta Capital Holdings Ltd | https://www.1011now.com/prnewswire/2022/04/14/liquid-meta-announces-third-quarter-results/ | 2022-04-14T12:11:46 | 0 | https://www.1011now.com/prnewswire/2022/04/14/liquid-meta-announces-third-quarter-results/ |
HOUSTON, April 14, 2022 /PRNewswire/ -- Main Street Capital Corporation (NYSE: MAIN) ("Main Street") is pleased to announce the following recent activity in its private loan portfolio. During the first quarter of 2022, Main Street originated approximately $226.6 million in new commitments in its private loan portfolio across six new and two existing borrowers and funded total investments across its private loan portfolio with a cost basis totaling approximately $201.5 million.
The following represent notable new and increased private loan commitments and investments during the first quarter of 2022:
- $37.3 million in a first lien senior secured loan and $6.2 million in a first lien senior secured revolver to a provider of outsourced marketing services that help brands and retailers manage all parts of the consumer lifecycle;
- New commitments of $22.9 million in a first lien senior secured loan, $4.6 million in a first lien senior secured revolver, and $15.3 million in a first lien senior secured delayed draw loan to a provider of supply chain solutions for vendor managed inventory programs to refinance an existing borrower's loan and revolver;
- $25.6 million in a first lien senior secured loan and $7.9 million in a first lien senior secured revolver to an operator of a newspaper publishing business;
- Increased commitments of $27.5 million in a first lien senior secured loan to an importer, mixer, roaster, and packager of bulk nuts and dried fruits;
- $18.4 million in a first lien senior secured loan, $4.3 million in a first lien senior secured revolver, and $3.8 million in a first lien senior secured delayed draw loan to a provider of clinical infusion and pharmacy services;
- $22.0 million in a first lien senior secured delayed draw loan to the largest express-only tunnel car wash operator in the U.S.;
- $13.3 million in a first lien senior secured loan, $1.8 million in a first lien senior secured revolver, and $0.7 million in equity to a regional thrift retailer with locations throughout the Southeast U.S.; and
- $10.8 million in a first lien senior secured loan, $2.4 million in a first lien senior secured delayed draw loan, and $1.5 million in equity to a leading independent provider of maintenance, repair, and operations services for the private aviation industry.
As of March 31, 2022, Main Street's private loan portfolio included total investments at cost of approximately $1.3 billion across 79 unique borrowers. The private loan portfolio, as a percentage of cost, included 95.3% invested in first lien debt investments, 0.3% invested in second lien debt investments, and 4.4% invested in equity investments or other securities.
ABOUT MAIN STREET CAPITAL CORPORATION
Main Street (www.mainstcapital.com) is a principal investment firm that primarily provides long-term debt and equity capital to lower middle market companies and debt capital to middle market companies. Main Street's portfolio investments are typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. Main Street seeks to partner with entrepreneurs, business owners and management teams and generally provides "one stop" financing alternatives within its lower middle market investment strategy. Main Street's lower middle market companies generally have annual revenues between $10 million and $150 million. Main Street's middle market debt investments are made in businesses that are generally larger in size than its lower middle market portfolio companies.
Main Street, through its wholly owned portfolio company MSC Adviser I, LLC ("MSC Adviser"), also maintains an asset management business through which it manages investments for external parties. MSC Adviser is registered as an investment adviser under the Investment Advisers Act of 1940.
Contacts:
Main Street Capital Corporation
Dwayne L. Hyzak, CEO, dhyzak@mainstcapital.com
Jesse E. Morris, CFO and COO, jmorris@mainstcapital.com
713-350-6000
Dennard Lascar Investor Relations
Ken Dennard | ken@dennardlascar.com
Zach Vaughan | zvaughan@dennardlascar.com
713-529-6600
View original content:
SOURCE Main Street Capital Corporation | https://www.1011now.com/prnewswire/2022/04/14/main-street-announces-first-quarter-2022-private-loan-portfolio-activity/ | 2022-04-14T12:11:54 | 0 | https://www.1011now.com/prnewswire/2022/04/14/main-street-announces-first-quarter-2022-private-loan-portfolio-activity/ |
Innovative and modern design featuring clear and concise content
MISSISSAUGA, ON, April 14, 2022 /PRNewswire/ - Maple Leaf Foods Inc. (TSX: MFI), the world's first major carbon neutral food company, today unveiled its new corporate website, www.mapleleaffoods.com, inviting visitors to explore the company's journey to become the most sustainable protein company on earth.
The clean, crisp, modern design offers engaging content featuring stunning visuals reflecting Maple Leaf Foods' values, products, operations and sustainability focus. The new, intuitively built website is loaded with easy-to-digest, informative content mixed with beautiful imagery.
Using latest technology, the new website is optimized for a mobile user experience designed with accessibility and SEO best practices in mind.
Key features of the new website include:
- Careers and Job Search: In the new careers section of the website, job seekers can find an abundance of information about career opportunities at Maple Leaf Foods in a vast number of areas of the organization and apply for jobs directly on the website.
- Locations: The new locations feature offers a transparent view of the company's 25+ locations across North America, including directions and details about each facility.
- Media Centre: The upgraded media centre is a one-stop-shop for company resources from news releases and fact sheets to multimedia assets, including high res photos, videos and logos.
- Investors: Visitors are invited to learn more about how Maple Leaf Foods is creating shared value for multiple stakeholders in the investors microsite.
- Brands: Maple Leaf Foods is a family of brands and in the new website's enhanced brands section, consumers can learn more about Maple Leaf Foods' iconic brands, Maple Leaf® and Schneiders®, and dive deeper into the 21 additional brands in the company's portfolio.
- Stories: Learn more about life at Maple Leaf Foods through first-person accounts written on the company blog.
The new corporate website evokes the true essence of Maple Leaf Foods. It offers a visually appealing platform with transparent content where the company showcases its purpose to Raise the Good in Food and demonstrates its leadership in delivering shared value to its customers, consumers, investors, communities, its people and the environment. Visit www.mapleleaffoods.com and join Maple Leaf Foods on its journey to become the most sustainable protein company on earth.
Maple Leaf Foods is a carbon neutral company with a vision to be the most sustainable protein company on earth, responsibly producing food products under leading brands including Maple Leaf®, Maple Leaf Prime®, Maple Leaf Natural Selections®, Schneiders®, Schneiders® Country Naturals®, Mina®, Greenfield Natural Meat Co.®, Lightlife® and Field Roast™. The Company employs approximately 13,500 people and does business primarily in Canada, the U.S. and Asia. The Company is headquartered in Mississauga, Ontario and its shares trade on the Toronto Stock Exchange (MFI).
View original content to download multimedia:
SOURCE Maple Leaf Foods Inc. | https://www.1011now.com/prnewswire/2022/04/14/maple-leaf-foods-unveils-new-corporate-website/ | 2022-04-14T12:12:01 | 0 | https://www.1011now.com/prnewswire/2022/04/14/maple-leaf-foods-unveils-new-corporate-website/ |
Esteemed higher education leader to oversee CLU operations
CLAREMONT, Calif., April 14, 2022 /PRNewswire/ -- Higher education executive Mark Mendoza has joined Claremont Lincoln University (CLU) as its Chief Operations Officer and Executive Vice President. In this role, Mr. Mendoza will oversee all aspects of operations, marketing, enrollment, and technology; spearhead key collaborations with strategic partners; and set operational and strategic priorities to achieve CLU's long-term vision.
"Mark Mendoza's focus on student success, his collaborative leadership style, and his considerable managerial strengths, innovative practices, and strategic agility are exactly suited to CLU's ambitious vision for the future," states Dr. Lynn Priddy, President of Claremont Lincoln University. "He knows both the mission and business of higher education, valuing academic excellence and the student experience in ways fully aligned with CLU's values and focus on ethics and equity."
Mr. Mendoza brings two decades of higher education experience and extensive operations expertise in building effective teams and innovating solutions that lead to better student outcomes. He is known for collaborative leadership that creates strategic growth and that achieves operational efficiencies and organizational goals. While in the business sector supporting higher education, Mark worked with over 30 non-profit and private regional colleges and universities, guiding their leadership teams, helping them surpass enrollment and revenue goals, and assuring their effective educational and operational technology integrations.
Mr. Mendoza holds a Bachelor of Arts in Sociology from University of Central Oklahoma, a Master of Arts in Human Relations from University of Oklahoma, and a Master of Business Administration (MBA) from University of Phoenix.
"I am honored to join CLU, an organization with an entrepreneurial spirit and a socially conscious leadership model, an approach to teaching and learning that I believe is missing in most other universities," said Mr. Mendoza. "CLU has exceptional, forward-looking, and distinctive programs, and I look forward to championing the strategic vision through student-focused strategies and excellence in quality, service, compliance, and brand expansion."
About Claremont Lincoln University
Claremont Lincoln University (CLU) is a non-profit graduate university offering affordable online master's degrees, graduate certificates, and professional development programs. Through a socially conscious education framework, CLU's mission is to create a new leadership ecosystem through its proprietary Claremont Core®, a distinctive model that encompasses the knowledge needed to become an effective leader of positive change in the workplace or community. CLU is regionally accredited by the highly regarded WASC Senior College and University Commission (WSCUC), which ensures institutions meet strict standards and fulfill their missions to serve their students and the public good. Master's degree programs at CLU focus on civic engagement, ethics, healthcare administration, higher education, human resources, organizational leadership, management, professional studies, public administration, social impact, and sustainability leadership.
View original content to download multimedia:
SOURCE Claremont Lincoln University | https://www.1011now.com/prnewswire/2022/04/14/mark-mendoza-joins-claremont-lincoln-university-chief-operations-officer-executive-vice-president/ | 2022-04-14T12:12:09 | 0 | https://www.1011now.com/prnewswire/2022/04/14/mark-mendoza-joins-claremont-lincoln-university-chief-operations-officer-executive-vice-president/ |
PITTSBURGH, April 14, 2022 /PRNewswire/ -- Mastech Digital, Inc. (NYSE American: MHH), a leading provider of Digital Transformation IT Services, has scheduled a conference call to discuss the results for the first quarter ended March 31, 2022. The conference call will occur on Wednesday, April 27th at 9:00 a.m. Eastern Time and will be hosted by Mr. Vivek Gupta, CEO, Mr. Jack Cronin, CFO and Mr. Ganeshan Venkateshwaran, Chief Executive Officer of Mastech InfoTrellis (the Company's data and analytics business segment).
The conference call can be accessed through a listen-only dial-in number or through a live webcast. To listen to the conference call, please dial 877-407-3980. The webcast will be available at http://www.mastechdigital.com via the Investors section. Investors should log on 10 minutes prior to the start of the program.
A replay of the call will be available for 7 days following its conclusion. Domestic callers can access the replay by dialing 877-660-6853 and entering conference number 13729230. International callers can access the replay by dialing 201-612-7415 and entering the same conference number 13729230. The webcast will be available for 7 days on Mastech Digital's corporate website.
About Mastech Digital, Inc.:
Mastech Digital (NYSE American: MHH) is a leading provider of Digital Transformation IT Services. The Company offers Data Management and Analytics Solutions, Digital Learning, and IT Staffing Services with a Digital First approach. A minority-owned enterprise, Mastech Digital is headquartered in Pittsburgh, PA with offices across the U.S., Canada, EMEA, India and ASEAN.
For more information, contact:
Donna Kijowski
Manager, Investor Relations
Mastech Digital, Inc.
+1-888-330-5497
View original content:
SOURCE Mastech Digital, Inc. | https://www.1011now.com/prnewswire/2022/04/14/mastech-digital-inc-discuss-first-quarter-2022-financial-results-april-27-2022/ | 2022-04-14T12:12:15 | 1 | https://www.1011now.com/prnewswire/2022/04/14/mastech-digital-inc-discuss-first-quarter-2022-financial-results-april-27-2022/ |
The company will present its innovative cultured meat processes and go-to-market plans at one of the world's leading food and beverage trade fairs
REHOVOT, Israel, April 14, 2022 /PRNewswire/ -- MeaTech 3D Ltd. (Nasdaq: MITC), an international deep-tech food company at the forefront of the cultured meat revolution, today announced that it will be sharing its vision and efforts in the development of cultured meat at the 2022 Anuga FoodTec Trade Fair in Cologne, Germany at the Cologne Exhibition Center from April 26-29th, 2022.
Come visit the MeaTech team in Hall 6.1, Stand A093. They will be on-hand to discuss the company's vision, latest achievements, and initial go-to-market strategy of offering cultured chicken fat biomass as an ingredient for enhancing the meaty taste and mouthfeel of plant-based meat alternatives. The chicken product is being developed by MeaTech's wholly owned Belgian subsidiary, Peace of Meat.
On Friday, April 29th at 11:50am in the Hall 6 speaking area, Simon Fried, Head of Business Development, will talk about how cultured meat can revolutionize agriculture and MeaTech's leading role in this burgeoning industry.
About MeaTech 3D
MeaTech is an international deep-tech food company at the forefront of the cultured meat revolution. The company initiated activities in 2019 and is listed on the Nasdaq Capital Market under the ticker "MITC". MeaTech maintains facilities in Rehovot, Israel and Antwerp, Belgium and is in the process of expanding activities to California, USA. The company believes cultivated meat technologies hold significant potential to improve meat production, simplify the meat supply chain, and offer consumers a range of new product offerings.
MeaTech aims to provide an alternative to industrialized animal farming that dramatically reduces carbon footprint, minimizes water and land usage, and prevents the slaughtering of animals. By adopting a modular factory design, MeaTech will be able to offer a sustainable solution for producing a variety of beef, chicken and pork products, both as raw materials and whole cuts.
For more information, please visit: https://meatech3d.com
Forward-Looking Statements
This press release contains forward-looking statements concerning MeaTech's business, operations and financial performance and condition as well as plans, objectives, and expectations for MeaTech's business operations and financial performance and condition. Any statements that are not historical facts may be deemed to be forward-looking statements. Forward-looking statements reflect MeaTech's current views with respect to future events and are based on assumptions and subject to known and unknown risks and uncertainties, which change over time, and other factors that may cause MeaTech's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and are typically identified with words such as "may," "could," "should," "will," "would," "believe," "anticipate," "estimate," "expect," "aim," "intend," "plan" or words or phases of similar meaning and include, without limitation, MeaTech's expectations regarding the success of its cultured meat manufacturing technologies it is developing, which will require significant additional work before MeaTech can potentially launch commercial sales; MeaTech's research and development activities associated with technologies for cultured meat manufacturing, including three-dimensional meat production, which involves a lengthy and complex process; MeaTech's ability to obtain and enforce its intellectual property rights and to operate its business without infringing, misappropriating, or otherwise violating the intellectual property rights and proprietary technology of third parties; and other risks and uncertainties, including those identified in MeaTech's Annual Report on Form 20-F for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission on March 24, 2022. New risks and uncertainties may emerge from time to time, and it is not possible for MeaTech to predict their occurrence or how they will affect MeaTech. If one or more of the factors affecting MeaTech's forward-looking information and statements proves incorrect, then MeaTech's actual results, performance or achievements could differ materially from those expressed in, or implied by, forward-looking information and statements contained in this press release. Therefore, MeaTech cautions you not to place undue reliance on its forward-looking information and statements. MeaTech disclaims any duty to revise or update the forward-looking statements, whether written or oral, to reflect actual results or changes in the factors affecting the forward-looking statements, except as specifically required by law.
Logo: https://mma.prnewswire.com/media/1753830/MeaTech_Logo.jpg
View original content:
SOURCE MeaTech 3D Ltd. | https://www.1011now.com/prnewswire/2022/04/14/meatech-3d-participate-anuga-foodtec-trade-fair-cologne-germany-april-26-29-2022/ | 2022-04-14T12:12:22 | 1 | https://www.1011now.com/prnewswire/2022/04/14/meatech-3d-participate-anuga-foodtec-trade-fair-cologne-germany-april-26-29-2022/ |
TORONTO , April 14, 2022 /PRNewswire/ - Mijem Newcomm Tech Inc. ("Mijem or the "Company") (CSE: MJEM), a North American social media and technology company, announces they will be giving away a tuition scholarship to eligible post-secondary students residing in the Continental United States. The scholarship prize is US$2,500 cash and the equivalent of US$2,500 in Bitcoin SV (BSV). The prize giveaway is in collaboration with Bitcoin Association for BSV.
"This incredible campaign focuses on giving back to students who have been disproportionately impacted by the pandemic. This giveaway is an opportunity to help students financially with alleviating the cost of post-secondary tuition, while helping them to kick-start their crypto portfolio." said Laurie Freudenberg, Mijem's Chief Executive Officer. "Bitcoin Association for BSV is a tremendous supporter not only of Bitcoin SV but also of students with its Satoshi Nakamoto Scholarship, making it the perfect partner for this initiative."
Commenting on today's announcement, Bitcoin Association for BSV Founding President Jimmy Nguyen, said:
"We are excited to be partnering with Mijem to supply financial aid to students through this tuition scholarship and to introduce them to the world of blockchain technology and the powerful utility of BSV– the world's only public blockchain capable of scaling to meet the needs of enterprise and government. Fostering the development of young talent is of vital importance to Bitcoin Association for BSV, as this is a crucial step in building the skills necessary to create the blockchain-based applications of the future."
Mijem is a community buy-and-sell app designed for Gen Z, college and university students. Centred around campuses, Mijem provides a safe and convenient platform to buy-and-sell goods and services such as textbooks, clothing, electronics and more. The app represents a new way to build community and connect with peers, save money and live sustainably. What's more, for every US$1 transacted through the app, Mijem users can earn rewards and build their crypto portfolio through an integrated digital wallet that allows them to redeem points for Bitcoin SV.
The Mijem app has been installed by thousands of students across more than 1,500 colleges and universities in North America and has recently been updated with new features and functionality to help students connect, transact and build wealth in a sustainable manner. The app is available for free on the Apple or Google Play stores and can be downloaded from the links below.
Download on iOS
Download on Android
According to a recent survey by Capitalize, over 50% of Gen Z believe cryptocurrencies will become widely used in the future, and about 17% of the entire cryptocurrency market is already being occupied by Gen Z.
A notable benefit to Bitcoin SV is how it transacts quickly and inexpensively, scales easily and is far more environmentally friendly than many other cryptos - all features that are important to Gen Z.
The sweepstakes is open to Mijem users who are eligible students. To be considered eligible for a chance to win the scholarship, students must be legal residents of the Continental United States who are of the age of majority in their state of residence at the time of entry, and who are enrolled in or accepted for enrolment at a post-secondary college or university in the United States or Canada in the Summer 2022 or Fall 2022. The giveaway runs for 60 days, ending on June 13, 2022 at 11:59 EDST. Winners will be chosen by random draw from eligible entries on or around June 27, 2022, and announced on Mijem's social media channels.
Full details and Official Rules can be found at: https://mijem.com/us-giveaway
Based in Switzerland, Bitcoin Association for BSV is the global industry organization that works to advance business on the Bitcoin SV blockchain. It brings together essential components of the Bitcoin SV ecosystem – enterprises, start-up ventures, developers, merchants, exchanges, service providers, blockchain transaction processors (miners), and others – working alongside them, as well as in a representative capacity, to drive further use of the Bitcoin SV blockchain and uptake of the BSV digital currency. The Association works to build a regulation-friendly ecosystem that fosters lawful conduct while facilitating innovation using all aspects of Bitcoin technology. More than a digital currency and blockchain, Bitcoin is also a network protocol; just like Internet protocol, it is the foundational rule set for an entire data network. The Association supports use of the original Bitcoin protocol to operate the world's single blockchain on Bitcoin SV.
Mijem is a Canadian-based social media and technology company that provides innovative solutions to create a vibrant social marketplace for Generation Z to connect and to efficiently buy, sell and trade goods and services. Mijem's patent-pending flagship technology currently permits thousands of university and college students across the United States and Canada to both connect on-line and engage in consumer-to-consumer commerce.
This news release contains "forward-looking statements" within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking statements. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or may contain statements that certain actions, events or results "may", "could", "would", "might" or "will be taken", "will continue", "will occur" or "will be achieved".
Forward-looking information in this news release is based on certain assumptions and expected future events. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
View original content to download multimedia:
SOURCE Mijem Newcomm Tech Inc. | https://www.1011now.com/prnewswire/2022/04/14/mijem-newcomm-tech-inc-announces-scholarship-giveaway-with-bitcoin-association-bsv/ | 2022-04-14T12:12:28 | 0 | https://www.1011now.com/prnewswire/2022/04/14/mijem-newcomm-tech-inc-announces-scholarship-giveaway-with-bitcoin-association-bsv/ |
- Cardiac Electrophysiology Key Opinion Leaders to include Bruce Stambler, MD and Sean Pokorney, MD
- Conference call and webcast on Thursday, April 21, 2022 at 1:00 p.m. ET
MONTREAL and CHARLOTTE, N.C., April 14, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that the Company will host a virtual Key Opinion Leader (KOL) event on Thursday, April 21, 2022 at 1:00 p.m. ET. The event will focus on etripamil, the Company's lead investigational product, for the treatment of patients with paroxysmal supraventricular tachycardia (PSVT). Etripamil is currently being assessed in multiple clinical trials, including the pivotal Phase 3 RAPID trial in patients with PSVT for which topline data are expected in the middle of the second half of 2022.
The agenda for the event will include an overview of PSVT, including the current treatment landscape and patient and healthcare system burdens, a review of the existing etripamil dataset in patients with PSVT, and a discussion of the potential commercial opportunity. Joining Milestone's management team will be:
- Bruce Stambler, MD, FHRS, Director of Cardiac Arrhythmia Research and Education, Piedmont Heart Institute, Atlanta, GA
- Sean Pokorney, MD, MBA, Director of the Arrhythmia Core Laboratory, Duke Clinical Research Institute, Assistant Professor of Medicine, Duke University School of Medicine, Durham, NC
Conference Call and Webcast
To access a live or recorded webcast of the event and accompanying slides, please visit the News & Events section of Milestone's website at www.milestonepharma.com. To access the live call by phone, dial (203) 518-9713 (domestic) or (866) 518-6930 (international) and enter the passcode 2230168. The recorded webcast and slides will be available on the Company's website following the call.
About Paroxysmal Supraventricular Tachycardia
Paroxysmal supraventricular tachycardia (PSVT) is a condition characterized by intermittent episodes of rapid heartbeat that starts and stops suddenly and without warning that Milestone Pharmaceuticals estimates affects approximately two million Americans. Episodes of PSVT are often associated with symptoms including palpitations, sweating, chest pressure or pain, shortness of breath, sudden onset of fatigue, lightheadedness or dizziness, fainting, and anxiety. Certain intravenous medications, including adenosine, beta-blockers and calcium channel blockers, have long been used for the acute treatment of PSVT. However, these medications must be administered under medical supervision, usually in an emergency department or other acute care setting.
About Etripamil
Etripamil, Milestone's lead investigational product, is a novel calcium channel blocker designed to be a rapid-response therapy for episodic cardiovascular conditions. As a nasal spray that is self-administered by the patient, etripamil has the potential to shift the current treatment experience for many patients from the emergency department to a medically-unsupervised setting. Milestone is conducting a comprehensive development program for etripamil, with Phase 3 trials ongoing in paroxysmal supraventricular tachycardia (PSVT) and a Phase 2 proof-of-concept trial underway in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR).
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone's lead product candidate etripamil is currently in a Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit www.milestonepharma.com and follow the Company on Twitter at @MilestonePharma.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "will," "expect," "continue," "estimate," "potential," "progress" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the potential of etripamil to serve as a promising therapy for PSVT patients, the design, progress, timing, scope and results of the RAPID and ReVeRA trials; Milestone's ability to execute on the remainder of the PSVT program, Milestone's ongoing plans to study etripamil in atrial fibrillation patients, the sufficiency of Milestone's current cash resources to support its operations, and estimates about the addressable market and commercial potential for treatments of atrial fibrillation with rapid ventricular rate. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, the risks inherent in biopharmaceutical product development and clinical trials, including the lengthy and uncertain regulatory approval process, uncertainties related to the timing of initiation, enrollment, completion and evaluation of clinical trials, and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others, as well as risks related to pandemics and public health emergencies, including those related to the ongoing COVID-19 pandemic, and risks related the sufficiency of Milestone's capital resources and its ability to raise additional capital. These and other risks are set forth in Milestone's filings with the U.S. Securities and Exchange Commission, including in its annual report on Form 10-K for the year ended December 31, 2020, under the caption "Risk Factors," as such discussion may be updated from time to time by subsequent filings we may make with the U.S. Securities & Exchange Commission. Except as required by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Contact
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com
View original content to download multimedia:
SOURCE Milestone Pharmaceuticals, Inc. | https://www.1011now.com/prnewswire/2022/04/14/milestone-pharmaceuticals-host-virtual-key-opinion-leader-event-etripamil-treatment-psvt/ | 2022-04-14T12:12:35 | 0 | https://www.1011now.com/prnewswire/2022/04/14/milestone-pharmaceuticals-host-virtual-key-opinion-leader-event-etripamil-treatment-psvt/ |
THE WOODLANDS, Texas, April 14, 2022 /PRNewswire/ -- MIND Technology, Inc. (NASDAQ: MIND) announced today that it will release financial results for its fiscal 2022 fourth quarter and full year ended January 31, 2022 after the market closes on Wednesday, April 20, 2022. In conjunction with the release, the Company has scheduled a conference call, which will be broadcast live over the Internet, for Thursday, April 21st at 9:00 a.m. Eastern Time / 8:00 a.m. Central Time.
For those who cannot listen to the live call, a replay will be available through April 28, 2022 and may be accessed by dialing (201) 612-7415 and using pass code 13728499#. Also, an archive of the webcast will be available shortly after the call at http://mind-technology.com/ for 90 days. For more information, please contact Dennard Lascar Investor Relations at MIND@dennardlascar.com.
About MIND Technology
MIND Technology, Inc. provides technology to the oceanographic, hydrographic, defense, seismic and security industries. Headquartered in The Woodlands, Texas, MIND has a global presence with key operating locations in the United States, Singapore, Malaysia, and the United Kingdom. Its Seamap and Klein units, design, manufacture and sell specialized, high performance, marine sonar and seismic equipment.
View original content:
SOURCE MIND Technology, Inc. | https://www.1011now.com/prnewswire/2022/04/14/mind-technology-announces-fiscal-2022-fourth-quarter-year-end-earnings-release-conference-call-schedule/ | 2022-04-14T12:12:42 | 1 | https://www.1011now.com/prnewswire/2022/04/14/mind-technology-announces-fiscal-2022-fourth-quarter-year-end-earnings-release-conference-call-schedule/ |
- "LSD as a Treatment for Anxiety Disorders: New Evidence of Efficacy" will present the most recent and robust data on LSD in patients with anxiety -
- This study builds on decades of research on the effects of LSD in humans -
NEW YORK, April 14, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that Dr. Frederike Holze and Prof. Dr. Matthias Liechti, MindMed collaborators at University Hospital Basel (UHB), will present results from the LSD-Assist Study, a Phase 2 investigator-initiated clinical trial of LSD in the treatment of anxiety disorders, at London's PSYCH Symposium on May 11, 2022.
The presentation, titled "LSD as a Treatment for Anxiety Disorders: New Evidence of Efficacy," will present preliminary topline safety and efficacy results for lysergic acid diethylamide (LSD) in 46 patients with clinically significant anxiety. The trial was conducted at two centers, at UHB and at the private psychiatry practice of Dr. Peter Gasser. MindMed supports the UHB Liechti Lab in conducting investigator-initiated trials for LSD and other novel therapies and has exclusive access and rights to the data generated by these studies.
Prof. Dr. Liechti said, "Anxiety disorders are widespread and often insufficiently managed with available medications. I look forward to sharing the preliminary findings from this important study, including patients with anxiety associated with life-threatening illness but also patients with anxiety disorder without severe somatic illness, adding to our understanding of how LSD may be used safely to treat anxiety disorders."
"Since the 1940s, LSD has been extensively investigated for its effects in humans, showing particular benefit in mitigating symptoms of anxiety and depression," added Robert Barrow, Chief Executive Officer and Director of MindMed. "The results from this study, if positive, would further validate our approach to develop MM-120 in the treatment of Generalized Anxiety Disorder and would support the progression of our MM-120 development program. We are proud to support Dr. Liechti and his team and to extend their findings through our commercial drug development programs."
About MindMed
MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.
MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
View original content to download multimedia:
SOURCE Mind Medicine (MindMed) Inc. | https://www.1011now.com/prnewswire/2022/04/14/mindmed-collaborator-dr-matthias-liechti-present-topline-clinical-trial-results-lsd-anxiety-disorders-psych-symposium/ | 2022-04-14T12:12:51 | 0 | https://www.1011now.com/prnewswire/2022/04/14/mindmed-collaborator-dr-matthias-liechti-present-topline-clinical-trial-results-lsd-anxiety-disorders-psych-symposium/ |
NEW YORK, April 14, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MP Materials Corp. f/k/a Fortress Value Acquisition Corp. ("MP Materials" or the "Company") (NYSE: MP) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MP Materials investors who were adversely affected by alleged securities fraud between May 1, 2020 and February 2, 2022. Follow the link below to get more information and be contacted by a member of our team:
MP investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Fortress Value Acquisition Corp. ("FVAC") had overstated its due diligence efforts and expertise with respect to identifying target companies to acquire; (ii) FVAC performed inadequate due diligence into Legacy MP Materials prior to the business combination, or else ignored significant red flags regarding, inter alia, Legacy MP Materials' management, compliance policies, and Mountain Pass's profitability; (iii) as a result, the Company's future business and financial prospects post-business combination were overstated; (iv) MP Materials engaged in an abusive transfer price manipulation scheme with a related party in the People's Republic of China to artificially inflate the Company's profits; (v) MP Materials' ore at the Mountain Pass Rare Earth Mine and Processing Facility was not economically viable to harvest for rare earth metals; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
WHAT'S NEXT? If you suffered a loss in MP Materials during the relevant time frame, you have until April 25, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
View original content to download multimedia:
SOURCE Levi & Korsinsky, LLP | https://www.1011now.com/prnewswire/2022/04/14/mp-lawsuit-alert-levi-amp-korsinsky-notifies-mp-materials-corp-fka-fortress-value-acquisition-corp-investors-class-action-lawsuit-upcoming-deadline/ | 2022-04-14T12:13:01 | 0 | https://www.1011now.com/prnewswire/2022/04/14/mp-lawsuit-alert-levi-amp-korsinsky-notifies-mp-materials-corp-fka-fortress-value-acquisition-corp-investors-class-action-lawsuit-upcoming-deadline/ |
SINGAPORE, April 14, 2022 /PRNewswire/ -- China Yuchai International Limited (NYSE: CYD) ("China Yuchai" or the "Company") a leading manufacturer and distributor of engines for on- and off-road applications in China through its main operating subsidiary, Guangxi Yuchai Machinery Company Limited ("GYMCL"), announced today that, MTU Yuchai Power Co., Ltd ("MTU Yuchai Power"), a 50-50 joint venture between GYMCL and MTU Friedrichshafen GmbH ("MTU"), a subsidiary of Rolls-Royce Power Systems (LON: RR), has produced its 1,000th unit of the renowned MTU Series 4000 high-horsepower diesel engines.
The MTU Series 4000 of diesel engines produces power outputs ranging from 1,400 to 3,490 kW, primarily for the Chinese off-road market, and is especially suited for power generation, mining and oil and gas markets.
Established in early 2017, MTU Yuchai Power began operations in April 2018 at GYMCL's main production plant in Yulin City. The joint venture uses similar manufacturing processes as in Germany, resulting in the highest quality production of high-end, high-speed, high-power MTU Series 4000 engines at the world's best-in-class technical level. By December 2018, MTU Yuchai Power produced its first 100th MTU Series 4000 engine. In December 2020, MTU Yuchai Power produced its 500th MTU Series 4000 engine.
Weng Ming Hoh, President of China Yuchai, commented, "The MTU Series 400 engines have added new high-horsepower products at the top of our engine portfolio and introduced us to more new customers in the Chinese powertrain market. Sales of MTU Series 4000 engines produced by MTU Yuchai Power were at record levels in 2021."
About China Yuchai International
China Yuchai International Limited, through its subsidiary, Guangxi Yuchai Machinery Company Limited ("GYMCL"), engages in the manufacture, assembly, and sale of a wide variety of light-, medium- and heavy-duty engines for trucks, buses, passenger vehicles, construction equipment, marine and agriculture applications in China. GYMCL also produces diesel power generators. The engines produced by GYMCL range from diesel to natural gas and hybrid engines. Through its regional sales offices and authorized customer service centers, GYMCL distributes its engines directly to auto OEMs and retailers and provides maintenance and retrofitting services throughout China. Founded in 1951, GYMCL has established a reputable brand name, strong research and development team and significant market share in China with high-quality products and reliable after-sales support. In 2021, GYMCL sold 456,791 engines and is recognized as a leading manufacturer and distributor of engines in China. For more information, please visit http://www.cyilimited.com.
Safe Harbor Statement:
This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe", "expect", "anticipate", "project", "targets", "optimistic", "confident that", "continue to", "predict", "intend", "aim", "will" or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical fact are statements that may be deemed forward-looking statements. These forward-looking statements including, but not limited to, statements concerning China Yuchai's and the joint venture's operations, financial performance and condition are based on current expectations, beliefs and assumptions which are subject to change at any time. China Yuchai cautions that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors such as government and stock exchange regulations, competition, political, economic and social conditions around the world and in China including those discussed in China Yuchai's Form 20-Fs under the headings "Risk Factors", "Results of Operations" and "Business Overview" and other reports filed with the Securities and Exchange Commission from time to time. Among others, if the COVID-19 pandemic is not effectively and timely controlled, our business operations and financial condition may be materially and adversely affected due to a deteriorating market for automotive sales, an economic slowdown in China and abroad, a potential weakening of the financial condition of our customers, or other factors that we cannot foresee. All forward-looking statements are applicable only as of the date it is made and China Yuchai specifically disclaims any obligation to maintain or update the forward-looking information, whether of the nature contained in this release or otherwise, in the future.
For more information:
Investor Relations
Kevin Theiss
Tel: +1-212-510-8922 (new)
Tel: +1-212-521-4050 (old)
Email: cyd@bluefocus.com
View original content:
SOURCE China Yuchai International Limited | https://www.1011now.com/prnewswire/2022/04/14/mtu-yuchai-power-announces-major-production-milestone/ | 2022-04-14T12:13:07 | 1 | https://www.1011now.com/prnewswire/2022/04/14/mtu-yuchai-power-announces-major-production-milestone/ |
NEW YORK, April 14, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Playstudios, Inc. ("Playstudios, Inc." or the "Company") (NASDAQ: MYPS) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Playstudios, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class consisting of all persons and entities other than defendants who: (a) purchased, or otherwise acquired securities of Playstudios between June 22, 2021 and March 1, 2022, both dates inclusive, including, but not limited to, those who purchased or acquired Playstudios securities pursuant to the offering of the private investment in public equity; (b) held common stock of Acies as of May 25, 2021, and were eligible to vote at Acies' June 16, 2021 special meeting who exchanged their shares of Acies stock for shares of Playstudios stock pursuant to the merger of Acies and Old Playstudios; and/or (c) purchased or otherwise acquired Playstudios common stock pursuant to or traceable to Acies' documents issued in connection with the June 2021 merger. Follow the link below to get more information and be contacted by a member of our team:
MYPS investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Playstudios was having significant problems with its flagship game, Kingdom Boss; (ii) Playstudios would not be releasing Kingdom Boss as expected; and (iii) Playstudios had not revised its financial projections to account for the problems it had encountered with Kingdom Boss. As a result of defendants' wrongful conduct, Class members paid artificially inflated prices for their Playstudios securities and suffered substantial losses and damages.
WHAT'S NEXT? If you suffered a loss in Playstudios, Inc. during the relevant time frame, you have until June 6, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
View original content to download multimedia:
SOURCE Levi & Korsinsky, LLP | https://www.1011now.com/prnewswire/2022/04/14/myps-lawsuit-alert-levi-amp-korsinsky-notifies-playstudios-inc-investors-class-action-lawsuit-upcoming-deadline/ | 2022-04-14T12:13:14 | 1 | https://www.1011now.com/prnewswire/2022/04/14/myps-lawsuit-alert-levi-amp-korsinsky-notifies-playstudios-inc-investors-class-action-lawsuit-upcoming-deadline/ |
ATLANTA, April 14, 2022 /PRNewswire/ -- Rollins, Inc. (NYSE:ROL), best known for its subsidiary pest control brand, Orkin, finalized the acquisition of NBC Environment headquartered at Banham, Norfolk, UK in early April 2022.
With a £500 Prince's Trust grant, John Dickson, managing director, founded NBC Environment in 1993. Initially, the company centered around bird control using falcons, but it has since grown into a nationwide, full-range pest control servicing business employing over 100 staff. Bird and wildlife management consultancy, such as the recently finalized predator rat eradication feasibility study on the Channel Islands, still remains a specialist core activity.
Commenting on the sale, John Dickson said: "We have a great team at NBC Environment who are all passionate about what they do. Customers recognize this, and as a result we have performed very well in recent years, growing both revenue and profit to significant levels. Together we have achieved so much."
He added: "However, NBC is an ambitious company and capable of much more. I recognized this and felt it was time to find a platform from which the company could realize its true potential."
John continues: "I could see Orkin's ambitions, and most importantly their culture, are aligned with our own. Their commitment to staff has been demonstrated by their approach to Safeguard and the other UK pest control businesses they have recently acquired. It was therefore a relatively easy decision to decide to align NBC with this family of Orkin businesses. I am confident this is a positive move, not only for the staff at NBC, but also our loyal customers."
Matt Turek, division president of Orkin International stated: "The acquisition of NBC is our largest acquisition so far in the UK. To date, the companies we have acquired have been based in and around London and the Home Counties, but with the addition of NBC Environment, we are now delighted to be able to offer customers nationwide coverage. This represents a significant expansion of our activities in the UK."
"Both Orkin and NBC share a culture of exceptional customer service and we recognize that their bird and wildlife management activities are unique. We are delighted John and his team will remain with the company, and we look forward to learning and sharing best practices," concludes Matt.
Paul Giannamore and Franco Villanueva-Meyer of The Potomac Company represented and acted as exclusive financial advisors to NBC Environment in this transaction.
Continued expansion for Orkin in the UK
NBC is the latest addition to the growing number of Orkin companies in the UK. This began with the acquisition of Safeguard Pest Control in 2016. Since then the AMES Group, Kestrel Pest Control, Enviropest, Baroque Pest Services, the Guardian Group, Albany Environmental, Van Vynck Environmental and, most recently, IPM have all been added to the Safeguard/Orkin family of businesses.
Rollins, Inc. is a premier global consumer and commercial services company. Through its family of leading brands, Orkin, HomeTeam Pest Defense, Clark Pest Control, Northwest Exterminating, McCall Service, Trutech, Critter Control, Western Pest Services, Waltham Services, OPC Pest Services, The Industrial Fumigant Company, PermaTreat, Crane Pest Control, Missquito, Orkin Canada, Orkin Australia, Safeguard (UK), Aardwolf Pestkare (Singapore), and more, the Company and its franchises provide essential pest control services and protection against termite damage, rodents and insects to more than two million customers in North America, South America, Europe, Asia, Africa, and Australia from more than 700 locations. You can learn more about Rollins and its subsidiaries by visiting our web sites at www.orkin.com, www.pestdefense.com, www.clarkpest.com, www.callnorthwest.com, www.mccallservice.com, www.trutechinc.com, www.crittercontrol.com, www.westernpest.com, www.walthamservices.com, www.opcpest.com, www.indfumco.com, www.permatreat.com, www.cranepestcontrol.com, www.missquito.com, www.orkincanada.ca, www.orkinau.com, www.safeguardpestcontrol.co.uk, www.aardwolfpestkare.com, and www.rollins.com. You can also find this and other news releases at www.rollins.com by accessing the news releases button.
View original content:
SOURCE Rollins, Inc. | https://www.1011now.com/prnewswire/2022/04/14/nbc-environment-acquired-by-orkin/ | 2022-04-14T12:13:21 | 0 | https://www.1011now.com/prnewswire/2022/04/14/nbc-environment-acquired-by-orkin/ |
VONJO is the only approved JAK inhibitor recommended by NCCN for myelofibrosis patients regardless of platelet count
SEATTLE, April 14, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that VONJO™ (pacritinib), its novel oral kinase inhibitor with specificity for JAK2 and IRAK1, without inhibiting JAK1, has been included as a recommended treatment in the latest National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Myeloproliferative Neoplasms.
"We are grateful that NCCN acted quickly to include VONJO with a Category 2A designation in its Clinical Practice Guidelines in Oncology as a first line treatment for high-risk patients with myelofibrosis with platelet counts <50 x 109/L who are not candidates for transplant. This therapeutic option helps address an unmet medical need for patients who previously have no other treatment options. There is no other FDA-approved first line treatment for these patients with a 2A designation within the NCCN guidelines," said Adam R. Craig, M.D., Ph.D., President, and Chief Executive Officer of CTI BioPharma. "Additionally, VONJO was included as a Category 2A designation as second line treatment for lower-risk and higher-risk patients with myelofibrosis with platelet counts ≥50 x 109/L who are not candidates for transplant. This placement provides additional treatment options for patients with myelofibrosis."
The new NCCN Guidelines are available online at www.nccn.org.
About VONJO (pacritinib)
Pacritinib is an oral kinase inhibitor with activity against wild type Janus Associated Kinase 2 (JAK2), mutant JAK2V617F form and FMS-like tyrosine kinase 3 (FLT3), which contribute to signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Myelofibrosis is often associated with dysregulated JAK2 signaling. Pacritinib has higher inhibitory activity for JAK2 over other family members, JAK3 and TYK2. At clinically relevant concentrations, pacritinib does not inhibit JAK1. Pacritinib exhibits inhibitory activity against additional cellular kinases (such as CSF1R and IRAK1), the clinical relevance of which is unknown.
VONJO is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Important VONJO Safety Information
Hemorrhage:
Serious (11%) and fatal (2%) hemorrhages have occurred in VONJO-treated patients with platelet counts <100 × 109/L. Serious (13%) and fatal (2%) hemorrhages have occurred in VONJO-treated patients with platelet counts <50 × 109/L. Grade ≥3 bleeding events (defined as requiring transfusion or invasive intervention) occurred in 15% of patients treated with VONJO compared to 7% of patients treated on the control arm. Due to hemorrhage, VONJO dose-reductions, dose interruptions, or permanent discontinuations occurred in 3%, 3%, and 5% of patients, respectively.
Avoid use of VONJO in patients with active bleeding and hold VONJO 7 days prior to any planned surgical or invasive procedures. Assess platelet counts periodically, as clinically indicated. Manage hemorrhage using treatment interruption and medical intervention.
Diarrhea:
VONJO causes diarrhea in approximately 48% of patients compared to 15% of patients treated on the control arm. The median time to resolution in VONJO-treated patients was 2 weeks. The incidence of reported diarrhea decreased over time with 41% of patients reporting diarrhea in the first 8 weeks of treatment, 15% in Weeks 8 through 16, and 8% in Weeks 16 through 24. Diarrhea resulted in treatment interruption in 3% of VONJO-treated patients. None of the VONJO-treated patients reported diarrhea that resulted in treatment discontinuation. Serious diarrhea adverse reactions occurred in 2% of patients treated with VONJO compared to no such adverse reactions in patients in the control arm.
Control pre-existing diarrhea before starting VONJO treatment. Manage diarrhea with antidiarrheal medications, fluid replacement, and dose-modification. Treat diarrhea with anti–diarrheal medications promptly at the first onset of symptoms. Interrupt or reduce VONJO dose in patients with significant diarrhea despite optimal supportive care.
Thrombocytopenia:
VONJO can cause worsening thrombocytopenia. VONJO dosing was reduced due to worsening thrombocytopenia in 2% of patients with pre–existing moderate to severe thrombocytopenia (platelet count <100 × 109/L). VONJO dosing was reduced due to worsening thrombocytopenia in 2% of patients with pre–existing severe thrombocytopenia (platelet count <50 × 109/L).
Monitor platelet count prior to VONJO treatment and as clinically indicated during treatment. Interrupt VONJO in patients with clinically significant worsening of thrombocytopenia that lasts for more than 7 days. Restart VONJO at 50% of the last given dose once the toxicity has resolved. If toxicity recurs hold VONJO. Restart VONJO at 50% of the last given dose once the toxicity has resolved.
Prolonged QT interval:
VONJO can cause prolongation of the QTc interval. QTc prolongation of >500 msec was higher in VONJO-treated patients than in patients in the control arm (1.4% vs 1%). QTc increase from baseline by 60 msec or higher was greater in VONJO-treated patients than in control arm patients (1.9% vs 1%). Adverse reactions of QTc prolongation were reported for 3.8% of VONJO-treated patients and 2% of control arm patients. No cases of torsades de pointes were reported.
Avoid use of VONJO in patients with a baseline QTc of >480 msec. Avoid use of drugs with significant potential for QTc prolongation in combination with VONJO. Correct hypokalemia prior to and during VONJO treatment. Manage QTc prolongation using VONJO interruption and electrolyte management.
Major Adverse Cardiac Events (MACE):
Another Janus associated kinase (JAK)-inhibitor has increased the risk of MACE, including cardiovascular death, myocardial infarction, and stroke (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which VONJO is not indicated.
Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with VONJO particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur.
Thrombosis:
Another JAK-inhibitor has increased the risk of thrombosis, including deep venous thrombosis, pulmonary embolism, and arterial thrombosis (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which VONJO is not indicated.
Patients with symptoms of thrombosis should be promptly evaluated and treated appropriately.
Secondary Malignancies:
Another JAK-inhibitor has increased the risk of lymphoma and other malignancies excluding non-melanoma skin cancer (NMSC) (compared to those treated with TNF blockers) in patients with rheumatoid arthritis, a condition for which VONJO is not indicated. Patients who are current or past smokers are at additional increased risk.
Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with VONJO, particularly in patients with a known malignancy (other than a successfully treated NMSC), patients who develop a malignancy, and patients who are current or past smokers.
Risk of Infection:
Another JAK-inhibitor has increased the risk of serious infections (compared to best available therapy) in patients with myeloproliferative neoplasms. Serious bacterial, mycobacterial, fungal and viral infections may occur in patients treated with VONJO. Delay starting therapy with VONJO until active serious infections have resolved. Observe patients receiving VONJO for signs and symptoms of infection and manage promptly. Use active surveillance and prophylactic antibiotics according to clinical guidelines.
Interactions with CYP3A4 Inhibitors or Inducers:
Co-administration of VONJO with strong CYP3A4 inhibitors or inducers is contraindicated. Avoid concomitant use of VONJO with moderate CYP3A4 inhibitors or inducers.
Drug interruptions due to an adverse reaction occurred in 27% patients who received VONJO 200 mg twice daily compared to 10% of patients treated with BAT. Dosage reductions due to an adverse reaction occurred in 12% of patients who received VONJO 200 mg twice daily compared to 7% of patients treated with BAT. Permanent discontinuation due to an adverse reaction occurred in 15% of patients receiving VONJO 200 mg twice daily compared to 12% of patients treated with BAT.
Please visit http://www.ctibiopharma.com/vonjo_prescribing_information for full Prescribing Information and the Medication Guide.
About National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information and follow NCCN on Facebook @NCCNorg, Instagram @NCCNorg, and Twitter @NCCN.
About CTI BioPharma Corp.
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJOTM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
VONJOTM is a trademark of CTI BioPharma Corp.
CTI BioPharma Investor Relations and Media Contacts:
Argot Partners
+212-600-1902
cti@argotpartners.com
View original content to download multimedia:
SOURCE CTI BioPharma Corp. | https://www.1011now.com/prnewswire/2022/04/14/nccn-guidelines-recommend-vonjo-pacritinib-treatment-myeloproliferative-neoplasms/ | 2022-04-14T12:13:24 | 1 | https://www.1011now.com/prnewswire/2022/04/14/nccn-guidelines-recommend-vonjo-pacritinib-treatment-myeloproliferative-neoplasms/ |
NEW YORK, April 14, 2022 /PRNewswire/ -- The Necessity Retail REIT, Inc. (Nasdaq: RTL / RTLPP / RTLPO) ("RTL" or the "Company") announced today it will release its financial results for the first quarter ended March 31, 2022 on Wednesday, May 4, 2022 after the close of trading on the Nasdaq.
The Company will host a conference call and audio webcast on Thursday, May 5, 2022, beginning at 11:00 a.m. ET, to discuss the first quarter results and provide commentary on business performance. The call will be conducted by RTL's management team and a question and answer session with analysts and investors will follow the prepared remarks.
Dial-in instructions for the conference call and the replay are outlined below. This conference call will also be broadcast live over the Internet and can be accessed by all interested parties through the RTL website, www.necessityretailreit.com, in the "Investor Relations" section. To listen to the live call, please go to the "Investor Relations" section of the Company's website at least 15 minutes prior to the start of the call to register and download any necessary audio software. For those who are not able to listen to the live broadcast, a replay will be available shortly after the call on the RTL website.
Conference Call Details
Live Call
Dial-In (Toll Free): 1-877-407-0792
International Dial-In: 1-201-689-8263
Conference Replay*
Domestic Dial-In (Toll Free): 1-844-512-2921
International Dial-In: 1-412-317-6671
Conference Number: 13728724
*Available from 2:00 p.m. ET on May 5, 2022 through August 5, 2022.
About The Necessity Retail REIT - Where America Shops
The Necessity Retail REIT (Nasdaq: RTL) is the preeminent publicly traded real estate investment trust (REIT) focused "Where America Shops". RTL acquires and manages a diversified portfolio of primarily necessity-based retail single tenant and open-air shopping center properties in the U.S. Additional information about RTL can be found on its website at www.necessityretailreit.com.
Important Notice
The statements in this press release that are not historical facts may be forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the outcome to be materially different. In addition, words such as "anticipates," "believes," "expects," "estimates," "projects," "plans," "intends," "may," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of RTL's control, which could cause actual results to differ materially from the results contemplated by the forward-looking statements. These risks and uncertainties include the potential adverse effects of the ongoing global COVID-19 pandemic, including actions taken to contain or treat COVID-19, on RTL, RTL's tenants and the global economy and financial markets and that the information about rent collections may not be indicative of any future period, as well as those set forth in the Risk Factors section of RTL's most recent Annual Report on Form 10-K for the year ended December 31, 2021 filed on February 24, 2022, and all other filings with the SEC after that date, as such risks, uncertainties and other important factors may be updated from time to time in RTL's subsequent reports. Further, forward-looking statements speak only as of the date they are made, and RTL undertakes no obligation to update or revise any forward-looking statement to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time, unless required by law.
Contacts:
Investor Relations
ir@rtlreit.com
(866) 902-0063
View original content to download multimedia:
SOURCE The Necessity Retail REIT, Inc. | https://www.1011now.com/prnewswire/2022/04/14/necessity-retail-reit-announces-release-date-first-quarter-2022-results/ | 2022-04-14T12:13:30 | 1 | https://www.1011now.com/prnewswire/2022/04/14/necessity-retail-reit-announces-release-date-first-quarter-2022-results/ |
Brooklyn's Petri Plumbing, Heating, Cooling & Drain Cleaning points to the life-saving contributions plumbers make every day as a reason to honor the profession
BROOKLYN, N.Y., April 14, 2022 /PRNewswire/ -- The experts at Petri Plumbing, Heating, Cooling & Drain Cleaning, a family-owned home service company serving Brooklyn and Manhattan for more than a century, are raising awareness of the global contributions from the plumbing industry in celebration of National Hug a Plumber Day on April 25.
The World Health Organization has noted that plumbers are one of the most important frontline health workers in the world because their contributions prevent outbreaks of a number of diseases, including cholera, tuberculosis and dysentery. These threats are largely non-existent today due to the public health focus on plumbing.
"Believe it or not, plumbers have saved lives on levels that are comparable to medical professionals and those serving in the military," said Michael Petri, owner of Petri Plumbing, Heating, Cooling & Drain Cleaning. "Being a plumber is physically demanding and often unacknowledged. However, without plumbers, we would not have easy access to clean water and could not remove unhealthy waste from our living areas."
Petri said good sanitation is a pillar upon which civilization has grown. There are still many parts of the world that don't have access to water or waste control on demand, and those villages are still considered third-world countries as a result.
While many know about the Romans' contribution to plumbing, few know that the Chinese used bamboo pipes and lakes as plumbing as many as 150,000 years ago. But it was the Roman word for plumber, plumbarius, that survived the ages and made plumbing a profession.
"We hope everyone remembers April 25 and considers how plumbers have improved our lives and our health," Petri said. "If you have to go without a toilet or sink for just a small part of the day, it's an awful inconvenience. In fact, I dare say that more people would rather go without their cell phone than a working toilet."
Petri said Americans should take to social media on April 25 and use the hashtag, #NationalHugAPlumberDay to show their appreciation.
"I know the hard-working plumbers at Petri and all over the nation would appreciate the recognition," he said.
For more information about Petri Plumbing, Heating, Cooling & Drain Cleaning, or to schedule a service call, visit https://www.petriplumbing.com/ or call (718) 717-1089.
About Petri Plumbing, Heating, Cooling & Drain Cleaning
Petri Plumbing, Heating, Cooling & Drain Cleaning is a family owned and operated business serving Brooklyn and the New York City area. Founded in 1906, the company offers a 100 percent guarantee on all services, upfront pricing, and friendly and knowledgeable Service Experts for all kinds of home and business plumbing and heating needs. Services offered include water and gas pipe leak repair and installation, fixture installations, inspections, boiler repair, water heater installation, complete bathroom, kitchen, laundry & utility room remodeling and more. Petri is also licensed and certified by Green Plumbers USA, the first in New York City to receive this designation. For more information, please visit www.petriplumbing.com or call (718) 717-1089.
MEDIA CONTACT:
Heather Ripley
Ripley PR
865-977-1973
hripley@ripleypr.com
View original content to download multimedia:
SOURCE Petri Plumbing & Heating, Inc. | https://www.1011now.com/prnewswire/2022/04/14/new-york-plumbing-experts-celebrate-national-hug-plumber-day/ | 2022-04-14T12:13:37 | 1 | https://www.1011now.com/prnewswire/2022/04/14/new-york-plumbing-experts-celebrate-national-hug-plumber-day/ |
IRVING, Texas, April 14, 2022 /PRNewswire/ -- NorthStar Anesthesia, an industry leader in providing modernized anesthesia care for nearly two decades, has announced new services for Chesapeake Regional Healthcare in Virginia, working with Chesapeake Regional Hospital and the Surgery Center of Chesapeake.
"As NorthStar continues to grow, we're excited to announce significant expansion in Virginia," said NorthStar CEO, Adam Spiegel. "This regional density and expanded reach will enable NorthStar to better serve patients across the Commonwealth."
Chesapeake Regional Healthcare is an independent healthcare system based in Chesapeake, Virginia with a focus on technologically advanced, compassionate care. NorthStar transitioned to provide anesthesia services at Chesapeake Regional Hospital and the Surgery Center of Chesapeake on February 20, 2022. The team has reported positive results on the ground as NorthStar continues to grow across the state of Virginia.
"At Chesapeake, we're constantly evolving and expanding the breadth of our services for the community," said Reese Jackson, President and CEO at Chesapeake Regional Healthcare. "Our teams look forward to working with NorthStar and continuing to grow together."
NorthStar will continue to expand across the nation as they work to increase their impact on the provision of anesthesia.
To learn more about NorthStar Anesthesia, visit www.northstaranesthesia.com.
About NorthStar Anesthesia
NorthStar Anesthesia is a company of caregivers, founded by an anesthesiologist and a Certified Registered Nurse Anesthetist (CRNA). With more than 2,000 anesthesiologists and CRNAs under its banner, NorthStar partners with more than 180 health care facilities to deliver a more productive and efficient model of anesthesia care. Its "care team" approach focuses on the provision of high-quality care while measurably improving operating room performance. For more information, visit www.northstaranesthesia.com.
Media Contact:
Simone Jackenthal
Trident DMG
202-923-5296
sjackenthal@tridentdmg.com
View original content:
SOURCE NorthStar Anesthesia | https://www.1011now.com/prnewswire/2022/04/14/northstar-anesthesia-announces-new-services-chesapeake-regional-healthcare/ | 2022-04-14T12:13:44 | 0 | https://www.1011now.com/prnewswire/2022/04/14/northstar-anesthesia-announces-new-services-chesapeake-regional-healthcare/ |
- Pelareorep-CAR T combination may expand the commercial potential of CAR T cells to solid tumors
- Combining CAR T cells with pelareorep prevented antigen escape by creating CAR T cells with dual specificity through a novel mechanism
- Loading CAR T cells with pelareorep led to dramatic improvements in their persistence and anti-cancer activity as well as cures in multiple murine solid tumor models
SAN DIEGO, Calif. and CALGARY, AB, April 14, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of preclinical data demonstrating the synergistic anti-cancer activity of pelareorep combined with chimeric antigen receptor (CAR) T cell therapy in solid tumors. The paper, entitled "Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice," was published in Science Translational Medicine in collaboration with researchers at several prestigious institutions, including the Mayo Clinic and Duke University. A link to the paper can be found by clicking here.
"Having these results published in such a high-impact journal provides important external validation of their significance," said Thomas Heineman, M.D., Ph.D., Chief Medical Officer of Oncolytics Biotech Inc. "While CAR T cells have generated long-term cures in hematologic malignancies1, the immunosuppressive tumor microenvironments (TMEs) of solid organ cancers have thus far limited their efficacy in these indications. Pelareorep has repeatedly been shown to reverse immunosuppressive TMEs, and in the present publication pelareorep is shown to enable the effectiveness of CAR T cells in multiple murine solid tumor models. This is a powerful finding that, if translated to the clinic, could significantly improve the prognosis of patients with a variety of highly prevalent cancers by providing a novel and potentially durable treatment option. By demonstrating the ability to improve T cell perseverance, reduce antigen escape, and overcome challenging solid tumor TMEs, the inclusion of pelareorep addresses the three most challenging roadblocks to effective CAR T therapy."
Andrew de Guttadauro, President of Oncolytics Biotech U.S. and Global Head of Business Development, added, "Despite revolutionizing the treatment of certain cancers and surpassing a billion dollars in sales last year, CAR T therapies currently only serve a small subset of patients suffering from hematologic malignancies. With these latest results, we now have strong preclinical evidence that pelareorep can fully unlock the value of CAR T therapies by expanding their commercial potential to the significantly larger market of cancer patients who are battling solid tumors."
Preclinical studies published in the paper evaluated the persistence and efficacy of pelareorep-loaded CAR T cells ("CAR/Pela therapy") in multiple murine solid tumor models. The effects of combining CAR/Pela therapy with a subsequent intravenous dose of pelareorep ("pelareorep boost") were also investigated. Key data and conclusions from the paper include:
- The persistence and anti-cancer activity of CAR T cells improved drastically when loaded with pelareorep. Compared to either treatment alone, treatment with CAR/Pela therapy led to statistically significant survival benefits in murine skin and brain cancer models.
- CAR/Pela therapy followed by a pelareorep boost led to enhanced efficacy in murine skin and brain cancer models and tumor cures in >80% of treated mice in each model.
- Loading CAR T cells with pelareoep led to improved cancer cell targeting and prevented antigen escape in vivo by generating CAR T cells with dual specificity that target their designed antigen and the native T cell receptor antigen. These results indicate that CAR/Pela therapy may provide longer-lasting therapeutic benefits compared to treatment with CAR T cells alone.
Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc. and co-author of the paper commented, "These exciting results are an excellent example of how we are leveraging collaborations with key opinion leaders and premier research institutions to broaden pelareorep's potential therapeutic impact. This allows us to remain primarily focused on our lead breast cancer program, which has shown how pelareorep's ability to promote tumor T cell infiltration leads to synergy with checkpoint inhibitors in the clinic. These newly published preclinical findings show pelareorep's synergistic benefits extend even beyond checkpoint inhibitors and highlight an opportunity to increase our addressable patient population. As we pursue this opportunity moving forward, we intend to utilize relationships with academic or industry partners so that we can continue to execute on our clinical and corporate objectives with efficiency."
About CAR T cells and CAR T therapy
The CAR T process begins when blood is drawn from a patient and their T cells are separated so they can be genetically engineered to produce chimeric antigen receptors (CARs). These receptors enable the T cells to recognize and attach to a specific protein or antigen on tumor cells. Once the engineering process is complete, a laboratory can increase the number of CAR T cells into the hundreds of millions. Finally, the CAR T cells will be infused back into the patient where, ideally, the engineered cells further multiply and recognize and kill cancer cells. Historically, solid tumors have been considered beyond the reach of CAR T therapy due to their tumor microenvironment, which is detrimental to CAR T cell entry and activity, amongst other challenges.2
About Science Translational Medicine
Science Translational Medicine is the leading weekly online journal publishing translational research at the intersection of science, engineering, and medicine. The goal of Science Translational Medicine is to promote human health by providing a forum for communicating the latest research advances from biomedical, translational, and clinical researchers from all established and emerging disciplines relevant to medicine. In addition to original research, Science Translational Medicine also publishes Reviews, Editorials, Focus articles, and Viewpoints.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.
References
1. Melenhorst, J.J., Chen, G.M., Wang, M. et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature (2022). https://doi.org/10.1038/s41586-021-04390-6
2. National Cancer Institute. CAR T Cells: Engineering Patients' Immune Cells to Treat Their Cancers. Updated July 31, 2019. Accessed February 18, 2021. https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential and benefits of pelareorep as a cancer therapeutic; Oncolytics' expectations as to the purpose, design, outcomes and benefits of its current or pending clinical trials involving pelareorep; including potentially significantly improving the prognosis of patients with a variety of highly-prevalent cancers by providing them with a novel and potentially durable treatment option and the opportunity to potentially expand our addressable patient population; our intention to utilize relationships with academic or industry partners so that we can continue to execute on our clinical and corporate objectives with efficiency; our leveraging of collaborations with key opinion leaders to broaden pelareorep's potential therapeutic impact; our plans to advance towards a registration study in metastatic breast cancer; and other statements related to anticipated developments in Oncolytics' business and technologies. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition. Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.
View original content:
SOURCE Oncolytics Biotech® Inc. | https://www.1011now.com/prnewswire/2022/04/14/oncolytics-biotech-announces-publication-preclinical-data-demonstrating-synergistic-anti-cancer-activity-pelareorep-combined-with-car-t-cell-therapy-solid-tumors-science-translational-medicine/ | 2022-04-14T12:13:50 | 0 | https://www.1011now.com/prnewswire/2022/04/14/oncolytics-biotech-announces-publication-preclinical-data-demonstrating-synergistic-anti-cancer-activity-pelareorep-combined-with-car-t-cell-therapy-solid-tumors-science-translational-medicine/ |
Tesla CEO Elon Musk is offering to buy Twitter, saying the social media platform he has criticized for not living up to free speech principles needs to be transformed as a private company.
Twitter Inc. said in a regulatory filing on Thursday that Musk, currently the company’s biggest shareholder, has proposed buying the remaining shares of Twitter that he doesn’t already own at $54.20 per share, an offer worth more than $43 billion.
Musk called that price his best and final offer, although he provided no details on financing. The offer is non-binding and subject to financing and other conditions.
“I invested in Twitter as I believe in its potential to be the platform for free speech around the globe, and I believe free speech is a societal imperative for a functioning democracy,” Musk said in the filing. “However, since making my investment I now realize the company will neither thrive nor serve this societal imperative in its current form. Twitter needs to be transformed as a private company.”
Twitter said it has received Musk’s offer and will decide whether it is in the best interests of shareholders to accept or continue to operate as a publicly traded company.
Musk revealed in regulatory filings over recent weeks that he’d been buying shares in almost daily batches starting Jan. 31, ending up with a stake of about 9%. Only Vanguard Group’s suite of mutual funds and ETFs controls more Twitter shares.
The billionaire has been a vocal critic of Twitter in recent weeks, mostly over his belief that it falls short on free speech principles. The social media platform has angered followers of Donald Trump and other far-right political figures who’ve had their accounts suspended for violating its content standards on violence, hate or harmful misinformation. Musk also has a history of his own tweets causing legal problems.
After Musk announced his stake, Twitter quickly offered him a seat on its board on the condition that he not own more than 14.9% of the company’s outstanding stock, according to a filing. But he said five days later that he’d declined.
He didn’t explain why, but the decision coincided with a barrage of now-deleted tweets from Musk proposing major changes to the company, such as dropping ads — its chief source of revenue — and transforming its San Francisco headquarters into a homeless shelter. Musk left a few clues on Twitter about his thinking, such as by “liking” a tweet that summarized the events as Musk going from “largest shareholder for Free Speech” to being “told to play nice and not speak freely.”
Musk’s 81 million Twitter followers make him one of the most popular figures on the platform, rivaling pop stars like Ariana Grande and Lady Gaga. But his prolific tweeting has sometimes gotten him into trouble with the SEC and others.
Musk and Tesla in 2018 agreed to pay $40 million in civil fines and for Musk to have his tweets approved by a corporate lawyer after he tweeted about having the money to take Tesla private at $420 per share. That didn’t happen, but the tweet caused Tesla’s stock price to jump. Musk’s latest trouble with the SEC could be his delay in notifying regulators of his growing stake in Twitter.
Musk has described himself as a “free speech absolutist” and has said he doesn’t think Twitter is living up to free speech principles — an opinion shared by followers of Donald Trump and a number of other right-wing political figures who’ve had their accounts suspended for violating Twitter content rules.
Shares of Twitter jumped 11% before the market open. The stock is still down from its 52-week high of about $73. Shares of Tesla, the electric vehicle manufacturer that Musk heads, slipped about 0.9%. | https://www.orlandosentinel.com/business/ct-biz-elon-musk-twitter-20220414-h6yg2tgxbfc4jhk4fdetn2lqzm-story.html | 2022-04-14T12:13:53 | 0 | https://www.orlandosentinel.com/business/ct-biz-elon-musk-twitter-20220414-h6yg2tgxbfc4jhk4fdetn2lqzm-story.html |
Enabling state-of-the-art 4G and 5G broadband communications and new applications
NASHUA, N.H., April 14, 2022 /PRNewswire/ -- Parallel Wireless, Inc., the U.S.-based Open RAN leader delivering the world's leading All G, cloud-native Open RAN solution, is partnering with Inatel, Telecom Infra Project (TIP), Brisanet, Claro, TIM, and Vivo to conduct a field trial enabling leading-edge 4G and 5G broadband communications throughout Brazil and other LATAM countries.
Inatel - National Institute of Telecommunications is an education, research, and technology development center created in 1965 and located in Santa Rita do Sapucaí, southern Minas Gerais, also known as the Electronics Valley. It was the first institution of higher education in Telecommunications Engineering in Brazil.
The Telecom Infra Project (TIP) is a global community of companies and organizations working together to accelerate the development and deployment of open, disaggregated, and standards-based technology solutions that deliver the high-quality connectivity that the world needs – now and in the decades to come.
Parallel Wireless will provide an Open RAN network enabling All Gs (2G, 3G, 4G and 5G) utilizing Band 7 for the trial as Inatel indicated in the announcement on their website: https://www.inatel.br/imprensa/noticias/negocios/3664-inatel-inicia-testes-de-open-ran-como-parte-do-programa-open-field . This leading-edge network field trial will enable new services and applications for consumers and businesses.
Mobile Network Operators (MNOs) in the Latin American region are encouraged to visit the Parallel Wireless cloud-native, Open RAN solutions in action at Inatel in Brazil now through June 2022. Contact Russell Ribeiro at Parallel Wireless to learn more.
Russell Ribeiro, Regional VP LATAM Sales at Parallel Wireless said, "We are excited to partner with Inatel and TIP to showcase our leading-edge cloud-native, O-RAN compliant, Open RAN solutions enabling 4G and 5G broadband connectivity, providing leading edge applications for the citizens of Brazil and other LATAM countries. We are starting this Open Field program with 4G and will evolve to 5G later this year. We believe this program is a very good showroom for MNOs throughout Latin America to come and see our platform in operation in a real field environment."
Gleyson A. dos Santos, Business Development Specialist at Inatel said, "I am thrilled to participate in this field trial with Parallel Wireless and TIP where we will showcase how Open RAN technology enables robust wireless telecommunications products with improved software quality, less maintenance, faster adoption of new technologies and better user experiences."
The setup in test has Comba and Dell Technologies solutions. Mobile Network Operators Brisanet, Claro, TIM and Vivo are partners in the Open Field program.
About Parallel Wireless
Parallel Wireless's ALL G (2G, 3G, 4G, 5G) O-RAN compliant software platform has been deployed with global Mobile Network Operators from across six continents and forms an open, secure, and intelligent RAN architecture to deliver wireless connectivity, so all people can be connected whenever, wherever, and however they choose. For more information, visit: www.parallelwireless.com. Connect with Parallel Wireless on LinkedIn and Twitter.
About Inatel
Inatel - National Institute of Telecommunications is an education, research and technology development center, created in 1965, in Santa Rita do Sapucaí, south of Minas Gerais. It was the first graduate education institution in Telecommunications Engineering in Brazil and currently offers seven graduation courses, lato sensu courses, distance courses and Master's and Doctoral Degrees in Telecommunications. Inatel transfers technology to the market in the areas of software, hardware, consulting, and calibration. It has partnerships with national and multinational technology companies. More information: www.inatel.br.
About the Telecom Infra Project (TIP)
The Telecom Infra Project (TIP) is a global community of companies and organizations that are pushing infrastructure solutions to promote global connectivity. Half of the world's population is not yet connected to the Internet, and for those who are, connectivity is often insufficient. This limits access to the myriad of commercial and consumer benefits provided over the Internet, thus impacting GDP growth globally. However, the lack of flexibility in current solutions – exacerbated by a limited choice of technology providers – makes it challenging for operators to efficiently build and upgrade networks. Founded in 2016, TIP is a multi-member community that includes hundreds of companies - from service providers and technology partners to systems integrators and other connectivity stakeholders. We're working together to develop, test and deploy open, disaggregated, standards-based solutions that deliver the high-quality connectivity the world needs – now and for decades to come. Find out more: www.telecominfraproject.com
View original content to download multimedia:
SOURCE Parallel Wireless | https://www.1011now.com/prnewswire/2022/04/14/parallel-wireless-partners-with-inatel-telecom-infra-project-tip-brisanet-claro-tim-vivo-conduct-open-ran-field-trial-brazil/ | 2022-04-14T12:13:57 | 0 | https://www.1011now.com/prnewswire/2022/04/14/parallel-wireless-partners-with-inatel-telecom-infra-project-tip-brisanet-claro-tim-vivo-conduct-open-ran-field-trial-brazil/ |
Elon Musk is offering to buy Twitter, just days after the Tesla and SpaceX CEO said he would no longer be joining the social media company’s board of directors.
Twitter Inc. said in a regulatory filing on Thursday that Musk, who currently owns slightly more than 9% of its stock and is the company’s biggest shareholder, provided a letter to the company on Wednesday that contained a proposal to buy the remaining shares of Twitter that he doesn’t already own. Musk offered $54.20 per share of Twitter’s stock.
He called that price his best and final offer, although the billionaire provided no details on financing. The offer is non-binding and subject to financing and other conditions.
“I invested in Twitter as I believe in its potential to be the platform for free speech around the globe, and I believe free speech is a societal imperative for a functioning democracy,” Musk says in the filing. “However, since making my investment I now realize the company will neither thrive nor serve this societal imperative in its current form. Twitter needs to be transformed as a private company.”
The buyout offer from Musk is just the latest development in his relationship with Twitter. The billionaire revealed in regulatory filings over recent weeks that he’d been buying shares in almost daily batches starting Jan. 31. Only Vanguard Group’s suite of mutual funds and ETFs controls more Twitter shares.
Musk has been a vocal critic of of Twitter in recent weeks, mostly over his belief that it falls short on free speech principles. The social media platform has angered followers of Donald Trump and other far-right political figures who’ve had their accounts suspended for violating its content standards on violence, hate or harmful misinformation. Musk also has a history of his own tweets causing legal problems.
Musk said last week that he informed Twitter he wouldn’t be joining its board of directors five days after he was invited. He didn’t explain why, but the decision coincided with a barrage of now-deleted tweets from Musk proposing major changes to the company, such as dropping ads — its chief source of revenue — and transforming its San Francisco headquarters into a homeless shelter. Musk left a few clues on Twitter about his thinking, such as by “liking” a tweet that summarized the events as Musk going from “largest shareholder for Free Speech” to being “told to play nice and not speak freely.”
After Musk announced his stake, Twitter quickly gave Musk a seat on its board on the condition that he not own more than 14.9% of the company’s outstanding stock, according to a filing. But Musk backed out of the deal.
Musk’s 81 million Twitter followers make him one of the most popular figures on the platform, rivaling pop stars like Ariana Grande and Lady Gaga. But his prolific tweeting has sometimes gotten him into trouble with the SEC and others.
Musk and Tesla in 2018 agreed to pay $40 million in civil fines and for Musk to have his tweets approved by a corporate lawyer after he tweeted about having the money to take Tesla private at $420 per share. That didn’t happen but the tweet caused Tesla’s stock price to jump. Musk’s latest trouble with the SEC could be his delay in notifying regulators of his growing stake in Twitter.
Musk has described himself as a “free speech absolutist” and has said he doesn’t think Twitter is living up to free speech principles — an opinion shared by followers of Donald Trump and a number of other right-wing political figures who’ve had their accounts suspended for violating Twitter content rules.
Shares of Twitter jumped 11% before the market open. The stock is still down from its 52-week high of about $73. Shares of Tesla, the electric vehicle manufacturer that Musk heads, slipped about 0.9%. | https://www.orlandosentinel.com/business/os-bz-elon-musk-offers-to-buy-twitter-20220414-bda33bdxjfcq3dvpyy4rwtrm44-story.html | 2022-04-14T12:13:59 | 0 | https://www.orlandosentinel.com/business/os-bz-elon-musk-offers-to-buy-twitter-20220414-bda33bdxjfcq3dvpyy4rwtrm44-story.html |
Grew loans; controlled expenses; maintained strong credit quality
Raised quarterly common stock dividend 20% to $1.50 per share on April 1, 2022
PITTSBURGH, April 14, 2022 /PRNewswire/ -- The PNC Financial Services Group, Inc. (NYSE: PNC) today reported:
First quarter 2022 compared with fourth quarter 2021
- Net income of $1.4 billion increased $123 million, or 9%, driven by lower integration costs and well-controlled expenses.
- Total revenue of $4.7 billion decreased $435 million, or 8%, primarily due to lower noninterest income.
- Net interest income of $2.8 billion decreased $58 million as increased average securities balances, loans outstanding and securities yields were more than offset by a decline in Paycheck Protection Program (PPP) loan interest income and two fewer days in the first quarter.
- Noninterest income of $1.9 billion, which included $16 million of integration costs, decreased $377 million, or 17%.
- Noninterest expense of $3.2 billion decreased $619 million, or 16%. Excluding the impact of integration expenses, noninterest expense decreased 7% primarily driven by lower personnel costs.
- The first quarter included a provision recapture of $208 million, primarily reflecting the impact of improved COVID-19 related economic conditions. The fourth quarter included a provision recapture of $327 million.
- The effective tax rate was 17.3% for the first quarter and 21.5% for the fourth quarter.
First quarter 2022 compared with fourth quarter 2021 or March 31, 2022 compared with December 31, 2021
- Average loans of $290.7 billion increased $1.8 billion, or 1%.
- Credit quality performance:
- Average deposits of $453.3 billion increased $0.5 billion, driven by growth in consumer deposits, partially offset by commercial deposit outflows.
- Average investment securities of $133.9 billion grew $6.0 billion, or 5%.
- Average Federal Reserve Bank balances of $62.3 billion decreased $12.8 billion, reflecting the impact of securities purchases, lower borrowed funds and higher loans outstanding.
- PNC maintained strong capital and liquidity positions.
First quarter 2022 net income of $1.4 billion, or $3.23 per diluted common share, included integration costs of $31 million pretax resulting from the acquisition of BBVA USA. Excluding the impact of integration costs, adjusted diluted earnings per common share was $3.29.
The Consolidated Financial Highlights accompanying this news release include additional information regarding reconciliations of non-GAAP financial measures to reported (GAAP) amounts. This information supplements results as reported in accordance with GAAP and should not be viewed in isolation from, or as a substitute for, GAAP results. Effective for the first quarter of 2022, the presentation of noninterest income has been recategorized. Fee income, a non-GAAP financial measure, refers to noninterest income in the following categories: asset management and brokerage, capital markets related, card and cash management, lending and deposit services and residential and commercial mortgage. See a description of each updated noninterest income revenue category in PNC's Current Report on Form 8-K filed on March 31, 2022. All periods presented herein reflect this change. Information in this news release, including the financial tables, is unaudited.
Total revenue for the first quarter of 2022 decreased $435 million compared with the fourth quarter of 2021 primarily due to lower noninterest income. Compared with the first quarter of 2021, total revenue increased $472 million largely reflecting the acquisition of BBVA USA.
Net interest income of $2.8 billion for the first quarter of 2022 decreased $58 million compared to the fourth quarter of 2021 as increased average securities balances, loans outstanding and securities yields were more than offset by a decline in PPP loan interest income and two fewer days in the first quarter. PPP loan interest income was $36 million in the first quarter of 2022 compared to $110 million in the fourth quarter of 2021.
In comparison with the first quarter of 2021, net interest income increased $456 million as a result of higher interest earning assets, partially offset by lower loan and securities yields.
The net interest margin was 2.28% in the first quarter of 2022 and 2.27% in both the fourth and first quarter of 2021.
Noninterest income for the first quarter of 2022 decreased $377 million compared with the fourth quarter of 2021. The first quarter of 2022 included $16 million of integration costs compared to $47 million in the fourth quarter of 2021. Asset management and brokerage fees decreased $8 million primarily as a result of lower average equity markets. Capital markets related revenue declined $208 million primarily due to lower merger and acquisition advisory fees, in part due to transactions being delayed. Card and cash management revenue decreased $26 million primarily due to seasonally lower transaction volumes and activity. Lending and deposit services declined $4 million and included lower loan commitment fees as a result of higher utilization rates. Residential and commercial mortgage revenue was $50 million lower primarily due to decreased revenue from commercial mortgage banking activities. Other noninterest income decreased $81 million, primarily reflecting lower private equity revenue.
Noninterest income for the first quarter of 2022 increased $16 million compared with the first quarter of 2021. Asset management and brokerage fees increased $49 million primarily as a result of higher average equity markets and the benefit of BBVA USA. Capital markets related revenue decreased $59 million primarily due to a decline in advisory business activity and decreased underwriting fees. Card and cash management revenue grew $128 million due to the addition of BBVA USA customers and higher treasury management product revenue. Lending and deposit services increased $15 million due to the benefit of BBVA USA. Residential and commercial mortgage revenue decreased $28 million and included lower revenue from commercial mortgage banking activities. Other noninterest income decreased $89 million and included lower private equity revenue and a net securities loss of $4 million in the first quarter of 2022 compared to a net securities gain of $25 million in the first quarter of 2021.
Noninterest expense for the first quarter of 2022 decreased $619 million compared with the fourth quarter of 2021. Integration expenses were $15 million in the first quarter of 2022 and $391 million in the fourth quarter of 2021. Excluding the impact of integration expenses, noninterest expense was $3,157 million and $3,400 million, respectively, for the first quarter of 2022 and fourth quarter of 2021, decreasing $243 million, or 7%, driven by a decline in personnel costs reflecting lower incentive compensation related to decreased business activity as well as seasonally lower costs.
Noninterest expense increased $598 million in comparison with the first quarter of 2021 primarily driven by the addition of operating expenses from BBVA USA.
The effective tax rate was 17.3% for the first quarter of 2022, 21.5% for the fourth quarter of 2021 and 16.9% for the first quarter of 2021.
Average total assets were $550.1 billion in the first quarter of 2022 compared with $559.4 billion in the fourth quarter of 2021 and $468.2 billion in the first quarter of 2021. Compared to the fourth quarter of 2021, the decrease resulted from lower Federal Reserve Bank balances. In comparison to the first quarter of 2021, the increase was primarily driven by the BBVA USA acquisition.
Average loans for the first quarter of 2022 were $290.7 billion, increasing $1.8 billion compared to the fourth quarter of 2021. Average commercial loans increased $1.8 billion as growth in PNC corporate banking and business credit businesses of $5.7 billion was partially offset by PPP loan forgiveness of $2.2 billion and a decline in PNC's real estate business of $1.6 billion. Average consumer loans of $95.1 billion were stable.
Average loans for the first quarter of 2022 increased $52.6 billion compared to the first quarter of 2021, reflecting the acquisition of BBVA USA and commercial loan growth, partially offset by PPP loan forgiveness.
First quarter 2022 average and period-end PPP loans outstanding were $2.5 billion and $1.8 billion, respectively.
Average investment securities for the first quarter of 2022 were $133.9 billion, increasing $6.1 billion and $47.5 billion from the fourth quarter of 2021 and first quarter of 2021, respectively, reflecting securities purchases, primarily of U.S. Treasury and government agency securities. Compared to the first quarter of 2021, the increase was also attributable to BBVA USA.
Investment securities at March 31, 2022 of $132.4 billion decreased $0.6 billion compared to the fourth quarter of 2021, as net purchases during the quarter were more than offset by net unrealized losses on available for sale securities, reflecting the impact of higher interest rates. Net unrealized losses on available for sale securities were $4.3 billion at March 31, 2022, compared with net unrealized gains of $0.7 billion at December 31, 2021 and $2.0 billion at March 31, 2021. On March 31, 2022, PNC transferred $20.0 billion of available for sale securities, net of $1.3 billion of unrealized losses, to held to maturity securities.
Average Federal Reserve Bank balances for the first quarter of 2022 were $62.3 billion, decreasing $12.8 billion and $22.9 billion from the fourth quarter of 2021 and the first quarter of 2021, respectively. The decrease in both comparisons reflects the impact of securities purchases, lower borrowed funds and higher loans outstanding. In comparison to the first quarter of 2021, the decrease was partially offset by higher deposits.
Average deposits for the first quarter of 2022 were $453.3 billion, increasing $0.5 billion compared with the fourth quarter of 2021, driven by growth in consumer deposits, partially offset by commercial deposit outflows. Compared with the first quarter of 2021, average deposits increased $87.9 billion primarily reflecting the acquisition of BBVA USA.
Deposits at March 31, 2022 of $450.2 billion, decreased $7.1 billion from December 31, 2021 as a result of lower commercial deposits, primarily due to seasonal declines.
Average borrowed funds of $30.3 billion in the first quarter of 2022 decreased $4.0 billion and $4.9 billion compared with the fourth quarter and first quarter of 2021, respectively, reflecting lower bank notes and senior debt.
PNC maintained a strong capital position. Common shareholders' equity at March 31, 2022 decreased $6.5 billion from December 31, 2021 as the benefit of first quarter net income was more than offset by a decrease in accumulated other comprehensive income, reflecting the impact of higher rates on net unrealized securities losses, as well as share repurchases and dividends paid in the first quarter.
In the first quarter of 2022, PNC returned $1.7 billion of capital to shareholders through $1.2 billion of common share repurchases, representing 6.4 million shares, and $0.5 billion of dividends on common shares. Applying the Stress Capital Buffer (SCB) framework, which allows for capital return in amounts up to the level of capital in excess of the SCB minimum, our board of directors has recently authorized a new repurchase framework, under the already approved authorization for repurchases of up to 100 million common shares of which approximately 64% were still available for repurchase at March 31, 2022. This framework allows for the continuation of our recent quarterly average share repurchase levels as well as the flexibility to increase those levels should conditions warrant.
On April 1, 2022, the PNC board of directors raised the quarterly cash dividend on common stock to $1.50 per share, an increase of 25 cents per share, or 20%, effective with the May 5, 2022 dividend payment.
For information regarding PNC's Basel III capital ratios, see Capital Ratios in the Consolidated Financial Highlights. PNC elected a five-year transition provision effective March 31, 2020 to delay until December 31, 2021 the full impact of the Current Expected Credit Losses (CECL) standard on regulatory capital, followed by a three-year transition period. Effective for the first quarter 2022, PNC is now in the three-year transition period, and the full impact of the CECL standard is being phased-in to regulatory capital over the next three years. The fully implemented ratios reflect the full impact of CECL and exclude the benefits of this transition provision.
The first quarter of 2022 included a provision recapture of $208 million, primarily reflecting the impact of improved COVID-19 related economic conditions. The fourth quarter of 2021 included a provision recapture of $327 million.
Net loan charge-offs were $137 million in the first quarter of 2022, increasing $13 million from the fourth quarter of 2021 driven by modest increases in both consumer and commercial net loan charge-offs. Compared to the first quarter of 2021, net loan charge-offs decreased $9 million.
The allowance for credit losses was $5.2 billion at March 31, 2022, $5.5 billion at December 31, 2021 and $5.2 billion at March 31, 2021. The allowance for credit losses as a percentage of total loans was 1.76% at March 31, 2022, 1.92% at December 31, 2021 and 2.20% at March 31, 2021.
Nonperforming loans were $2.3 billion at March 31, 2022, decreasing $182 million compared to December 31, 2021, driven by lower commercial nonperforming loans. Nonperforming loans increased $160 million compared to March 31, 2021, due to nonperforming loans from the BBVA USA acquisition.
Delinquencies at March 31, 2022 of $1.7 billion decreased $286 million compared to December 31, 2021, reflecting lower consumer and commercial loan delinquencies of $240 million and $46 million, respectively. The decrease in total delinquencies was primarily due to progress resolving BBVA USA conversion-related administrative and operational delays. Compared to the first quarter of 2021, total delinquencies increased $553 million related to delinquencies from the BBVA USA acquisition.
First quarter 2022 compared with fourth quarter 2021
- Earnings decreased 6% due to lower net interest income, lower noninterest income and higher noninterest expense, partially offset by a provision recapture.
- Average loans decreased 2% as growth in residential mortgage loans was more than offset by PPP loan forgiveness and a decline in auto loans.
- Average deposits increased 1% driven by seasonal growth in savings and demand deposits.
First quarter 2022 compared with first quarter 2021
- Earnings decreased 44%, primarily due to increased noninterest expense and a lower provision recapture, partially offset by higher net interest income and noninterest income.
- Average loans and deposits increased 20% and 27%, respectively, driven by the BBVA USA acquisition.
First quarter 2022 compared with fourth quarter 2021
- Earnings decreased 28%, primarily due to a lower provision recapture and a decline in noninterest income, partially offset by lower noninterest expense.
- Average loans increased 2%, reflecting growth in PNC corporate banking and business credit businesses, partially offset by a decline in PNC's real estate business and PPP loan forgiveness.
- Average deposits decreased 4%, primarily due to seasonal declines in commercial deposits.
First quarter 2022 compared with first quarter 2021
- Earnings decreased 10%, as higher net interest income was more than offset by a lower provision recapture and higher noninterest expense.
- Average loans increased 21%, reflecting the addition of BBVA USA and growth in PNC's corporate banking, business credit and real estate businesses, partially offset by PPP loan forgiveness.
- Average deposits increased 13%, and included the addition of BBVA USA.
First quarter 2022 compared with fourth quarter 2021
- Earnings decreased 4%, primarily due to an increase in provision for credit losses.
- Discretionary client assets under management decreased 5%, primarily driven by lower spot equity markets.
- Average loans increased 4%, driven by higher residential mortgage loans.
- Average deposits increased 13%, and included seasonal growth in interest-bearing deposits.
First quarter 2022 compared with first quarter 2021
- Earnings increased 3%, primarily due to the benefit of BBVA USA.
- Discretionary client assets under management increased 5%, primarily driven by the addition of BBVA USA and higher spot equity markets.
- Average loans and deposits increased 60% and 62%, respectively, reflecting the acquisition of BBVA USA and growth in residential mortgage and transactional deposits.
The "Other" category, for the purposes of this release, includes residual activities that do not meet the criteria for disclosure as a separate reportable business, such as asset and liability management activities including net securities gains or losses, other-than-temporary impairment of investment securities, certain trading activities, certain runoff consumer loan portfolios, private equity investments, intercompany eliminations, certain corporate overhead, tax adjustments that are not allocated to business segments, exited businesses, and differences between business segment performance reporting and financial statement reporting under generally accepted accounting principles.
PNC Chairman, President and Chief Executive Officer William S. Demchak and Executive Vice President and Chief Financial Officer Robert Q. Reilly will hold a conference call for investors today at 11:00 a.m. Eastern Time regarding the topics addressed in this news release and the related financial supplement. Dial-in numbers for the conference call are (877) 272-3520 and (312) 281-2958 (international) and Internet access to the live audio listen-only webcast of the call is available at www.pnc.com/investorevents. PNC's first quarter 2022, related financial supplement, and presentation slides to accompany the conference call remarks will be available at www.pnc.com/investorevents prior to the beginning of the call. A telephone replay of the call will be available for one week at (800) 633-8284 and (402) 977-9140 (international), conference ID 22015678 and a replay of the audio webcast will be available on PNC's website for 30 days.
The PNC Financial Services Group, Inc. is one of the largest diversified financial services institutions in the United States, organized around its customers and communities for strong relationships and local delivery of retail and business banking including a full range of lending products; specialized services for corporations and government entities, including corporate banking, real estate finance and asset-based lending; wealth management and asset management. For information about PNC, visit www.pnc.com.
[TABULAR MATERIAL FOLLOWS]
PNC's regulatory risk-based capital ratios in 2022 are calculated using the standardized approach for determining risk-weighted assets. Under the standardized approach for determining credit risk-weighted assets, exposures are generally assigned a pre-defined risk weight. Exposures to high volatility commercial real estate, past due exposures and equity exposures are generally subject to higher risk weights than other types of exposures.
PNC elected a five-year transition provision effective March 31, 2020 to delay until December 31, 2021 the full impact of the CECL standard on regulatory capital, followed by a three-year transition period. Effective for the first quarter 2022, PNC is now in the three-year transition period, and the full impact of the CECL standard is being phased-in to regulatory capital over the next three years. See the table below for the December 31, 2021, March 31, 2021 and estimated March 31, 2022 ratios. For the full impact of PNC's adoption of CECL, which excludes the benefits of the five-year transition provision, see the March 31, 2022 and December 31, 2021 (Fully Implemented) estimates presented in the table below.
Our Basel III capital ratios may be impacted by changes to the regulatory capital rules and additional regulatory guidance or analysis.
Pretax pre-provision earnings is a non-GAAP measure and is based on adjusting income before income taxes and noncontrolling interests to exclude provision for (recapture of) credit losses. We believe that pretax, pre-provision earnings is a useful tool to help evaluate the ability to provide for credit costs through operations and provides an additional basis to compare results between periods by isolating the impact of provision for (recapture of) credit losses, which can vary significantly between periods.
Pretax pre-provision earnings excluding integration costs is a non-GAAP measure and is based on adjusting pretax pre-provision earnings to exclude integration costs during the period. We believe that pretax, pre-provision earnings excluding integration costs is a useful tool in understanding PNC's results by providing greater comparability between periods, as well as demonstrating the effect of significant items.
The adjusted diluted earnings per common share excluding integration costs is a non-GAAP measure and excludes the integration costs related to the BBVA USA acquisition. It is calculated based on adjusting net income attributable to diluted common shareholders by removing post-tax integration costs in the period. We believe this non-GAAP measure serves as a useful tool in understanding PNC's results by providing greater comparability between periods, as well as demonstrating the effect of significant items.
Tangible book value per common share is a non-GAAP measure and is calculated based on tangible common shareholders' equity divided by period-end common shares outstanding. We believe this non-GAAP measure serves as a useful tool to help evaluate the strength and discipline of a company's capital management strategies and as an additional, conservative measure of total company value.
The interest income earned on certain earning assets is completely or partially exempt from federal income tax. As such, these tax-exempt instruments typically yield lower returns than taxable investments. To provide more meaningful comparisons of net interest income, we use interest income on a taxable-equivalent basis by increasing the interest income earned on tax-exempt assets to make it fully equivalent to interest income earned on taxable investments. This adjustment is not permitted under GAAP. Taxable equivalent net interest income is only used for calculating net interest margin and net interest income shown elsewhere in this presentation is GAAP net interest income.
The efficiency ratio excluding integration costs is a non-GAAP measure and excludes the integration costs related to the BBVA USA acquisition. It is calculated based on adjusting the efficiency ratio calculation by excluding integration costs during the period from noninterest expense and total revenue. We believe that this non-GAAP measure is a useful tool for the purpose of evaluating PNC's results. The exclusion of integration costs increases comparability across periods, demonstrates the impact of significant items and provides a useful measure for determining PNC's revenue and expenses that are core to our business operations and expected to recur over time.
We make statements in this news release and related conference call, and we may from time to time make other statements, regarding our outlook for financial performance, such as earnings, revenues, expenses, tax rates, capital and liquidity levels and ratios, asset levels, asset quality, financial position, and other matters regarding or affecting us and our future business and operations that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements are typically identified by words such as "believe," "plan," "expect," "anticipate," "see," "look," "intend," "outlook," "project," "forecast," "estimate," "goal," "will," "should" and other similar words and expressions.
Forward-looking statements are necessarily subject to numerous assumptions, risks and uncertainties, which change over time. Future events or circumstances may change our outlook and may also affect the nature of the assumptions, risks and uncertainties to which our forward-looking statements are subject. Forward-looking statements speak only as of the date made. We do not assume any duty and do not undertake any obligation to update forward-looking statements. Actual results or future events could differ, possibly materially, from those anticipated in forward-looking statements, as well as from historical performance. As a result, we caution against placing undue reliance on any forward-looking statements.
Our forward-looking statements are subject to the following principal risks and uncertainties.
- Our businesses, financial results and balance sheet values are affected by business and economic conditions, including:
- Our forward-looking financial statements are subject to the risk that economic and financial market conditions will be substantially different than those we are currently expecting and do not take into account potential legal and regulatory contingencies. These statements are based on our views that:
- PNC's ability to take certain capital actions, including returning capital to shareholders, is subject to PNC meeting or exceeding a stress capital buffer established by the Federal Reserve Board in connection with the Federal Reserve Board's Comprehensive Capital Analysis and Review (CCAR) process.
- PNC's regulatory capital ratios in the future will depend on, among other things, the company's financial performance, the scope and terms of final capital regulations then in effect and management actions affecting the composition of PNC's balance sheet. In addition, PNC's ability to determine, evaluate and forecast regulatory capital ratios, and to take actions (such as capital distributions) based on actual or forecasted capital ratios, will be dependent at least in part on the development, validation and regulatory review of related models.
- Legal and regulatory developments could have an impact on our ability to operate our businesses, financial condition, results of operations, competitive position, reputation, or pursuit of attractive acquisition opportunities. Reputational impacts could affect matters such as business generation and retention, liquidity, funding, and ability to attract and retain management. These developments could include:
- Impact on business and operating results of any costs associated with obtaining rights in intellectual property claimed by others and of adequacy of our intellectual property protection in general.
- Business and operating results are affected by our ability to identify and effectively manage risks inherent in our businesses, including, where appropriate, through effective use of systems and controls, third-party insurance, derivatives, and capital management techniques, and to meet evolving regulatory capital and liquidity standards.
- We grow our business in part through acquisitions and new strategic initiatives. Risks and uncertainties include those presented by the nature of the business acquired and strategic initiative, including in some cases those associated with our entry into new businesses or new geographic or other markets and risks resulting from our inexperience in those new areas, as well as risks and uncertainties related to the acquisition transactions themselves, regulatory issues, and the integration of the acquired businesses into PNC after closing. Many of these risks and uncertainties are present in our acquisition and integration of BBVA USA Bancshares, Inc., including its U.S. banking subsidiary, BBVA USA.
- Competition can have an impact on customer acquisition, growth and retention and on credit spreads and product pricing, which can affect market share, deposits and revenues. Our ability to anticipate and respond to technological changes can also impact our ability to respond to customer needs and meet competitive demands.
- Business and operating results can also be affected by widespread natural and other disasters, pandemics, dislocations, terrorist activities, system failures, security breaches, cyberattacks or international hostilities through impacts on the economy and financial markets generally or on us or our counterparties specifically.
We provide greater detail regarding these as well as other factors in our 2021 Form 10-K, including in the Risk Factors and Risk Management sections and the Legal Proceedings and Commitments Notes of the Notes To Consolidated Financial Statements in that report, and in our other subsequent SEC filings. Our forward-looking statements may also be subject to other risks and uncertainties, including those we may discuss elsewhere in this news release or in our SEC filings, accessible on the SEC's website at www.sec.gov and on our corporate website at www.pnc.com/secfilings. We have included these web addresses as inactive textual references only. Information on these websites is not part of this document.
MEDIA:
Marcey Zwiebel
(412) 762-4550
media.relations@pnc.com
INVESTORS:
Bryan Gill
(412) 768-4143
investor.relations@pnc.com
View original content to download multimedia:
SOURCE The PNC Financial Services Group, Inc. | https://www.1011now.com/prnewswire/2022/04/14/pnc-reports-first-quarter-2022-net-income-14-billion-323-diluted-eps-or-329-adjusted/ | 2022-04-14T12:14:04 | 1 | https://www.1011now.com/prnewswire/2022/04/14/pnc-reports-first-quarter-2022-net-income-14-billion-323-diluted-eps-or-329-adjusted/ |
Q: I have recently been given an opportunity to leave my company with a year’s salary and 12 months of health care. Can I obtain Medicare at age 62, or what are some of my other options? – H.B., Davenport
A: To claim Medicare early at age 62, you must have a qualifying disability for which you have been receiving Social Security benefits for at least 24 months. You should log into the Affordable Health Care website at healthcare.gov to explore your options for health insurance before age 65. – Christopher Dale
Q: My husband has a traditional IRA and I have a Roth IRA. Can I take his traditional IRA and make it a Roth IRA upon his death? – J.F., St. Cloud
A: You will have to transfer the ownership of the traditional to your own name upon his passing, then you can convert the traditional to the Roth after taking the Required Minimum Distribution. This assumes the tax laws have not changed when our husband dies. - Nancy Hecht
Have a question? E-mail askanexpert@fpafla.com. Include your name (only your initials will be printed), hometown and phone. Questions are answered by Certified Financial Planners from the Financial Planning Association of Central Florida. Answers are for educational purposes only; you should also consult a financial professional. Questions and answers may be edited for space considerations. | https://www.orlandosentinel.com/business/os-cfb-ask-expert-health-insurance-medicare-20220414-iqftw3wzxffqfjpwzuxejx3jyu-story.html | 2022-04-14T12:14:05 | 0 | https://www.orlandosentinel.com/business/os-cfb-ask-expert-health-insurance-medicare-20220414-iqftw3wzxffqfjpwzuxejx3jyu-story.html |
KIT GRAY NAMED ONE OF MOST INFLUENTIAL IN PODCASTING
ELI DVORKIN CHOSEN AS TOP 40 UNDER 40
PODCASTONE EXCEEDS 2.4 BILLION ANNUAL DOWNLOADS
LOS ANGELES, April 14, 2022 /PRNewswire/ -- PodcastOne, a leading podcast platform and a subsidiary of LiveOne (NASDAQ: LVO), announced today that its President Kit Gray has been named one of the twenty-two most influential people in podcasting and that Eli Dvorkin, Vice President of Brand and Talent Partnerships of PodcastOne, has been named to this year's Top 40 Under 40 in podcasting as chosen by Podcast Magazine.
As one of the earliest executives in the podcasting genre, Gray's skill and acumen for developing a network-talent partnership model set the tone and has since been emulated by many major podcasters. In 2012, he partnered with Norm Pattiz, founder of Westwood One, and together, they built a company that changed the world of digital audio, PodcastOne. Additionally, Gray's knowledge and passion from his time in advertising set PodcastOne apart from its competitors and is attributed to the early and consistent continued success of the company as a whole. PodcastOne is home to more than 200 produced programs, many of which such as The Adam Carolla Show, The LadyGang and The Jordan Harbinger Show have been overseen by Gray since their start with the network.
Dvorkin, a founding member of PodcastOne, joins industry heavyweights and notables from a wide range of prominent podcast categories from marketing and distribution to hosting and reporting on this year's list. In his role as Vice President of Brand and Talent Partnerships, Dvorkin is responsible for bringing winning talent to the network including the recent additions of Uncut with Jay Cutler, The Prosecutors and Strictly Stalking. He also is key to identifying shows and content that develop into long-term successes for PodcastOne, including Baby Mamas No Drama, On Display with Melissa Gorga, True Crime All the Time Unsolved, And This is Monsters.
"Every podcast network should be fortunate enough to have a Kit Gray and an Eli Dvorkin helping to captain the ship. Individually they are invaluable and as a team they are unstoppable. They are as integral to our successes today as they were when PodcastOne was the new kid on the block, and we wouldn't want it any other way," said Robert Ellin, CEO and Chairman of LiveOne.
Recently named #8 on the list of top podcast publishers in the United States by Podtrac, the industry-leading podcast metric company, PodcastOne's full roster of programming is available on PodcastOne, Apple Podcasts, Spotify, Amazon Music and wherever podcasts are heard.
About PodcastOne
PodcastOne is a leading advertiser-supported podcast company, offering a 360-degree solution for both content creators and advertisers, including content development, brand integration and distribution. Acquired by LiveOne (NASDAQ: LVO) in 2020, the two entities have subsequently teamed to create a new video podcast (Vodcast) network under the LiveOne umbrella. Amassing more than 2.48 billion downloads per year with 300+ episodes distributed per week across a stable of hundreds of top podcast programs, including influencer talent like Adam Carolla, Kaitlyn Bristowe, Steve Austin, Armando "Pitbull'' Perez, Jordan Harbinger, Heather Dubrow, The LadyGang, Kail Lowry, Melissa Gorga, Dr. Drew, Jay Cutler, Michael Irvin, Robert Horry, Dr. Gundry and top-rated true crime shows including Bad Bad Thing, True Crime All the Time Unsolved, This is MONSTERS, Court Junkie, A&E's Cold Case Files, American Nightmare and more. Its shows are distributed across its own platform as well as LiveOne's owned-and-operated channels on mobile, mobile web, desktop and SmartTV's. PodcastOne is the parent company of LaunchpadOne, an innovative self-serve platform developed to launch, host, distribute and monetize independent user-generated podcasts. PodcastOne is the brainchild of Radio Hall of Famer, Norm Pattiz, also the founder of Network Radio-giant, Westwood One.
About LiveOne, Inc.
Headquartered in Los Angeles, California, LiveOne, Inc. (NASDAQ: LVO) (the "Company") is an award-winning, creator-first, music, entertainment and technology platform focused on delivering premium experiences and content worldwide through memberships and live and virtual events. As of April 1, 2022, the Company has accrued a paid and free membership base of over 2.23 million**, streamed over 2,900 artists, has a library of 30 million songs, 600 curated radio stations, nearly 270 podcasts/vodcasts, hundreds of pay-per-views, personalized merchandise, released music-related NFTs, and created a valuable connection between fans, brands, and bands. The Company's wholly-owned subsidiaries include Slacker Radio, React Presents, Gramophone Media, Palm Beach Records, Custom Personalization Solutions, LiveXLive, PPVOne and PodcastOne, which generates more than 2.48 billion downloads per year and 300+ episodes distributed per week across its stable of top-rated podcasts. LiveOne is available on iOS, Android, Roku, Apple TV, Amazon Fire, and through OTT, STIRR, and XUMO. For more information, visit www.liveone.com and follow us on Facebook, Instagram, TikTok, and Twitter at @liveone.
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are "forward-looking statements," which may often, but not always, be identified by the use of such words as "may," "might," "will," "will likely result," "would," "should," "estimate," "plan," "project," "forecast," "intend," "expect," "anticipate," "believe," "seek," "continue," "target" or the negative of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including: the Company's reliance on one key customer for a substantial percentage of its revenue; the Company's ability to consummate any proposed financing, acquisition, spin-out, distribution or transaction, the timing of the closing of such proposed event, including the risks that a condition to closing would not be satisfied within the expected timeframe or at all, or that the closing of any proposed financing, acquisition, spin-out, distribution or transaction will not occur or whether any such event will enhance shareholder value; the Company's ability to continue as a going concern; the Company's ability to attract, maintain and increase the number of its users and paid subscribers; the Company identifying, acquiring, securing and developing content; the Company's intent to repurchase shares of its common stock from time to time under its announced stock repurchase program and the timing, price, and quantity of repurchases, if any, under the program; the Company's ability to maintain compliance with certain financial and other covenants; the Company successfully implementing its growth strategy, including relating to its technology platforms and applications; management's relationships with industry stakeholders; the effects of the global Covid-19 pandemic; changes in economic conditions; competition; risks and uncertainties applicable to the businesses of the Company's subsidiaries; and other risks, uncertainties and factors including, but not limited to, those described in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2021, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 14, 2021, Quarterly Report on Form 10-Q for the quarter ended June 30, 2021, filed with the SEC on August 16, 2021, Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2021, filed with the SEC on October 29, 2021, Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2021, filed with the SEC on February 14, 2022, and in the Company's other filings and submissions with the SEC. These forward-looking statements speak only as of the date hereof, and the Company disclaims any obligations to update these statements, except as may be required by law. The Company intends that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995.
** Included in the total number of paid members for the reported periods are certain members which are the subject of a contractual dispute. LiveOne is currently not recognizing revenue related to these members.
Press Contact:
310.246.4600
Susan@Guttmanpr.com
LiveOne IR Contact:
(310) 601-2505
ir@LiveOne.com
View original content to download multimedia:
SOURCE LiveOne, Inc. | https://www.1011now.com/prnewswire/2022/04/14/podcastones-executives-honored-by-podcast-magazine/ | 2022-04-14T12:14:11 | 0 | https://www.1011now.com/prnewswire/2022/04/14/podcastones-executives-honored-by-podcast-magazine/ |
A woman was shot Wednesday night at an Orlando apartment complex and deputies are searching for a suspect, according to Orange County Sheriff’s Office.
At around 9 p.m. deputies responded to a shooting at Southern Oaks Apartments on Park Hamilton Boulevard near Silver Star Road, OCSO said.
Deputies found a woman, in her 20s, suffering from a gunshot, OCSO said. The victim told deputies she knew the shooter; a man in his 20s. The man threatened her with a gun, shot her, and then fled the scene, OCSO said.
The woman was taken to the hospital with a non-life-threatening injury.
Deputies have not released any suspect information.
This is a developing story, check back here for updates. | https://www.orlandosentinel.com/news/breaking-news/os-ne-orange-county-shooting-southern-oaks-silver-star-road-20220414-jtnohhyngbabpkxr37zt5cjqra-story.html | 2022-04-14T12:14:17 | 1 | https://www.orlandosentinel.com/news/breaking-news/os-ne-orange-county-shooting-southern-oaks-silver-star-road-20220414-jtnohhyngbabpkxr37zt5cjqra-story.html |
Quantum Software and Services Leader Will Use Funding to Develop New Quantum Software APIs for Deep Learning and Finance and Fuel Expansion of European Operations in Paris
PALO ALTO, Calif. and PARIS, April 14, 2022 /PRNewswire/ -- QC Ware, a leading quantum software and services company, today announced that it has been awarded a $1.5M project in Deeptech Development Funding from Bpifrance. The funding will be used to develop two new quantum software APIs for deep learning and finance which will be integrated into QC Ware's Forge quantum-as-a-service platform. With a goal to create a quantum software ecosystem in Europe, the funds will also be used to hire ten new employees for QC Ware's Paris office within the next three years.
"We are honored to have been awarded our second grant from Bpifrance after the i-Nov award," said Iordanis Kerenidis, Head of Quantum Algorithms for QC Ware. "Quantum computing promises to revolutionize the future of information technology. With this new funding, we plan to continue growing the quantum software ecosystem in Europe from our Paris offices and fuel our mission to help companies in Europe and around the world prepare for the upcoming quantum disruption."
QC Ware's growing network of customers - which includes Aisin Group, Airbus, Air Force Research Laboratory (AFRL), BMW Group, Equinor, Goldman Sachs, and Total - collaborate with QC Ware on the design of practical algorithms that deliver performance on near-term quantum computing hardware. By potentially halving the industry timeline for quantum advantage, QC Ware has boosted enterprise and U.S. federal sector adoption of its algorithms for quantum machine learning, quantum Monte Carlo simulations, and quantum optimization. The company is experiencing brisk growth in collaborations with customers and hardware partners in fields that are ripe for quantum disruption, including chemistry simulations, materials discovery, drug design, and beyond.
Designed for data scientists and quantum engineers, Forge delivers a competitively advantageous path to quantum readiness. Forge distinguishes itself from other quantum computing cloud services by providing data scientists with access to pioneering and fine-tuned turnkey quantum algorithms for practical industry problems. Furthermore, quantum engineers can use Forge to gain access to the fundamental components of QC Ware's unique algorithmic IP and reuse these as building blocks for more complex approaches.
About QC Ware
QC Ware is a quantum software and services company focused on ensuring enterprises are prepared for the emerging quantum computing disruption. QC Ware specializes in the development of applications for near-term quantum computing hardware with a team composed of some of the industry's foremost experts in quantum computing. Its growing network of customers includes AFRL, Aisin Group, Airbus, BMW Group, Covestro, Equinor, Goldman Sachs, and Total. QC Ware Forge, the company's flagship quantum computing cloud service, is built for data scientists with no quantum computing background. It provides unique, performant, turnkey quantum computing algorithms. QC Ware is headquartered in Palo Alto, California, and supports its European customers through its subsidiary in Paris. QC Ware also organizes Q2B, the largest annual gathering of the international quantum computing community.
Press Contact:
Tim Smith
Element Public Relations
tsmith@elementpr.com
415-350-3019
View original content to download multimedia:
SOURCE QC Ware Corp. | https://www.1011now.com/prnewswire/2022/04/14/qc-ware-awarded-15-million-project-deeptech-development-funding-bpifrance-create-quantum-computing-software-ecosystem-europe/ | 2022-04-14T12:14:18 | 1 | https://www.1011now.com/prnewswire/2022/04/14/qc-ware-awarded-15-million-project-deeptech-development-funding-bpifrance-create-quantum-computing-software-ecosystem-europe/ |
GRAND RAPIDS, MICH. — A Black man face-down on the ground was fatally shot in the back of the head by a Michigan police officer, the violent climax of a traffic stop, brief foot chase and struggle over a stun gun, according to videos of the April 4 incident.
Patrick Lyoya, 26, was killed outside a house in Grand Rapids. The white officer repeatedly ordered Lyoya to “let go” of his Taser, at one point demanding: “Drop the Taser!”
Citing a need for transparency, the city’s new police chief, Eric Winstrom, on Wednesday released four videos, including critical footage of the shooting recorded by a passenger in Lyoya’s car on that rainy morning.
“I view it as a tragedy. ... It was a progression of sadness for me,” said Winstrom, a former high-ranking Chicago police commander who became Grand Rapids chief in March. The city of about 200,000 people is about 150 miles northwest of Detroit.
Video shows Lyoya running from the officer who stopped him for driving with a license plate that didn’t belong to the vehicle. They struggled in front of several homes while Lyoya’s passenger got out and watched.
Winstrom said the fight over the Taser lasted about 90 seconds. In the final moments, the officer was on top of Lyoya, kneeling on his back at times to subdue him.
“From my view of the video, Taser was deployed twice. Taser did not make contact,” Winstrom told reporters. “And Mr. Lyoya was shot in the head. However, that’s the only information that I have.”
State police are investigating the shooting. Kent County’s chief medical examiner, Dr. Stephen Cohle, said he completed the autopsy but toxicology tests haven’t been finished.
The traffic stop was tense from the start. Video shows Lyoya, a native of the Democratic Republic of Congo, getting out of the car before the officer approached. He ordered Lyoya to get back in the vehicle but the man declined.
The officer asked him if he spoke English and demanded his driver’s license. The foot chase began soon after, video shows.
Winstrom didn’t identify the officer, a seven-year veteran who is on paid leave during the investigation.
“Me being from Chicago for the last 20 years, I’ve handled many police shootings myself, so I do have a lot of experience in this,” the chief said. “I was hoping to never have to utilize that experience here.”
Video was collected from Lyoya’s passenger, the officer’s body-worn camera, the officer’s patrol car and a doorbell camera. Prosecutor Chris Becker, who will decide whether any charges are warranted, objected to the release but said Winstrom could act on his own.
Becker said the public shouldn’t expect a quick decision.
“While the videos released today are an important piece of evidence, they are not all of the evidence,” he said.
City Manager Mark Washington warned that the videos would lead to “expressions of shock, of anger and of pain.” Some downtown businesses boarded up their storefronts, and concrete barricades surrounded police headquarters.
Lyoya had two young daughters and five siblings, said Gov. Gretchen Whitmer, who spoke to his family.
“He arrived in the United States as a refugee with his family fleeing violence. He had his whole life ahead of him,” Whitmer, a Democrat, said.
Prominent civil rights attorney Ben Crump, speaking on behalf of Lyoya’s family, on Wednesday called for the officer in the shooting to be fired and prosecuted.
“The video clearly shows that this was an unnecessary, excessive, and fatal use of force against an unarmed Black man who was confused by the encounter and terrified for his life,” Crump said in a release.
“It should be noted that Patrick never used violence against this officer even though the officer used violence against him in several instances for what was a misdemeanor traffic stop,” he added.
Crump and Lyoya’s family were expected to hold a news conference Thursday afternoon.
More than 100 people marched to Grand Rapids City Hall before a City Commission meeting Tuesday night, chanting “Black lives matter” and “No justice, no peace.”
On Wednesday, several hundred protesters gathered outside the Grand Rapids Police Department following the release of the videos, with some cursing and shouting from behind barricades. The group demanded that officials make public the name of the officer in the shooting.
Some businesses cut their hours short Wednesday, closing early. Some boarded up windows. But the demonstration remained nonviolent with protesters demanding justice for Lyoya and other Black lives lost in shootings involving police.
Winstrom last week said he met Lyoya’s father, Peter Lyoya, and that they both cried.
“I get it as a father. ... It’s just heart-wrenching,” the chief told WOOD-TV.
As in many U.S. cities, Grand Rapids police have been occasionally criticized over the use of force, particularly against Black people, who make up 18% of the population.
In November, the Michigan Supreme Court heard arguments in a lawsuit over the practice of photographing and fingerprinting people who were never charged with a crime. Grand Rapids said the policy changed in 2015.
A downtown street has been designated Breonna Taylor Way, named for the Black woman and Grand Rapids native who was killed by police in Louisville, Kentucky, during a botched drug raid in 2020.
White reported from Detroit. AP reporters Corey Williams in West Bloomfield, Michigan; David Eggert in Lansing, Michigan; and John Flesher in Traverse City, Michigan, contributed to this story. | https://www.orlandosentinel.com/news/nationworld/ct-aud-nw-grand-rapids-patrick-lyoya-police-shooting-20220414-kpob2kecbnaopn4fsfz5dj7e7y-story.html | 2022-04-14T12:14:24 | 1 | https://www.orlandosentinel.com/news/nationworld/ct-aud-nw-grand-rapids-patrick-lyoya-police-shooting-20220414-kpob2kecbnaopn4fsfz5dj7e7y-story.html |
TORONTO, April 14, 2022 Quarterhill Inc. ("Quarterhill") (TSX: QTRH) (OTCQX: QTRHF), is providing details of its upcoming Annual and Special Meeting of shareholders ("AGM") to be held virtually on Thursday April 21, 2022, at 9:30 a.m. (Eastern Daylight Time).
TO VOTE AHEAD OF THE VIRTUAL AGM
As in prior years, shareholders have multiple options to cast their vote ahead of the AGM, which include on-line, via telephone or via mail. Details on using each method are included in the management information circular and the form of proxy. Shareholders who are planning to vote ahead of the AGM must submit their proxy voting instructions to Computershare no later than 9:30 a.m. (Eastern Daylight Time) on Tuesday, April 19, 2022.
A notice package containing a description of the matters to be addressed at the AGM and of the notice-and-access procedures to access the meeting materials, as well as a form of proxy (for registered shareholders) or a voting instruction form (for non-registered shareholders) (collectively, the "Notice Package") was mailed on or about March 17, 2022. If you have not yet received your copy of the Notice Package, please contact your broker if you are a non-registered shareholder or contact Computershare if you are a registered shareholder. These materials outline in detail how to participate at the AGM.
The Meeting Materials are available to view at Quarterhill's profile on SEDAR at www.sedar.com as well as in the Investor Section of Quarterhill's website at www.quarterhill.com.
LISTENING TO THE VIRTUAL AGM
All shareholders will be able to listen to the AGM and view the Company's slide presentation as guests via audio webcast. To do so, login online at: https://web.lumiagm.com/429372562, click "Guest" and then complete the online form. Please log in 30-45 minutes prior to the start time of the AGM on April 21, 2022.
TO VOTE OR ASK QUESTIONS AT THE VIRTUAL AGM
For registered shareholders and duly appointed proxyholders to vote their proxies and/or ask questions at the AGM, please follow the instructions set out in our Circular.
All shareholders wishing to have a question addressed at the virtual AGM can avoid the registration requirements set out in the Circular by submitting them in advance to ir@quarterhill.com. Questions will be collected, organized by theme and posed to management at the AGM. Quarterhill is committed to addressing all appropriate questions submitted by shareholders either live during the AGM or in advance, as timing and circumstances permit.
Shareholders who have questions on how to vote their proxy in advance of the AGM, or on how to register to vote at the AGM, can contact Quarterhill's strategic shareholder advisor and proxy solicitation agent, Kingsdale Advisors, at 1-855-476-7980 or, from outside North America, by collect call to 1-416-867-2272, or by Email at: contactus@kingsdaleadvisors.com.
About Notice and Access
As permitted by the Canadian Securities Administrators and pursuant to exemptions from the management proxy solicitation and financial statement and management's discussion and analysis delivery requirements received from the Director appointed under the Canada Business Corporations Act, Quarterhill is using "notice and access" to deliver proxy-related materials including Quarterhill's notice of meeting, management information circular and related materials (collectively the "Meeting Materials") to both registered and non-registered shareholders. "Notice and access" is a set of rules for reducing the volume of materials that must be physically mailed to shareholders by posting the Meeting Materials online and providing shareholders with a notice stating where they are available. Rather than receiving a paper copy of the Meeting Materials in the mail, shareholders will have access to them online and will receive a Notice Package as described earlier in this release. Where a shareholder has previously consented to electronic delivery, the Notice Package will be sent to the shareholder electronically, and otherwise will be mailed to the shareholder.
About Quarterhill
Quarterhill is a leading provider of tolling and enforcement solutions in the Intelligent Transportation System (ITS) industry, as well as, through its Wi-LAN Inc. subsidiary, a leader in Intellectual Property licensing. Our goal is global leadership in ITS, via organic growth of the Electronic Transaction Consultants, LLC (ETC) and International Road Dynamics, Inc. (IRD) platforms, and by continuing an acquisition-oriented investment strategy that capitalizes on attractive growth opportunities within ITS and its adjacent markets. Quarterhill is listed on the TSX under the symbol QTRH and on the OTCQX Best Market under the symbol QTRHF. For more information, visit www.quarterhill.com
Forward-looking Information
This news release contains forward-looking statements regarding Quarterhill and its business. Forward-looking statements are based on estimates and assumptions made by Quarterhill in light of its experience and its perception of historical trends, current conditions, expected future developments and the expected effects of new business strategies, as well as other factors that Quarterhill believes are appropriate in the circumstances. The forward-looking events and circumstances discussed herein may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting Quarterhill, including: potential risks and uncertainties relating to the ultimate geographic spread of the novel coronavirus ("COVID-19"); the severity of the disease; the duration of the COVID-19 outbreak; actions that may be taken by governmental authorities to contain the COVID-19 outbreak or to treat its impact; the potential negative impacts of COVID-19 on the global economy and financial markets and any resulting impact on Quarterhill and/or its business. Other factors include, without limitation, the risks described in Quarterhill's March 11, 2021 annual information form for the year ended December 31, 2021 (the "AIF"). Copies of the AIF may be obtained at www.sedar.com. Quarterhill recommends that readers review and consider all of these risk factors and notes that readers should not place undue reliance on any of Quarterhill's forward-looking statements. Quarterhill has no intention, and undertakes no obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
View original content:
SOURCE Quarterhill Inc. | https://www.1011now.com/prnewswire/2022/04/14/quarterhill-host-virtual-agm-april-21-2022/ | 2022-04-14T12:14:27 | 1 | https://www.1011now.com/prnewswire/2022/04/14/quarterhill-host-virtual-agm-april-21-2022/ |
The South Florida Sun Sentinel continues its 10-part series looking at the top prospects in the upcoming NFL draft (April 28-30) with linebackers. This is one of the deepest positions in the 2022 draft, but the caliber of the top linebackers doesn’t match last year’s class. There could be a few Day 3 gems the Dolphins could select with either their late third-round pick or their fourth-round selection to develop for the future.
Utah’s Devin Lloyd
Lloyd, who produced 165 sacks and five interceptions during his four college seasons, is a pure playmaker who can do everything asked of a linebacker in today’s pro game. He can defend the run, rush the passer and drop back into coverage. His football intellect and versatility should ensure he’s taken in the first round.
Georgia’s Nakobe Dean
Despite being a tad undersized (6-foot, 225 pounds), Dean was the heart of the Georgia defense. He’s a rangy playmaker who fires into gaps and strikes defenders. The only concerns about his game center on his size and the possibility that he might be forced to run around blocks in the NFL.
Georgia’s Channing Tindall
While Tindall was a role player for the Bulldogs elite defense, he’s flashed playmaking ability and traits that indicate he’s an athletic mover who could become a sideline-to-sideline defender. The only knock on Tindall is that he seems hesitant when dropping into zones. But he can be a core special teams player who brings value to the third phase of the game.
Alabama’s Christian Harris
Harris is a true three-down linebacker with loose hips, speed and athleticism needed to cover in space. His quickness and speed allow him to beat blockers, but he also has the size (6-2, 230) needed work in traffic. However, offenses seemed to target him in coverage in college and that could become an issue in the NFL.
LSU’s Damone Clark
Clark is a large (6-3, 245) well proportioned linebacker whose length and speed help him in coverage. He has an aggressive temperament, and his effort is never lacking. While he was highly productive (135 tackles, 5.5 sacks and one interception) in his final season at LSU there’s still room for growth and improvement.
Best of the rest
Oklahoma’s Nik Bonitto, who produced 18.5 sacks, and would make an outstanding outside linebacker in a 3-4 defensive scheme. Georgia’s Quay Walker has the makeup of a starting strong side linebacker or outside linebacker in a 3-4 scheme. Wyoming’s Chad Muma is a tackling machine who could play all three linebacker positions in the NFL. And Penn State’s Brandon Smith and Zakoby McClain are fluid athletes who might become multi-year starters.
Class grade: C+
Linebacker has gradually become the defensive position that gets undervalued, much like running back on offense. Only a handful of linebackers are expected to be taken in the first two days of the draft, but nearly a dozen have the talent to eventually become NFL starters in a year or two if they are put in the right scheme. This comes down to each team’s personal taste, and their evaluation skills. But don’t be surprised if the next Darius Leonard, a three-time Pro Bowler who was a second-round pick by the Colts, is in this class.
Teams in need
The Giants, 49ers, Bills, Dolphins, Jets, Titans, Broncos and Chargers all need linebacker help immediately, they should fortify their units with players who could become starters in year one or two. Linebacker might be the position with the most rookies on NFL rosters come September. Problem is, they won’t be priority picks in the early rounds.
Dolphins’ focus
Elandon Roberts’ career history indicates he’s a two-down linebacker considering he’s struggled in pass coverage, and Jerome Baker thrived playing outside linebacker last season. If Baker remains in the same role he played the second half of last season, the Dolphins need to find an inside linebacker who has good run-game instincts and pass coverage skills. At the moment, Duke Riley and Brennan Scarlett would be part-time starters so it would be ideal for the Dolphins to add some competition. | https://www.orlandosentinel.com/sports/miami-dolphins/fl-sp-dolphins-draft-kelly-lb-20220414-odir2cpf5ngldnuencat443vli-story.html | 2022-04-14T12:14:30 | 1 | https://www.orlandosentinel.com/sports/miami-dolphins/fl-sp-dolphins-draft-kelly-lb-20220414-odir2cpf5ngldnuencat443vli-story.html |
Uh oh.
Make sure to bring an umbrella today as rain returns to Orlando’s forecast starting Thursday and will be sticking around through the Easter weekend.
First, Thursday’s peak temperature is rising up to 88 degrees during the day, said Bryan Karrick a Spectrum News 13 meteorologist. The low should fall to 68 in the evening.
Second, showers and thunderstorms make their way into the forecast this afternoon and will stick around into the evening all the way up to 10 p.m. Karrick said.
“You’ll hear a few rumbles of thunder toward the evening hours in the east and west coast,” he said.
Thursday has a 30% chance of showers during the day. Those odds will linger Friday and into the weekend. Easter Sunday has the strongest chance of showers at 40%. The start of the work week also has a 40% chance of showers, but skies will clear up starting Tuesday.
Jpedersen@orlandosentinel.com | https://www.orlandosentinel.com/weather/os-ne-rain-showers-thursday-forecast-update-20220414-jrgba6gnhrhjxdkqtjzvlj23xy-story.html | 2022-04-14T12:14:33 | 0 | https://www.orlandosentinel.com/weather/os-ne-rain-showers-thursday-forecast-update-20220414-jrgba6gnhrhjxdkqtjzvlj23xy-story.html |
South Mississippi Area Real Estate Broker Aritt Davis Named Principal Broker
TORONTO and NEW YORK, April 14, 2022 /PRNewswire/ -- The Real Brokerage Inc. ("Real" or the "Company") (NASDAQ: REAX), (TSXV: REAX), an international, technology-powered real estate brokerage, today announced its launch of operations in Mississippi. Real is now operating in 44 states, the District of Columbia and Canada.
As part of the state launch, Real has appointed real estate broker Aritt Davis as Principal Broker. Davis entered the real estate industry after serving 21 years in the Mississippi Army National Guard. Davis was a top tier producer in southern Mississippi for three years before launching The Aritt Davis Team and now his own brokerage, Sail & Anchor Group.
The Aritt Davis Team/Sail & Anchor Group completed 101 transactions in 2021, totaling an approximate value of sold homes just under $20 million as a first year team. Their group will soon account for more than 30 Real agents in the area.
"We are grateful for the opportunity to join Real," Davis said. "Real presents growth opportunities that I simply could not offer as an independent broker, such as revenue share and equity participation. Real also provides the opportunity to collaborate and work with a national referral base."
"We are gaining momentum, opening in more states and quickly approaching our goal of serving all U.S. agents," said Real Chairman and CEO Tamir Poleg. "We look forward to working with Aritt to recruit agents and expand our footprint in Mississippi and throughout the Southeast."
About Real
Real (www.joinreal.com) is a technology-powered real estate brokerage operating in 44 U.S. states, the District of Columbia, and Ontario and Alberta, Canada. Real is building the future, together with more than 4,500 agents and their clients. Real creates financial opportunities for agents through better commission splits, best-in-class technology, revenue sharing and equity incentives.
Contact Information
For additional information, please contact:
The Real Brokerage Inc.
Elisabeth Warrick
elisabeth@therealbrokerage.com
Caroline Glennon
thunder11@therealbrokerage.com
1+201-564-4221
Investors, for more information, please contact:
Hayden IR
James Carbonara
james@haydenir.com
646-755-7412
Forward-Looking Information
This press release contains forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking information is often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect", "likely" and "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof. Forward-looking information in this press release includes, without limiting the foregoing, information relating to Real's expansion to Mississippi and the business and strategic plans of Real.
Forward-looking information is based on assumptions that may prove to be incorrect, including but not limited to Real's business objectives, expected growth, results of operations, performance, business projects and opportunities and financial results. Real considers these assumptions to be reasonable in the circumstances. However, forward-looking information is subject to known and unknown risks, uncertainties and other factors that could cause actual results, performance or achievements to differ materially from those expressed or implied in the forward-looking information. These factors should be carefully considered and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Real cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and Real assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release, and the NASDAQ has neither approved nor disapproved the contents of this press release.
View original content:
SOURCE The Real Brokerage Inc. | https://www.1011now.com/prnewswire/2022/04/14/real-brokerage-inc-opens-mississippi/ | 2022-04-14T12:14:33 | 1 | https://www.1011now.com/prnewswire/2022/04/14/real-brokerage-inc-opens-mississippi/ |
National rents hit a new high of $1,807 in March; Sun Belt metros top the list of biggest two-year rent gains, beating out large tech hubs
SANTA CLARA, Calif., April 14, 2022 /PRNewswire/ -- U.S. rental prices grew by nearly 20% from March 2020 to 2022 during the pandemic, according to the Realtor.com® Monthly Rental Report released today. Additionally, two-year rental trends indicate some redistribution of higher rents across the 50 largest markets during COVID, as renters migrated from expensive big tech cities to relatively more affordable areas. Sun Belt metros topped the list of fastest-growing rental markets from March 2020-2022, led by Miami, Riverside, Calif. and Tampa, Fla., while big tech hubs posted many of the country's smallest two-year rent gains.
"With asking rents nearly 1.2 times higher than two years ago, our March data highlights rising rental affordability challenges faced by many Americans today," said Realtor.com® Chief Economist Danielle Hale. "At the same time, March rental trends offer early signs of relief from the feverish pace of rent growth, which moderated year-over-year for the second month in a row. We expect cooling to continue over time, but the jury is still out on whether rent growth will hit single-digits by the end of 2022. This is largely due to the mismatch between rental supply, with vacancy rates at record-lows, and demand rising as some would-be buyers potentially turn to renting in the face of higher home prices and mortgage rates. While the jobs market is strong, it's unlikely that we'll see enough income growth to keep rents under 30% of monthly paychecks – especially with higher inflation and everyday costs. Still, there is a silver lining for renters, as rents won't be able to sustain an accelerated pace if incomes can't keep up."
March 2022 Rental Metrics – National
The U.S. median rental price hit a new high of $1,807 in March, up 19.3% in just two years, highlighting a roller coaster ride of change since the pandemic began. Following a slowdown in 2020 at the onset of COVID, rents significantly made up lost ground in 2021 and have since maintained a feverish pace of annual rent growth. In fact, March marked the eighth consecutive month of double-digit annual rent gains (+17.0%), even as the pace moderated slightly over February (+17.1%).
Although the underlying reasons have shifted over the course of the pandemic, data suggests that renting remains a popular option for Americans who desire flexibility. With the rise in remote work earlier on, renting offered an attractive option for those looking to explore living in relatively affordable markets further from big tech cities. Now that for-sale home prices and mortgage rates are climbing, many would-be buyers are turning to renting and driving up rental prices. In March, rents grew nearly four-times faster year-over-year (+17.0%) than in March 2020 (+4.3%).
With demand for more living space rising during COVID, rental prices for two-bedroom (+21.9%) and one-bedroom (+17.9%) units increased at the fastest rates from March 2020-2022. Studio rents, which experienced the biggest rental declines at the onset of COVID, posted relatively smaller two-year gains (+12.6%) in March. However, studio rents are quickly making up lost ground, posting the highest annual rental price gains among unit sizes for the third consecutive month in March.
Among the 50 largest U.S. metros, COVID rental trends indicate some redistribution of high rents from the biggest tech cities to relatively more affordable metros outside of major downtowns. In March, big tech cities accounted for none of the top 10 metros by highest two-year rent growth. Instead, this list was dominated by Sun Belt markets, led by Miami with an increase of 58.0% over March 2020 (see table below).
Additionally, big tech cities represented five of the 10 slowest-growing rental markets from March 2020-2022. Despite these setbacks, many major tech hubs continue to command some of the nation's highest rents. Even San Jose, where rents remain largely unchanged from March 2020 levels (+0.1%), claimed the country's highest median rent ($3,075). Still, March rental data signals some final opportunities for renters to find savings in major metros like San Francisco, where rents for studios (-13.0%) and one-beds (-3.3%) declined over March 2020.
"With booming employment and the growing back-to-office wave stoking demand, big rents are back in big tech cities. Still, our March data suggests select tech hubs like San Francisco might still offer bargains on studios relative to pre-COVID rents. And for some, such as Gen Zers striking out on their own, even small rental savings could make a large difference," said George Ratiu, Realtor.com® Senior Economist & Manager of Economic Research. "Regardless of your stage of life, with rising prices taking a bigger bite out of paychecks, it's important to stay focused on financial health by keeping rental costs to a smaller percentage of your take-home pay. A tool like the Realtor.com® Rental App can help you customize your search and get alerts about newly-listed rentals in your budget."
March 2022 Rental Metrics – Top Markets by Biggest & Smallest Rent Gains Over March 2020
*10 largest U.S. tech cities
Rental data as of March 2022 for units advertised as for-rent on Realtor.com®. Rental units include apartment communities as well as private rentals (condos, townhomes, single-family homes). All units were studio, 1-bedroom, or 2-bedroom units. We use communities that reliably report data each month within the top 50 largest metropolitan areas. National rents were calculated by averaging the medians of the 50 largest metropolitan areas. *Providence, RI March 2022 rental data is currently under review.
Realtor.com® makes buying, selling, renting and living in homes easier and more rewarding for everyone. Realtor.com® pioneered the world of digital real estate more than 25 years ago, and today through its website and mobile apps offers a marketplace where people can learn about their options, trust in the transparency of information provided to them, and get services and resources that are personalized to their needs. Using proprietary data science and machine learning technology, Realtor.com® pairs buyers and sellers with local agents in their market, helping take the guesswork out of buying and selling a home. For professionals, Realtor.com® is a trusted provider of consumer connections and branding solutions that help them succeed in today's on-demand world. Realtor.com® is operated by News Corp [Nasdaq: NWS, NWSA] [ASX: NWS, NWSLV] subsidiary Move, Inc. For more information, visit Realtor.com®.
Media Contact
rachel.conner@move.com
View original content:
SOURCE Realtor.com | https://www.1011now.com/prnewswire/2022/04/14/realtorcom-march-rental-report-us-rental-prices-soar-by-nearly-20-just-two-years/ | 2022-04-14T12:14:40 | 1 | https://www.1011now.com/prnewswire/2022/04/14/realtorcom-march-rental-report-us-rental-prices-soar-by-nearly-20-just-two-years/ |
Companies to develop a New Shovel-Ready Site at Repauno Port & Rail Terminal, subject to BPU approval of the Outerbridge Renewable Connector project
Will Strengthen New Jersey's Position as a Manufacturing Hub for the Growing U.S. Offshore Wind Industry and Create Hundreds of Good-Paying Local Jobs
GREENWICH TOWNSHIP, N.J., April 14, 2022 /PRNewswire/ -- Rise Light & Power (Rise) and Delaware River Partners LLC (DRP) today announced an historic partnership to position New Jersey as a leading manufacturing hub in the growing offshore wind industry.
As part of its Outerbridge Renewable Connector project, Rise announced it is prepared to invest millions to develop a shovel-ready site for a submarine cable manufacturing facility at DRP-owned Repauno Port & Rail Terminal in Greenwich Township (Repauno).
The proposed submarine cable manufacturing facility will have a footprint of approximately 30 acres, along with dock access. Upon approval of the Outerbridge Renewable Connector project, pending before the BPU, Rise and DRP will commence development and permitting work to make the site shovel-ready and to attract an offshore cable manufacturer, who would ultimately construct and operate the facility. Submarine cable manufacturing facilities of similar size typically generate approximately 500 jobs during construction and over 100 good-paying, full-time jobs during operations.
"This opportunity will bolster New Jersey's leadership in offshore wind with a major investment to create good-paying jobs and become a national supply chain leader," said Clint Plummer, CEO of Rise Light & Power. "The Outerbridge Renewable Connector will revitalize and repurpose infrastructure to meet New Jersey's bold clean energy goals. We are excited about this partnership with Delaware River Partners."
"We are proud to enter into a partnership with Rise Light & Power to develop New Jersey's first submarine cable manufacturing facility," said Hank Alexander, DRP's CEO. "The Repauno Port & Rail Terminal is an ideal location for this project. Conveniently situated along the Delaware River, we are accessible and fully capable of meeting the offshore wind industry's needs."
"Wind power is coming to Jersey. Atlantic Shores, Ocean Wind, New York Bight are underway and I'm sure others will follow. Submarine cables taking the power generated by offshore wind to the Rise Light & Power site for distribution is a sensible plan," said Senator Edward Durr, representing the District of New Jersey in which Repauno is located. "Manufacturing those submarine cable at Repauno is a great opportunity to bring good paying jobs to the Third Legislative District and help generate additional economic development in our community."
Vince Giovannitti, Mayor of Gibbstown said, "New Jersey's first cable manufacturing facility will inject new life into Greenwich Township's manufacturing sector and provide good-paying local jobs for our residents. This is an ideal re-use of the former DuPont property and will be a driver of our local economy."
Upon hearing of the new effort to develop the facility in Gibbstown, Christina M. Renna, President & CEO of the Chamber of Commerce Southern New Jersey (CCSNJ) said, "CCSNJ proudly welcomes this new partnership between Repauno Port & Rail and Rise Light & Power. Having a shovel-ready site will attract manufacturers to our region, paving the way for hundreds of new manufacturing jobs and connecting our community with the on-going clean energy transition in New Jersey."
With a demand for 800 to 1,000 miles of cable per year in the U.S. and growing, the addition of a new submarine cable manufacturing factory positions New Jersey as a critical link in the offshore wind supply chain to meet this growing demand. Currently, there is only one operational U.S. offshore wind cable manufacturing facility out of South Carolina. A typical offshore wind cable manufacturing plant may produce approximately 120 miles of cable per year, depending on size.
Rise and DRP will develop the site to be shovel-ready and collaborate to attract manufactures of two types of subsea cables required for offshore wind farms. First are inter-array cables that connect turbines within the offshore wind farm to an offshore substation, and the second are export cables that connect the offshore substation to the onshore grid.
Rise is committed to advancing a regional supply chain for offshore wind submarine cable manufacturing in the region, and Repauno is the first step in establishing the regional supply chain to support the growth of the offshore wind industry.
Rise's Outerbridge Renewable Connector is an innovative plan for turning the nearly 100-year-old retired coal-fired E.H. Werner power plant into a state-of-the-art clean energy hub to deliver renewable offshore wind energy, making it a valuable part of the South Amboy waterfront, contributing to the local tax base, and creating good-paying union jobs. The site is located directly on the coastline with an existing substation and high-voltage transmission connection to the grid. In contrast, many of the other substations proposed for offshore wind integration are located 10-20 miles from the coast, often directly adjacent to beach communities and Wildlife Management Areas, and requiring significant new infrastructure. Outerbridge is an innovative response to a joint call by the NJ Board of Public Utilities (NJBPU) and the regional grid operator, PJM Interconnection, for qualified developers to submit potential transmission solutions that would help deliver offshore wind energy to the existing power grid. NJBPU and PJM will evaluate all submissions to determine which projects can meet the state's offshore wind policy goals. For more information, please visit www.outerbridgenj.com.
Rise Light & Power is a Queens, NY-based energy asset manager and developer. Its core asset, Ravenswood Generation Station, is New York City's largest power-generating facility, which provides more than 20 percent of New York City's generation capacity. In addition, Rise is pursuing an exciting growth-oriented strategy, including modernization and resiliency upgrades at Ravenswood Generation Station, as well as new large-scale clean energy infrastructure to facilitate the renewable energy transition taking place in New York State and New Jersey. Rise Light & Power is a wholly owned affiliate of LS Power. For more information, please visit www.riselight.com
Repauno Port & Rail Terminal is owned by Delaware River Partners and located on a 1,600-acre site along the Delaware River in Greenwich Township, New Jersey, one of the most active maritime markets in the nation.
Formerly the home of a DuPont manufacturing facility, the site is being redeveloped into a multi-use port facility for energy products, roll-on/roll-off, project cargo, bulk cargo, warehousing and logistics. Its first dock opened in January 2021 and can handle all types of cargo.
Repauno offers tremendous logistical optionality as it sits directly on the Delaware River, served by Conrail with access to CSX and Norfolk Southern, and easy truck access to I-295 and I-95. Additionally, the site features a new multi-purpose dock with 40-foot draft, capable of safely handling a wide variety of products and available acreage with build-to-suit logistical solutions available for development.
To-date, more than $100 million in investments have been completed on the site, including rehabilitation of a hard rock cavern for storing bulk liquid/gases and construction of a state-of-the-art transloading system and deep-water dock.
Repauno is owned by Fortress Transportation and Infrastructure Investors LLC (NYSE: FTAI), which is externally managed by an affiliate of Fortress Investment Group LLC, a leading, diversified global investment firm.
View original content to download multimedia:
SOURCE Rise Light & Power | https://www.1011now.com/prnewswire/2022/04/14/rise-light-amp-power-delaware-river-partners-collaborate-new-jerseys-first-offshore-wind-cable-manufacturing-facility/ | 2022-04-14T12:14:44 | 1 | https://www.1011now.com/prnewswire/2022/04/14/rise-light-amp-power-delaware-river-partners-collaborate-new-jerseys-first-offshore-wind-cable-manufacturing-facility/ |
EVANSTON, Ill., April 14, 2022 /PRNewswire/ -- In a recent announcement, SellersCommerce, the Illinois-based SaaS provider of eCommerce solutions revealed its plans of pivoting toward a headless, 360° B2B ECommerce Platform by 2023 to enable businesses to keep up with fast-evolving digital trends and the increasing consumer reliance on a more fluid, personalized shopping experience.
As businesses resume normal operations after two years of pandemic-induced disruption, the need for agile eCommerce solutions is now more than ever before. Buyers expect to be able to purchase right from their initial touchpoints, whether it be directly through Instagram, via personal voice assistance like Alexa or Google Home, on wearable devices, or even from their cars. And moving beyond monolithic, full-stack eCommerce infrastructure to 360° eCommerce is the way to effectively serve enterprises & mid-market going into the future.
Here's How the Company is Gearing Up to Ride the Headless Wave
Going headless means having an eCommerce solution with decoupled front and back end that allows businesses the flexibility of pushing data or content of any type to the front-end using APIs.
"This transition was always on the cards for us because the eCommerce industry clearly demands a more robust architecture that allows rapid deployments without impacting the back-end system." said Ashok Reddy, CEO of SellersCommerce.
"Starting 2023 all our platforms will follow a headless model built on microservices that will enable our customers to deliver a more dynamic buying experience without resorting to a complete rip-and-replace approach to scale their business." he added.
An eCommerce Experience Tailored for Enterprises
SellersCommerce's headless eCommerce infrastructure will offer unlimited flexibility to businesses to improve customer experience and technical performance by enabling them to:
- Seamlessly manage multiple business models (B2B, B2C & B2X) from one platform.
- Add new channels & touchpoints to improve customer experience without additional development effort.
- Integrate with any system natively by configuring workflows using simple drag & drop.
- Centralize business operations with PIM, CMS, Order Management & Warehouse Management.
About SellersCommerce: Founded in 2013, SellersCommerce is the fastest-growing B2B eCommerce company providing enterprise solutions to manufacturers, distributors, and retailers to launch and grow their online business. Their focus on digital innovation and creating customized sales solutions is what makes their platforms a game changer for both B2B & B2C businesses.
Contact: pr@sellerscommerce.com
View original content to download multimedia:
SOURCE SellersCommerce | https://www.1011now.com/prnewswire/2022/04/14/sellerscommerce-set-pivot-towards-360-b2b-ecommerce-platform-by-2023/ | 2022-04-14T12:14:51 | 0 | https://www.1011now.com/prnewswire/2022/04/14/sellerscommerce-set-pivot-towards-360-b2b-ecommerce-platform-by-2023/ |
HONG KONG, April 14, 2022 /PRNewswire/ -- Sharing Economy International Inc. ("SEII") (OTCQB: SEII), announced today that the board of directors has appointed Mr. Pak Hei Jefferson Chan to be the Chairman and CEO, after Mr. Anthony Che Chung Chan has resigned as Chairman and CEO.
Mr. Jefferson Chan graduated from Hult International School with a Bachelor degree in Business Administration, Entrepreneurship. Mr. Chan is the co-founder of ECrent Worldwide Company Limited since 2013, which has developed and operates a sharing economy platform ECrent.com, promoting "Share through Renting" for a sustainable future.
Mr. Chan's previous experiences include Smart Work Media (New Jersey, USA), Brighton Management LTD (Hong Kong), Rothschild Bank (Zurich, Switzerland) and Mouawad Jewellery (Dubai), covering wide range of professional trainings in research and marketing, as well as investment banking operations.
Mr. Chan will continue to lead the development of the ECrent business, and to look for other business opportunities that may grow the company.
About Sharing Economy International Inc.
Sharing Economy International Inc., through its affiliated companies, are focused on targeting the technology and global sharing economy markets, by developing online platforms and rental business partnerships that will drive the global development of sharing through economical rental business models. Moreover, the Company will actively pursue blockchain technology in its existing and to-be-acquired business, enabling the general public to realize the beauty of resource sharing. For more information visit www.seii.com
Cautionary Warning Regarding Forward-Looking Statements:
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may, and probably will, differ materially from the predictions discussed in these forward-looking statements. Changes in the circumstances upon which we base our predictions and/or forward-looking statements could materially affect our actual results. Additional factors that could materially affect these forward-looking statements and/or predictions include, among other things: (1) our ability to raise additional capital to continue our operations; (2) our ability to pay down existing debt; (3) our ability to attract and retain key executive officers and the professional advisors; (4) the effect of the COVID-19 outbreak on our operations; (5) potential litigation with our shareholders, creditors and/or former or current investors; (6) the effect of political instability on our operations; and (7) other factors over which we have little or no control. Any forward-looking statements speak only as of the date on which they are made, and Sharing Economy International does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on Sharing Economy International's website does not constitute a part of this release.
Company Contacts:
Sharing Economy International Inc.
Email: ir@seii.com
+852-31060372
View original content:
SOURCE Sharing Economy International Inc. | https://www.1011now.com/prnewswire/2022/04/14/sharing-economy-appoints-jefferson-chan-chairman-ceo/ | 2022-04-14T12:14:59 | 0 | https://www.1011now.com/prnewswire/2022/04/14/sharing-economy-appoints-jefferson-chan-chairman-ceo/ |
Trading Symbol: TSX: SVM
NYSE AMERICAN: SVM
VANCOUVER, BC, April 14, 2022 /PRNewswire/ - Silvercorp Metals Inc. ("Silvercorp" or the "Company") (TSX: SVM) (NYSE American: SVM) reports production and sales figures for the fiscal year 2022 ended March 31, 2022 ("Fiscal 2022"). The Company expects to release its Fiscal 2022 audited financial results on Thursday, May 26, 2022 after market close.
In Fiscal 2022, the Company produced approximately 6.1 million ounces of silver, 3,400 ounces of gold, 64.4 million pounds of lead, and 26.8 million pounds of zinc, slightly below the guidance of 6.3 to 6.6 million ounces of silver, 65.7 to 68.9 million pounds of lead, and 26.9 to 28.5 million pounds of zinc. The shortfall was mainly due to the disruptions arising from the mining contract renewal negotiation process and the heavy rainfall experienced at the Ying Mining District as reported in previous quarters.
The Company reiterates its Fiscal 2023 production guidance of 7.0 to 7.3 million ounces of silver, 6,300 to 7,900 ounces of gold, 68.4 to 71.3 million pounds of lead, and 32.0 to 34.5 million pounds of zinc. Fiscal 2023 production guidance represents anticipated increases of 14% to 19% in silver, 85% to 132% in gold, 6% to 11% in lead, and 19% to 29% in zinc compared to Fiscal 2022 production results.
FISCAL 2022 OPERATING HIGHLIGHTS
- At the Ying Mining District, 681,398 tonnes of ore were mined, up 5% over Fiscal 2021, and 684,293 tonnes of ore were milled, up 5% over Fiscal 2021. Approximately 5.5 million ounces of silver, 3,400 ounces of gold, 54.9 million pounds of lead, and 6.8 million pounds of zinc were produced, representing decreases of 2%, 3%, 5%, and 2%, respectively, in silver, gold, lead, and zinc over Fiscal 2021.
- At the GC Mine, 314,882 tonnes of ore were mined, comparable to 314,900 tonnes in Fiscal 2021, and 318,042 tonnes of ore were milled, up 1% over Fiscal 2021. Approximately 640 thousand ounces of silver, 9.5 million pounds of lead, and 20.0 million pounds of zinc were produced, representing decreases of 11%, 9% and 5%, respectively, in silver, lead, and zinc over Fiscal 2021.
- On a consolidated basis, 996,280 tonnes of ore were mined, up 3% over Fiscal 2021, and 1,002,335 tonnes of ore were milled, up 4% over Fiscal 2021. Approximately 6.1 million ounces of silver, 3,400 ounces of gold, 64.4 million pounds of lead, and 26.8 million pounds of zinc were produced, representing decreases of 3%, 3%, 6%, and 4%, respectively, in silver, gold, lead, and zinc over Fiscal 2021.
- On a consolidated basis, the Company sold approximately 6.3 million ounces of silver, 63.6 million pounds of lead, 26.8 million pounds of zinc, and 3,400 ounces of gold, representing decreases of 1%, 5%, and 4%, respectively, in silver, lead, zinc and an 8% increase in gold sold excluding the one-time sale of 1,200 ounces of gold from the BYP Mine in Fiscal 2021.
The operational results at the Ying Mining District for the past five quarters are summarized as follows:
The operational results at the GC Mine for the past five quarters are summarized as follows:
About Silvercorp
Silvercorp is a Canadian mining company producing silver, gold, lead, and zinc with a long history of profitability and growth potential. The Company's strategy is to create shareholder value by 1) focusing on generating free cashflow from long life mines; 2) organic growth through extensive drilling for discovery; 3) equity investments in potential world class opportunities; 4) ongoing merger and acquisition efforts to unlock value; and 5) long term commitment to responsible mining and ESG. For more information, please visit our website at www.silvercorp.ca.
CAUTIONARY DISCLAIMER - FORWARD-LOOKING STATEMENTS
Certain of the statements and information in this news release constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian provincial securities laws (collectively, "forward-looking statements"). Any statements or information that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as "expects", "is expected", "anticipates", "believes", "plans", "projects", "estimates", "assumes", "intends", "strategies", "targets", "goals", "forecasts", "objectives", "budgets", "schedules", "potential" or variations thereof or stating that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative of any of these terms and similar expressions) are not statements of historical fact and may be forward-looking statements. Forward-looking statements relate to, among other things: the price of silver and other metals; the accuracy of mineral resource and mineral reserve estimates at the Company's material properties; the sufficiency of the Company's capital to finance the Company's operations; estimates of the Company's revenues and capital expenditures; estimated production from the Company's mines in the Ying Mining District and the GC Mine; timing of receipt of permits and regulatory approvals; availability of funds from production to finance the Company's operations; and access to and availability of funding for future construction, use of proceeds from any financing and development of the Company's properties.
Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors that could cause actual events or results to differ from those reflected in the forward-looking statements, including, without limitation, risks relating to: social and economic impacts of COVID-19; fluctuating commodity prices; calculation of resources, reserves and mineralization and precious and base metal recovery; interpretations and assumptions of mineral resource and mineral reserve estimates; exploration and development programs; feasibility and engineering reports; permits and licences; title to properties; property interests; joint venture partners; acquisition of commercially mineable mineral rights; financing; recent market events and conditions; economic factors affecting the Company; timing, estimated amount, capital and operating expenditures and economic returns of future production; integration of future acquisitions into the Company's existing operations; competition; operations and political conditions; regulatory environment in China and Canada; environmental risks; legislative and regulatory initiatives addressing global climate change or other environmental concerns; foreign exchange rate fluctuations; insurance; risks and hazards of mining operations; key personnel; conflicts of interest; dependence on management; internal control over financial reporting; and bringing actions and enforcing judgments under U.S. securities laws.
This list is not exhaustive of the factors that may affect any of the Company's forward-looking statements. Forward-looking statements are statements about the future and are inherently uncertain, and actual achievements of the Company or other future events or conditions may differ materially from those reflected in the forward-looking statements due to a variety of risks, uncertainties and other factors, including, without limitation, those referred to in the Company's Annual Information Form under the heading "Risk Factors". Although the Company has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated, described or intended. Accordingly, readers should not place undue reliance on forward-looking statements.
The Company's forward-looking statements are based on the assumptions, beliefs, expectations and opinions of management as of the date of this news release, and other than as required by applicable securities laws, the Company does not assume any obligation to update forward-looking statements if circumstances or management's assumptions, beliefs, expectations or opinions should change, or changes in any other events affecting such statements. For the reasons set forth above, investors should not place undue reliance on forward-looking statements.
View original content to download multimedia:
SOURCE Silvercorp Metals Inc | https://www.1011now.com/prnewswire/2022/04/14/silvercorp-reports-operational-results-financial-results-release-date-fiscal-2022/ | 2022-04-14T12:15:06 | 1 | https://www.1011now.com/prnewswire/2022/04/14/silvercorp-reports-operational-results-financial-results-release-date-fiscal-2022/ |
CALGARY, AB, April 14, 2022 /PRNewswire/ - Sundial Growers Inc. (Nasdaq: SNDL) ("Sundial" or the "Company") will be participating in the Benzinga Cannabis Capital Conference, which will take place on April 20 and April 21 at the Fontainebleau Miami Beach.
Zach George, Sundial's Chief Executive Officer, will be speaking at 11:50 a.m. ET on April 20, 2022. To watch the livestream of Mr. George's exclusive interview, please follow the link here.
Sundial will also be holding one-on-one investor meetings throughout the day.
To register and access, please follow this link.
Sundial is a public company whose shares are traded on Nasdaq under the symbol "SNDL". Its business is reported and analyzed under three operating segments: Cannabis Operations, Cannabis and Liquor Retail, and Investment Operations.
As a licensed producer that crafts small-batch cannabis using state-of-the-art indoor facilities, Sundial's 'craft-at-scale' modular growing approach, award-winning genetics, and experienced growers set us apart. Sundial's brand portfolio includes Top Leaf, Sundial Cannabis, Palmetto, and Grasslands. Sundial also operates the Spiritleaf retail banner. Spiritleaf aims to be the most knowledgeable and trusted source of recreational cannabis by offering a premium consumer experience and quality curated cannabis products. Sundial has acquired Alcanna Inc. and is now the largest private sector cannabis and liquor retailer in Canada.
Sundial's investment operations seek to deploy strategic capital through direct and indirect investments and partnerships throughout the global cannabis industry.
Sundial is proudly Albertan, headquartered in Calgary, AB. For more information on Sundial, please go to www.sndlgroup.com.
View original content to download multimedia:
SOURCE Sundial Growers Inc. | https://www.1011now.com/prnewswire/2022/04/14/sundial-growers-participate-benzinga-cannabis-capital-conference/ | 2022-04-14T12:15:13 | 1 | https://www.1011now.com/prnewswire/2022/04/14/sundial-growers-participate-benzinga-cannabis-capital-conference/ |
- Significant milestone in the only late-stage clinical trial targeting tau pathology of Alzheimer's
- TauRx on track to announce top line results in May
- Trial aims to confirm efficacy of first tau-based treatment for Alzheimer's
ABERDEEN, Scotland and SINGAPORE, April 14, 2022 /PRNewswire/ -- TauRx Pharmaceuticals Ltd, a global leader in tau-based Alzheimer's Disease (AD) research, has announced that the last patient has completed treatment in the blinded phase of their late-stage clinical trial, Lucidity (NCT03446001).
This milestone means TauRx will now progress to the data cleaning and analysis phase which enables the company to determine topline results on the safety and efficacy of Hydromethylthionine mesylate (HMTM). The topline results are due to be announced in May.
Professor Claude Wischik, Executive Chairman and Co-Founder, said: "AD is a leading cause of death in the UK and one of the world's greatest unmet medical needs. At TauRx, we've focused our efforts over the last few decades to developing an effective treatment for this devastating disease based on targeting the tau pathology which is the main driver of clinical dementia.
"This milestone takes us one step closer to announcing the topline results of our potentially ground-breaking Lucidity study. We're extremely grateful to all who are progressing the trial; the study coordinators and investigators, and most importantly the patients who volunteered to take part."
According to AD International, around 50 million people are affected by dementia worldwide, and in 2050 this will rise to 152 million – with AD being the most common form.
Lucidity is the only late-stage clinical trial specifically targeting the tau pathology of AD. Aggregation of abnormal tau is a hallmark of AD. Tau aggregation and the formation of tau tangles disrupt neuronal function, a process that begins years before dementia symptoms are seen. Tau pathology correlates strongly with AD severity and the clinical decline commonly seen in patients.
ABOUT
TauRx's mission is to discover, develop and commercialise innovative products for the diagnosis, treatment and cure of neurodegenerative diseases caused through protein aggregation. The company's drug research targets the misfolding and formation of tau aggregates that form inside nerve cells in the brain, playing a role in the disease pathology of Alzheimer's and other dementias. Headquarters are in Singapore and primary research facilities and operations are in Aberdeen.
https://taurx.com/
https://www.luciditytrial.com/
View original content:
SOURCE TauRx Pharmaceuticals Ltd | https://www.1011now.com/prnewswire/2022/04/14/taurxs-late-stage-clinical-trial-reaches-new-milestone/ | 2022-04-14T12:15:19 | 1 | https://www.1011now.com/prnewswire/2022/04/14/taurxs-late-stage-clinical-trial-reaches-new-milestone/ |
TEL-AVIV, Israel, April 14, 2022 /PRNewswire/ -- TriEye, the pioneer of the world's first mass-market Short-Wave Infrared (SWIR) sensing technology, announces collaboration with Toshiba Teli, a global leader in providing integrated cameras for automation. The two companies are working together to commercialise a SWIR camera for industrial-related processes and applications.
TriEye and Toshiba Teli have successfully built the world's first Industrial oriented CMOS-based HD SWIR camera. Currently, industrial machine vision systems lack vital image data required for full-range functionality. This new integration will leverage TriEye's SWIR sensing technology to provide vision systems with an additional layer of information, reshaping the industrial sector and enhancing processes capabilities. This partnership intends to make their solution available globally, introducing its advanced benefits to a wide range of verticals.
Although InGaAs-based SWIR sensing has been around for decades, it remained limited to industries like semiconductor fabrication, aerospace, and science due to the high costs and low production yield. TriEye's unique technology introduces the industry's first CMOS-based SWIR solutions for mass markets. Its technology enhances machine vision capabilities and assists in the detection of visible and invisible malfunctions, allowing them to accomplish tasks that were previously unattainable. Leveraging this solution will provide Toshiba's customers with vital information such as material sensing and quality control.
"We are excited to partner with Toshiba, such a respected and well-known industry leader," said Avi Bakal, CEO and Co-Founder of TriEye, "We believe their constant push to deliver value to their customers combined with their industrial specific advanced knowledge will be extremely beneficial to bring our SWIR sensing solution to be an industry standard."
"We are pleased to partner with TriEye and integrate its world's first CMOS-based SWIR technology," said Shinichi Itokawa, CTO of Toshiba Teli, "TriEye is providing markets with SWIR imaging capabilities needed for reliable automation in industrial processes at an unprecedented cost. This joint effort will accelerate the development of next-generation superior imaging tech capabilities for industrial cameras that will translate into every aspect of our lives. Toshiba Teli is thrilled to be at the front of this technological revolution."
Recently, TriEye's Raven sensor was named a top innovation by InVISION. In the past, the company announced collaborations with Hitachi Astemo, Porsche, Continental Engineering, Trimble and DENSO. TriEye recently announced a significant capital acquisition in funding to support their product commercialization and global expansion. This investment was led by M&G Investments and Varana Capital, Samsung Ventures, Deep Insight, Tawazun Group, Allied Group, and Discount Capital, including follow-on investors Intel Capital, Porsche and Marius Nacht.
About TriEye
TriEye is the pioneer of mass-market, CMOS-based Short-Wave infrared (SWIR) sensing solutions. Based on advanced academic research, TriEye's breakthrough and proprietary technology enables cost-effective, high-resolution image data and depth perception in all weather and lighting conditions. Founded in 2017, the company's cutting-edge technology allows perception systems to operate and deliver reliable image data and actionable information, while reducing expenditure by up to 1,000x the existing industry rates. For more information, visit www.TriEye.tech
About Toshiba Teli (Japan)
Toshiba Teli is an imaging company specializing in design, manufacture and sale of industrial camera and surveillance camera but also the provision of image-based system solution. The company continues to support corporate activities and society by providing high-precision image information through imaging system solutions focused on camera technologies. Toshiba Teli's industrial cameras are widely used as the eyes of various manufacturing and testing equipment as well as for quality control management and medical equipment. To find out more about Toshiba Teli, visit www.toshiba-teli.co.jp
Contact: news@trieye.tech
View original content:
SOURCE TriEye | https://www.1011now.com/prnewswire/2022/04/14/toshiba-teli-trieye-collaborate-deliver-swir-sensing-capabilities-industrial-vision-systems-market/ | 2022-04-14T12:15:26 | 1 | https://www.1011now.com/prnewswire/2022/04/14/toshiba-teli-trieye-collaborate-deliver-swir-sensing-capabilities-industrial-vision-systems-market/ |
With the trends of diversifying traders' portfolio, Trade TIME has joined the market as a reliable, trustworthy broker in 2022. With its emphasis on honesty, experience of customers and innovative features, Trade TIME secures all of traders' investment and provides them with absolutely appropriate guidance on expanding traders' portfolio.
HO CHI MINH CITY, Vietnam, April 14, 2022 /PRNewswire/ -- Trading in such a volatile market like the financial one not only requires bravery but also experience, wisdom, as well as quick and accurate judgment to be able to keep up with the ups and downs of the market. There exist many investors who have experienced several different financial exchanges but still have not found their destiny. With Trade TIME's entrance into the market, this platform brings about a whole new experience for investors. In 2022, Trade TIME has released its complete overview that is analysis0based. Precisely, The Trade TIME's Review covers the following features:
Trade TIME's Offers A Wide Range Of Trading Products In 2022
When it comes to choosing a broker, it is essential for traders to evaluate the broker' financial products. That Trade TIME provides a wide range of financial instruments proves that it is trusted by many investors and the broker's products are also interested.
At Trade TIME, investors can trade diversified products, including Forex; Indices; Stocks; Commodities and Cryptocurrencies, etc.
- Forex: 80+ popular currency pairs, with fast execution speed and the best commissions in the market.
- Commodities: metals such as gold, oil, silver, crude oil and natural gas.
- CFDs: CFD trading with lowest possible spreads and no commission
- Stocks: 500+ global stocks of famous brands such as Facebook, Apple, Tesla, Coca-cola, etc. as well as the stocks listed on major US stock exchanges such as NASDAQ, NYSE and DAX.
- Cryptocurrencies: trade multiple cryptocurrencies such as Bitcoin, Ethereum, Litecoin, Ripple, and more without owning the underlying asset, wallets or currency swaps.
With approximately USD 5 trillion of the trade volume every day, Forex is a fertile trading "land" and Trade TIME is the key to open the door to this land for traders. They might have access to the market operating 24 hours a day and 5 days per week. Trade Time allows investors to trade a wide variety of currency pairs, from the most popular majors, minors and exotics.
Trade TIME's account types
When participating in the Forex market, one of the problems concerned the most by investors is account types. Depending on the capital levels, different account types will have separate incentive programs and policies.
Currently, brokers have been offering users more account types, and so is Trade TIME. This helps users to have more account options to choose the most suitable one.
At the time of this Article, Trade TIME is offering 5 types of accounts, including:
- Raw Account
- Standard Account
- Fixed Account
- VIP Account
- Crypto Account
Why traders should trade with Trade TIME
Time saving transactions
With the slogan of "Invest time and money wisely with Trade TIME", this broker is committed to providing investors with one of the trading systems with minimal slippage and fast deposit/withdrawal time.
Besides, Trade Time is also an ideal destination for trading Forex or cryptocurrencies because this broker does not widen the spread arbitrarily like some of their rivals.
With the advantage of being a new trading broker, Trade TIME prioritizes bringing the most advanced and optimal technologies to investors. It also analyses the latest trading trends so that investors can learn and make their best investment plan.
Furthermore, Trade TIME prioritizes the use of the most advanced security measures to ensure the safety of all customer information.
Customer's trading funds at TradeTIME are kept in separate bank accounts in leading local and international banks to ensure customers' funds are not included in the company's capital and never used for other purposes.
Trading Platform
Trade TIME uses the MT5 (MetaTrader 5) platform, a popular forex trading platform with more outstanding features than the MT4 version, helping traders to trade in a more convenient manner.
MT5 desktop platform has the following key features:
- MQL5 Superior environment with ultimate functionality
- Automated trading with trading bots
- Market analysis & statistics with market depth
- Forex Calendar
- Money transfer between accounts
MT5 mobile platform has the following key features:
- Compatible with all available iOS or Android-powered smartphones and has a web-based version.
- Fast execution
- Practical and friendly user-interface
- Access anytime, anywhere
- Full control of a trading account
- Possible to set price alarms on all instruments to enter orders at the most suitable time.
Trade TIME has shown its presence not only in the Vietnamese but also the international markets. And of course, no broker is perfect, so is Trade TIME. So, to be able to fully experience a broker, it is impossible to ignore traders' own personal experience. Traders can start trading with Trade TIME today by opening an account at https://secure.tradetm.com/en/register/ and try it out in their own way. Wish everyone successful deals.
About Trade TIME
Trade TIME is considered as an ideal destination for trading Forex, indices, stocks, commodities, or cryptocurrencies. Serving investors looking for a single point of access to the global financial markets is exactly what this broker is aiming at.
Established in 2021, Trade TIME is one of the relatively new broker in the market. In spite of not gaining much reputation, its dynamism, optimal technology and fast, smooth order execution are the strengths that not all brokers can offer you.
View original content to download multimedia:
SOURCE Trade TIME | https://www.1011now.com/prnewswire/2022/04/14/trade-time-becomes-one-most-dynamic-brokers-2022/ | 2022-04-14T12:15:32 | 0 | https://www.1011now.com/prnewswire/2022/04/14/trade-time-becomes-one-most-dynamic-brokers-2022/ |
SAN FRANCISCO, April 14, 2022 /PRNewswire/ -- Twitter, Inc. (NYSE: TWTR) today confirmed it has received an unsolicited, non-binding proposal from Elon Musk to acquire all of the Company's outstanding common stock for $54.20 per share in cash.
The Twitter Board of Directors will carefully review the proposal to determine the course of action that it believes is in the best interest of the Company and all Twitter stockholders.
About Twitter, Inc. (NYSE: TWTR)
Twitter is what's happening and what people are talking about right now. To learn more, visit about.twitter.com and follow @Twitter. Let's talk.
Contacts
Investors:
Press
View original content:
SOURCE Twitter, Inc. | https://www.1011now.com/prnewswire/2022/04/14/twitter-confirms-receipt-unsolicited-non-binding-proposal-elon-musk/ | 2022-04-14T12:15:43 | 1 | https://www.1011now.com/prnewswire/2022/04/14/twitter-confirms-receipt-unsolicited-non-binding-proposal-elon-musk/ |
Regeneron continues to progress its next generation antibodies, and has initiated a first-in-human trial
TARRYTOWN, N.Y., April 14, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended by three months its review of the Biologics License Application (BLA) for REGEN-COV® (casirivimab and imdevimab) to treat COVID-19 in non-hospitalized patients and as prophylaxis in certain individuals. The extension is due to ongoing discussions with the FDA on pre-exposure prophylactic use, for which Regeneron has submitted additional data from its completed prophylaxis trial that the FDA has accepted for review. The FDA considers the submission of these additional data to be a Major Amendment to the BLA and has provided a new target action date of July 13, 2022. The FDA has not requested any new studies to complete its review of the current BLA at this time.
REGEN-COV, an investigational monoclonal antibody therapy, first became available to U.S. patients in November 2020, via the FDA's Emergency Use Authorization (EUA) process for medicines that may help diagnose, treat or prevent a life-threatening disease when adequate and approved alternatives are not available. In January 2022, FDA amended the EUA to exclude its use in geographic regions where infection or exposure is likely due to a variant that is not susceptible to the treatment. Therefore, REGEN-COV is not currently authorized for use in any U.S. states, territories or jurisdictions.
Regeneron remains committed to fighting this pandemic and believes that monoclonal antibody therapies will continue to play an important role. The company is progressing investigational next generation antibodies that are active against the currently circulating variants of concern, and has initiated a first-in-human clinical trial of one of these next generation antibodies.
The development and manufacturing of REGEN-COV have been funded in part with federal funds from the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, under OT number: HHSO100201700020C.
About REGEN-COV
REGEN-COV (casirivimab and imdevimab) is a cocktail of two monoclonal antibodies designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19, using Regeneron's proprietary VelocImmune® and VelociSuite® technologies. Regeneron invented the antibody cocktail and is collaborating with Roche, who is primarily responsible for development and distribution outside the U.S., where it is known as Ronapreve.
Since REGEN-COV first became available to U.S. patients under the EUA process, it has been used to treat millions of people with COVID-19 in the U.S. and around the globe. The EUA is for the duration of the declaration that circumstances exist justifying the authorization of the emergency uses under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. REGEN-COV is not approved by the FDA.
About Regeneron's VelocImmune Technology
Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create approximately one in five of all original, FDA-approved or authorized fully human monoclonal antibodies currently available. This includes REGEN-COV® (casirivimab and imdevimab), Dupixent® (dupilumab), Libtayo® (cemiplimab-rwlc), Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza® (evinacumab-dgnb) and Inmazeb™ (atoltivimab, maftivimab and odesivimab-ebgn).
AUTHORIZED USES AND LIMITATIONS OF AUTHORIZED USE
Treatment:
REGEN-COV is authorized for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death
Limitations of Authorized Use (Treatment)
- REGEN-COV is not authorized for treatment of mild to moderate COVID-19 in geographic regions where infection is likely to have been caused by a non-susceptible SARS-CoV-2 variant based on available information such as variant susceptibility to this drug and regional variant frequency.
- REGEN–COV (casirivimab and imdevimab) is not authorized for use in patients:
- Monoclonal antibodies, such as REGEN–COV, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID–19 requiring high flow oxygen or mechanical ventilation.
Post-Exposure Prophylaxis:
REGEN-COV is authorized in adult and pediatric individuals (12 years of age and older weighing at least 40 kg) for post-exposure prophylaxis of COVID-19 in individuals who are at high risk for progression to severe COVID-19, including hospitalization or death, and are:
- not fully vaccinated or who are not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination (for example, individuals with immunocompromising conditions including those taking immunosuppressive medications) and
Limitations of Authorized Use (Post-Exposure Prophylaxis)
- REGEN-COV is not authorized for post-exposure prophylaxis of COVID-19 in geographic regions where exposure is likely to have been to a non-susceptible SARS-CoV-2 variant, based on available information including variant susceptibility to this drug and regional variant frequency.
- Post-exposure prophylaxis with REGEN-COV (casirivimab and imdevimab) is not a substitute for vaccination against COVID-19.
- REGEN-COV (casirivimab and imdevimab) is not authorized for pre-exposure prophylaxis for prevention of COVID-19.
Healthcare providers should review the Fact Sheet for Healthcare Providers for information on the authorized uses of REGEN-COV and mandatory requirements of the EUA and must comply with the requirements of the EUA. The FDA Letter of Authorization is available for reference, as well as the Dear Healthcare Provider Letter and Patient Fact Sheet.
About Regeneron
Regeneron is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite technologies, such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the impact of SARS-CoV-2 (the virus that has caused the COVID-19 pandemic) on Regeneron's business and its employees, collaborators, and suppliers and other third parties on which Regeneron relies, Regeneron's and its collaborators' ability to continue to conduct research and clinical programs, Regeneron's ability to manage its supply chain, net product sales of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Products"), and the global economy; the nature, timing, and possible success and therapeutic applications of Regeneron's Products and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Product Candidates") and research and clinical programs now underway or planned, including without limitation the development programs relating to the casirivimab and imdevimab antibody cocktail known as REGEN-COV® in the United States and Ronapreve™ in other countries and other investigational next generation antibodies targeting SARS-CoV-2 being developed by Regeneron and referenced in this press release; the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's Product Candidates (such as REGEN-COV, including based on the Biologics License Application filed with the U.S. Food and Drug Administration (the "FDA") referenced in this press release) and new indications for Regeneron's Products; the scope of any such possible regulatory approval (including whether any possible FDA approval of REGEN-COV will include prophylactic use); whether and to what extent any of Regeneron's investigational next generation antibodies targeting SARS-CoV-2 will demonstrate and retain potency against the Omicron (B.1.1.529) variant, the Delta (B.1.617.2) variant, or other existing or potential variants of SARS-CoV-2 (as applicable); uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates (such as REGEN-COV), including the impact of recommendations, guidelines, or studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the REGEN-COV prophylaxis study referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron's Products and Regeneron's Product Candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees (such as those relating to the investigational next generational antibodies targeting SARS-CoV-2 referenced in this press release) may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; the ability of Regeneron's collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates (including REGEN-COV); the ability of Regeneron to manage supply chains for multiple products and product candidates; safety issues resulting from the administration of Regeneron's Products and Regeneron's Product Candidates (such as REGEN-COV) in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates, including without limitation REGEN-COV; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron's Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's Product Candidates (including any such competing drugs and product candidates that may provide more efficacious, more easily administered, more cost-effective, or otherwise superior treatment or prophylaxis for COVID-19); unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron's agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), as well as Regeneron's collaboration with Roche relating to the casirivimab and imdevimab antibody cocktail, to be cancelled or terminated; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection, Dupixent® (dupilumab), Praluent® (alirocumab), and REGEN-COV), other litigation and other proceedings and government investigations relating to the Company and/or its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2021. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.
Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).
1 FDA will monitor conditions to determine whether use in a geographic region is consistent with this scope of authorization, referring to available information, including information on variant susceptibility [see Microbiology/Resistance Information (15)], and CDC regional variant frequency data available at: https://covid.cdc.gov/covid-data-tracker/#variant-proportions.
View original content:
SOURCE Regeneron Pharmaceuticals, Inc. | https://www.1011now.com/prnewswire/2022/04/14/us-fda-extends-review-biologics-license-application-regen-cov-casirivimab-imdevimab-treatment-prophylaxis-covid-19/ | 2022-04-14T12:15:49 | 1 | https://www.1011now.com/prnewswire/2022/04/14/us-fda-extends-review-biologics-license-application-regen-cov-casirivimab-imdevimab-treatment-prophylaxis-covid-19/ |
Advanced identity verification technology and know your customer offerings enhance Alloy's suite of fraud solutions for banks and fintechs
NEW YORK, April 14, 2022 /PRNewswire/ -- Veriff, a global identity verification provider, today announced that it is partnering with Alloy, an identity decisioning platform that helps banks and fintech companies fight fraud and remain compliant, to bolster the company's existing identity verification and know your customer (KYC) offerings. Through this partnership, Veriff will provide Alloy customers with additional identity verification capabilities and KYC solutions to leverage during client onboarding in more than 190 countries.
Veriff's identity verification technology will be made accessible through Alloy's platform, allowing fintechs and banks to verify identities quickly and effectively during new customer onboarding while meeting their KYC requirements to ensure they remain compliant. Veriff provides best-in-class KYC verification with its video-first technology and offers an extra layer of protection for users through location verification.
"We saw the financial services industry evolve dramatically over the course of the COVID-19 pandemic, and with it, a rise in fintech fraud and stringent regulations," said Janer Gorohhov, co-founder, and CPO of Veriff. "As a result, it's never been more important for financial service institutions to be steps ahead of these bad actors. We're thrilled to partner with Alloy and work together to help banks and fintechs reestablish trust online among their customer base."
Alloy serves as a command center for identity that gives financial institutions a holistic view of each customer from the day they onboard and throughout their time with the organization. Alloy's identity decisioning platform combined with Veriff's added identity verification and compliance capabilities gives financial organizations the trust and security needed to manage their onboarding, transactions and credit decisions with confidence and reliability.
"The fraud landscape is constantly shifting, and financial institutions need to be able to adjust quickly to continue mitigating fraud," said Brian Bender, VP of Strategic Alliances at Alloy. "Our partnership with Veriff enables us to connect our clients with more identity verification and KYC offerings that meet each of their compliance needs and empower them to remain agile in the evolving market.
For more information about our partnership, please visit us at www.veriff.com.
About Alloy
Alloy is the command center for identity that covers your compliance and fraud-fighting needs. Our identity decisioning platform connects you to more than 120 data sources to help you verify identities, monitor transactions, and make credit decisions - giving you a holistic view of each customer from the day they onboard and throughout their time with your organization. From automatic decisions and fewer manual reviews to smooth onboarding, Alloy is how smart banks and fintech companies like Ally Bank, Aspiration and Brex take a closer look at the whole picture. Learn more at Alloy.com and on Twitter @UseAlloy.
About Veriff
Veriff is a global online identity verification company that enables organizations to build trust with their customers through intelligent, accurate, and automated online IDV. With the largest document specimen database on the market, Veriff's intelligent decision engine can analyze thousands of technological and behavioral variables in seconds, matching people to more than 10,000 government-issued IDs from over 190 countries. Founded in 2015, Veriff serves a global portfolio of organizations across fintech, crypto, and mobility sectors. To learn more, visit www.veriff.com.
Logo - https://mma.prnewswire.com/media/1654545/Veriff_Logo.jpg
View original content:
SOURCE Veriff | https://www.1011now.com/prnewswire/2022/04/14/veriff-identity-verification-solutions-now-available-alloy-identity-decisioning-platform-clients/ | 2022-04-14T12:15:58 | 0 | https://www.1011now.com/prnewswire/2022/04/14/veriff-identity-verification-solutions-now-available-alloy-identity-decisioning-platform-clients/ |
New Fund Builds on Existing Partnership and Will Create First-Ever Professorship at the Scott Polar Research Institute
LOS ANGELES, April 14, 2022 /PRNewswire/ -- Viking® (www.viking.com) today announced it has partnered with the University of Cambridge to establish a new Professorship aimed at advancing research in the field of polar environmental science. The Viking Polar Marine Geoscience Fund will endow the University's Scott Polar Research Institute with its first-ever fully funded professorship—the Viking Chair of Polar Marine Geoscience. This new post will enhance the scientific leadership at the Institute and will enable the development of new lines of research into the behavior of polar environments, including polar ice sheets, sea ice and ocean circulation. The research fund builds on Viking's existing partnership with Cambridge University's Scott Polar Research Institute, which played a significant role in developing the scientific enrichment program for the company's new expedition vessels that launched earlier this year.
Viking's first expedition vessel, the Viking Octantis®, debuted in January 2022 and spent the Austral summer in Antarctica. She is currently sailing toward the Great Lakes region, where she will be based for voyages throughout the Boreal summer. Scientists from the Scott Polar Research Institute—as well as other renowned academic institutions—have been undertaking fieldwork on board Viking Octantis and have joined voyages to share their expertise with guests. A second, identical sister ship, the Viking Polaris®, will join the fleet later in 2022.
"Our intention in creating 'the thinking person's expedition' is that every voyage should provide opportunities for scientific discovery—for our guests and for our partners," said Torstein Hagen, Chairman of Viking. "In addition to offering our guests the ability to explore some of the world's most pristine destinations in comfort and in the most responsible way possible, we are proud that our expedition vessels can also be utilized as ships of opportunity for important research that might not be possible otherwise. By establishing the Viking Polar Marine Geoscience Fund, we are also ensuring that the Scott Polar Research Institute is able to continue critical work in perpetuity—some of which will be conducted on board."
Viking has created the world's leading scientific enrichment environment in an expedition setting with the help of partnerships with esteemed scientific and academic institutions. Scientists from SPRI are part of the onboard 36-person Viking Expedition Team, a diverse group of experts that lead guests on shore excursions and provide world-class lectures on each sailing. University of Cambridge specialists were also consulted in the development of The Science Lab on Viking's expedition vessels; the 380-square-foot lab is comprehensively appointed with wet and dry laboratory facilities and supports a broad range of research. Julian Dowdeswell, Professor of Physical Geography at the University of Cambridge and former director of SPRI, serves as the Chair of the Viking Research Advisory Group, a consortium of scientific leaders from Viking's partner institutions who have been actively involved in overseeing the field research being undertaken on board.
"We are delighted with the support offered by Viking through both the endowment of a new Professorship at the Institute and the opportunity to use their expedition ships as well-equipped platforms for our scientific investigations of the icy world," said Professor Dowdeswell.
Established in 1920, the Scott Polar Research Institute's mission is to enhance the understanding of the polar regions through scholarly research and publication, educate new generations of polar researchers and communicate the history and environmental significance of the polar regions to the wider community.
In addition to SPRI, Viking's other scientific partners include:
- The Cornell Lab of Ornithology: Ornithologists are regularly on board Viking's expedition vessels, undertaking post-doctoral research on new observation methods and providing guest advice and interaction.
- National Oceanic and Atmospheric Administration (NOAA) Great Lakes Environmental Research Laboratory (GLERL): Conducts innovative research on the dynamic environments and ecosystems of the Great Lakes and coastal regions to provide information for resource use and management decisions that lead to safe and sustainable ecosystems, ecosystem services, and human communities. Viking's expedition ships have been designated official NOAA / US National Weather Service weather balloon stations, from which regular launches are undertaken.
- Norwegian Institute of Water Research, NIVA: Scientists from NIVA are engaged in cross-disciplinary research programs on water-related issues. On Viking's expedition ships, NIVA FerryBoxes are installed to sample sea and lake water to provide continuous information about chlorophyll, oxygen, temperature, salinity, microplastics and related meteorological data.
- Norwegian Polar Institute: The permitting authority for our Norwegian flagged expedition vessels, who review and approve all of Viking's expedition and science activities in Antarctica.
- Oceanites: Viking has partnered with Oceanites, an American Not-for-Profit field research entity that has led on Antarctic penguin monitoring for the past thirty years.
- The Polar Citizen Science Collective: Creates opportunities for research and public education through citizen science, leveraging the reach of polar travelers to enhance understanding and protection of the polar regions.
- The IUCN Species Survival Commission Species Monitoring Specialist Group: Viking has partnered with the group to develop marine biodiversity monitoring systems that will enable expedition vessels to collect data of value to scientists and conservationists.
With the launch of Viking Expeditions in January 2022, Viking is now exploring all seven continents. Destination-focused expeditions are currently available in Antarctica and North America's Great Lakes. Viking's expedition fleet includes the new Polar Class Viking Octantis and Viking Polaris, which host 378 guests in 189 staterooms. Designed for discovery by the same team that designed the award-winning Viking Longships® and ocean ships, the new vessels are purpose-built for expeditions, at an ideal size for safety, comfort and to support an unrivalled range of activities in remote destinations. With more indoor and outdoor viewing areas than other expedition vessels, guests are as close as possible to the most magnificent scenery on earth.
Viking was founded in 1997 and provides destination-focused journeys on rivers, oceans and lakes around the world. Designed for experienced travelers with interests in science, history, culture and cuisine, Chairman Torstein Hagen often says Viking offers guests The Thinking Person's Cruise® in contrast to mainstream cruises. With more than 250 awards to its name, Viking has been rated the #1 River Cruise Line and #1 Ocean Cruise Line by Condé Nast Traveler in the publication's 2021 Readers' Choice Awards. Viking has also been consistently rated the #1 ocean cruise line and one of the best river cruise lines in Travel + Leisure's "World's Best" Awards. For additional information, contact Viking at 1-800-2-VIKING (1-800-284-5464) or visit www.viking.com. For Viking's award-winning enrichment channel, visit www.viking.tv.
View original content to download multimedia:
SOURCE Viking | https://www.1011now.com/prnewswire/2022/04/14/viking-endows-new-chair-polar-marine-geoscience-university-cambridge/ | 2022-04-14T12:16:05 | 1 | https://www.1011now.com/prnewswire/2022/04/14/viking-endows-new-chair-polar-marine-geoscience-university-cambridge/ |
NEW YORK, April 14, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Volta Inc. ("Volta" or the "Company") (NYSE: VLTA) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Volta investors who were adversely affected by alleged securities fraud between August 2, 2021 and March 28, 2022. Follow the link below to get more information and be contacted by a member of our team:
VLTA investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Volta had improperly accounted for restricted stock units issued in connection with the business combination of Volta Industries, Inc. ("Legacy Volta") and Tortoise Acquisition Corp. II; (2) as a result, the Company had understated its net loss for third quarter 2021; (3) there were material weaknesses in the Company's internal control over financial reporting that resulted in a material error; (4) as a result of the foregoing, the Company would restate its financial statements; (5) as a result of the foregoing, Legacy Volta's founders would imminently exit the Company; (6) as a result, the Company's financial results would be adversely impacted; and (7) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
WHAT'S NEXT? If you suffered a loss in Volta during the relevant time frame, you have until May 31, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
View original content to download multimedia:
SOURCE Levi & Korsinsky, LLP | https://www.1011now.com/prnewswire/2022/04/14/vlta-lawsuit-alert-levi-amp-korsinsky-notifies-volta-inc-investors-class-action-lawsuit-upcoming-deadline/ | 2022-04-14T12:16:12 | 1 | https://www.1011now.com/prnewswire/2022/04/14/vlta-lawsuit-alert-levi-amp-korsinsky-notifies-volta-inc-investors-class-action-lawsuit-upcoming-deadline/ |